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1.0 Background 
Over the past decades, the development of new drugs and treatment modalities has 
improved the perspectives of many cancer patients. At present, numerous drugs are 
available for the treatment of these patients. The ever increasing number of available 
anticancer drugs, however, has not necessarily made it easier to treat patients, as it can 
be difficult to decide on the optimal treatment regimen for an individual patient. Most 
systemic anticancer treatments fail in a substantial number of patients and are 
associated with several toxicities, which can be severe. Therefore, refinement is needed 
to identify those patients who are likely to benefit from a specific drug and those who do 
not. Positron emission tomography (PET) is an imaging technique that may be useful for 
personalized treatment planning in cancer patients. In particular, radiolabeling of 
anticancer drugs with a positron emitter is promising for individualized treatment 
planning. In this chapter, the principles of PET and the applications of several PET tracers 
in oncology are introduced. Thereafter, the development of carbon-11 labeled docetaxel 
([11C]docetaxel), a newly radiolabeled anticancer drug, and its validation in patients with 
lung cancer is described. Finally, the other chapters of this thesis, in which [11C]docetaxel 
PET studies in lung cancer patients are reported, will be introduced.  
 
2.0 Positron emission tomography (PET) 
 
2.1 Principles of PET  
PET is a highly sensitive nuclear imaging technique that is suited for non-invasive in vivo 
monitoring of dynamic processes. A PET scanner usually consists of a ring of detectors 
and is capable of detecting high-energy gamma-rays that are emitted from tissue after 
administration of a PET tracer (usually by intravenous injection) to a patient (1). PET 
tracers are molecules of interest that are labeled with a positron emitting radionuclide. 
Such a radionuclide decays and produces two gamma-rays, following emission of a 
positron from its nucleus. For PET imaging, frequently short-lived radionuclides, such as 
carbon-11 (11C), fluorine-18 (18F) and oxygen-15 (15O), are used. These radionuclides are 
generated by a specific particle accelerator, called cyclotron. In tissue, an emitted 
positron can travel at most a few mm and eventually it combines with a nearby electron. 
In the following annihilation reaction, the masses of the positron and electron are 
converted into energy in the form of two photons of 511 keV, which are emitted in 
opposite directions to each other (Figure 1).  
9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic illustration of an annihilation reaction and the subsequent in coincidence 
detection. Positrons released from the nucleus of the radionuclide annihilate with electrons in 
tissue, releasing two coincidence photons of 511 keV, which are detected by scintillation crystals 
(blue rectangles).  
 
These photons are simultaneously detected (in coincidence) by two opposing detectors of 
the PET scanner. Coincidence detection of annihilated photons identifies a line-of-
response and makes it possible to localize the source of the annihilation. After 
reconstruction, data obtained provide information on the three-dimensional (3D) tracer 
concentration within the body. To date, a PET scanner is combined with an integrated 
computed tomography (CT) scanner [Figure 2; (2)]. The CT scanner is used to estimate 
tissue attenuation, a process in which gamma rays are absorbed by tissue as they pass 
through the patient. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Combined PET/CT scanner consisting of a PET (right) and a CT (left) component. 
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When a positron is emitted from a structure deeper in the body, gamma rays are more 
likely to be attenuated than from superficial structures. Consequently, without 
attenuation correction, reconstructed images would show falsely low tracer uptake in 
deeper structures. A low-dose CT scan can be used to correct for this tissue attenuation. 
In addition, the CT scan provides anatomical localization of the functional data that are 
obtained from the PET image.  
 
2.2 Kinetic modeling of PET data 
Although, in clinical practice, a PET image can be extremely useful for diagnosis and 
staging, absolute quantification of tracer kinetics in tissue is necessary for complete 
characterization of biochemical, physiological and pharmacological processes in vivo. This 
requires measurement of tracer uptake in tissue as function of time. To this end, PET 
data need to be acquired in dynamic rather than statical scans. For diagnostic purposes, 
usually whole body scans are performed, which consist of a series of static scans by 
moving the scanner bed over multiple bed positions. Dynamic scans, however, are 
limited by the field of view of the PET scanner, which is ~ 15-20 cm. As patients are 
scanned in only one bed position, only information on a selected part of the body is 
obtained. Hence, the tissue of interest needs to be defined prior to acquisition of the PET 
data. Net tracer uptake in tissue is determined by its delivery, extraction from blood, and 
washout from tissue as function of time. Each tracer has its own distinct behavior in vivo, 
which can be described by tracer kinetic models (3). These models are used to estimate 
underlying biologic parameters by fitting the (mathematical) model equations to the 
time-activity curves of a defined region of interest. In practice, most tracer kinetic 
models are compartmental models, in which the compartments are used to describe the 
distribution of the tracer in tissue. Several compartmental models have been developed 
to describe PET data. In Figure 3, schematic diagrams of standard single-tissue and two-
tissue compartment models are presented. The kinetic rate constants in these models 
can be estimated from dynamic PET data. To this end, a tissue time-activity curve (TAC; 
Figure 4) is fitted to the appropriate model equation using the arterial plasma TAC as 
input function, and the best fit then provides estimates of these kinetic parameters 
(Figure 5). The arterial input function can be obtained from arterial blood sampling using 
an online detection system [Figure 6; (4)]. Arterial blood sampling, however, is an 
invasive and cumbersome procedure. In principle, the time course of the tracer in a large 
arterial blood structure, e.g. the ascending aorta, can also be used to generate a non-
invasive image derived input function (IDIF). For appropriate estimation of the kinetic 
parameters, the input function needs to be corrected for changing plasma/blood ratios 
and the development of radiolabeled metabolites of the tracer during the course of the 
scan. 
11
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Compartment models to describe the behavior of the tracer in tissue. 
(A) Schematic diagram of a single-tissue compartment model in which only one tissue 
compartment can be distinguished, such as in the case of a flow tracer. According to this model, 
the tracer concentration in tissue (CTissue) depends on plasma concentration (CPlasma), influx from 
plasma (K1 or rate constant for transfer from plasma to tissue) and clearance from tissue to plasma 
(k2 or rate constant for transfer from tissue to plasma).  
(B) Schematic diagram of a two-tissue compartment model. CTissue consists of tracer concentrations 
in compartments 1 and 2, representing free (C1) and bound or metabolized tracer (C2), 
respectively. Tracer kinetics in tissue are regulated by CPlasma and four kinetic rate constants K1, k2, 
k3, and k4. K1 is the rate constant for transport from plasma to tissue, k2 for transport from tissue 
to plasma, and k3 and k4 are kinetic rate constants describing exchange between the two tissue 
compartments. For an irreversible two-tissue compartment model k4 = 0.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Example of time-activity curves of radioactivity concentrations in plasma and two 
different tissues of interest. 
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Figure 5. Schematic diagram of data required for analysis of PET data (TAC: time-activity curve).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Illustration of set-up for arterial sampling during a dynamic PET scan, using the space 
between PET (left) and CT (right) scanners. The radioactivity concentration in arterial blood is 
monitored using a fully programmable blood sampling device (4). Blood is withdrawn from the 
radial artery through 1 mm internal diameter tubing using a pump that can be operated at rates 
varying from 0 to 600 mL·h-1. Radioactivity is measured using a bismuth germanate crystal of 6 cm 
thickness. This crystal is connected to a photomultiplier and a multichannel analyzer, which are 
positioned within 6 cm lead shielding. 
13
 
 
2.3 PET imaging in oncology 
Over the past decade, clinical applications of PET have expanded, particularly in oncology 
(1). To date, 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is the most widely used PET 
tracer for evaluation of cancer. It is used for staging of various cancers (5) and for 
monitoring tumor response to therapy (6). The high [18F]FDG uptake in tumors is based 
on altered glucose metabolism in most cancer cells (7). In contrast to glucose, [18F]FDG 
lacks the hydroxyl group. As a result, the metabolite of [18F]FDG, FDG 6-phosphate, 
cannot act as a substrate for further glycolysis and is trapped in the cell, usually resulting 
in high contrast images of tumor tissue (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Example of an [18F]FDG PET-CT fusion image in a patient with lung cancer. Arrow 
indicates intense [18F]FDG uptake in the primary tumor in the left upper lobe.  
 
As [18F]FDG uptake in tissue is not specific for malignancy and does not provide 
information on other biological characteristics of tumors, other PET tracers have been 
developed. For example, 3-deoxy-3-[18F]fluorothymidine ([18F]FLT) has been developed 
to measure tumor proliferation (8). In addition, radioactive water ([15O]H2O) can be used 
to measure tumor perfusion (9), whereas hypoxia tracers such as [18F]fluoroazo-
mycinarabinofuranoside ([18F]FAZA) and [18F]fluoromisonidazole ([18F]FMISO) can be 
used to determine hypoxic areas in tumors (10). Although these PET tracers may provide 
additional information on various tumor characteristics and could be useful for response 
evaluation, they are not specific enough to predict tumor response to specific anti-cancer 
drugs. As an alternative, anti-cancer drugs themselves can also be labeled with positron 
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emitters. Using PET, these radiolabeled drugs can then be used to monitor drug 
pharmacokinetics and pharmacodynamics in patients non-invasively. Preliminary PET 
studies using fluorine-18 labeled 5-fluorouracil ([18F]5-FU) (11,12) and tamoxifen 
([18F]fluorotamoxifen) (13), showed that high tumor uptake of the radiolabeled anti-
cancer drug was associated with improved tumor response following corresponding 
therapy. These studies suggest that radiolabeled anticancer drugs may be useful for 
prediction of outcome prior to start of treatment. Consequently, an increasing number of 
anticancer drugs has now been radiolabeled for PET imaging. At the VU University 
Medical Center, Van Tilburg et al (14,15) succeeded in radiolabeling the anti-cancer drug 
docetaxel, which nowadays is one of the most important chemotherapeutic agents in the 
clinic.  
 
3.0 Docetaxel  
 
3.1 Mechanism of action  
Docetaxel (Taxotere®) is a taxane, a class of drugs consisting of microtubule stabilizing 
agents that function primarily by interfering with microtubule dynamics, inducing cell 
cycle arrest and apoptosis (16,17). Microtubules consist of long protein polymers, which 
have important functions in cellular activities, including maintenance of cell shape, 
cellular movement, cell signaling and mitosis (18). These key roles make microtubules an 
effective target for treatment of cancer. Microtubules are hollow cylindrical cores 
composed ?????????????bulin heterodimers (19). Polymerization and depolymerization of 
microtubules are important for cellular division and chromosome aggregation during 
mitosis. Docetaxel binds to the ??subunit of the tubulin heterodimer (20) and promotes 
the assembly of stable microtubule bundles, whilst simultaneously inhibiting their 
disassembly (Figure 8). This results in the production of stable, but dysfunctional 
microtubules, leading to the inhibition of mitosis in cells. 
   
 
 
 
 
 
 
 
 
Figure 8. Docetaxel acts by disrupting the microtubular network in cells. It promotes 
polymerization of microtubules, while simultaneously inhibiting depolymerization. This leads to 
disruption of cellular activities including cell cycle arrest and inhibition of mitosis. 
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3.2 Administration of docetaxel 
In the clinic, docetaxel is administered as a 1 hour intravenous infusion in a solution with 
polysorbate 80 and ethanol. Usually, the drug is given at a dose of 75 or 100 mg·m-2 in a 
three-weekly regimen (21). The duration of this three-weekly regimen depends on the 
indication and varies from four (22) to ten (23) cycles of treatment. In addition, 
docetaxel can be given weekly, but this schedule is rather poorly tolerated (24). Prior to 
administration of docetaxel, all patients need to be premedicated with oral cortico-
steroids, as this reduces the incidence and severity of docetaxel-induced fluid retention 
and hypersensitivity reactions significantly (25,26).  
 
3.3 Docetaxel for treatment of cancer  
In 1996, docetaxel was first approved for the treatment of anthracycline-refractory 
metastatic breast cancer (27,28). Thereafter, the drug was registered for treatment of 
platinum-refractory stage IIIB and IV non-small cell lung cancer (NSCLC) (29,30). To 
date, docetaxel has also been approved for combination strategies. In combination with 
other drugs, docetaxel has been approved for the following indications: (i) with 
doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable 
node-positive breast cancer (31); (ii) with cisplatin for the first-line treatment of patients 
with non-resectable, locally advanced or metastatic NSCLC (32); (iii) with prednisone for 
the treatment of patients with androgen independent (hormone refractory) metastatic 
prostate cancer (23); (iv) with cisplatin and fluorouracil for first-line treatment of 
patients with advanced gastric adenocarcinoma (33); (v) with cisplatin and fluorouracil 
for induction treatment of patients with locally advanced squamous cell carcinoma of the 
head and neck (22,34). In these malignancies, docetaxel has shown proven efficacy, 
including tumor response and improved survival. Nevertheless, failure of docetaxel 
therapy occurs and patients are often subjected to docetaxel related toxicities without 
gaining benefit.  
 
3.4 Side-effects associated with docetaxel treatment 
As single agent, docetaxel is associated with numerous hematological and non-
hematological toxicities. At a dose of 75 mg·m-2, non-hematological toxicities that are 
most frequently [i.e. ? 20% of all grades according to Common Terminology Criteria for 
Adverse Events (CTCAE) and Common Toxicity Criteria (CTC)] associated with docetaxel 
treatment include fever without infection (62%), asthenia (55%), nausea (36%), 
diarrhea (36%), infection (31%), stomatitis (26%), vomiting (24%) and neurosensory 
toxicity (20%) (30). Among these toxicities, severe (grade 3-4) asthenia is reported in 
approximately 18% of patients (30). At the same dose, severe (grade 3-4) hematological 
toxicities are neutropenia (54-67%), febrile neutropenia (2-8%), and anemia [0-6%; 
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(29,30)]. Combining docetaxel with other anti-cancer drugs may lead to more (severe) 
toxicities, depending on the drug that is co-administered with docetaxel. Based on both 
experienced toxicities and the (combination) schedule in which docetaxel is administered, 
dose reduction or discontinuation of docetaxel treatment can be required in case of 
severe toxicity.   
                                                 
4.0 [11C]docetaxel PET microdosing 
 
4.1 Radiolabeling of docetaxel  
Docetaxel has been radiolabeled with the radionuclide carbon-11 (14,15). As a stable 
carbon atom is replaced by carbon-11 (Figure 9), the chemical structure of 
[11C]docetaxel is identical to that of the drug docetaxel.  
 
 
            
 
 
 
Figure 9. [11C]docetaxel is synthesized by replacing a stable carbon atom by carbon-11 (14,15). 
Hence, pharmacokinetics of the tracer [11C]docetaxel and the drug docetaxel are also 
identical. To date, [11C]docetaxel can be produced according to Good Manufacturing 
Practice (GMP) standards, allowing for administration to patients. At time of injection, the 
specific activity is approximately 10 GBq·μmol-1, which leads to a dose of 30 μg docetaxel 
for a typical administration of 370 MBq [11C]docetaxel. This is about 0.02% of a 
therapeutic dose of docetaxel. Consequently, no docetaxel related toxicities are expected 
after administration of [11C]docetaxel. Therefore, a microdosing PET study using 
[11C]docetaxel may be useful to predict benefit from docetaxel therapy in individual 
patients without the risk of docetaxel related toxicities.  
 
4.2 Validation of [11C]docetaxel PET in lung cancer patients 
Before implementation of a new PET tracer in the clinic, technical and biological validation 
of the tracer is required. To this end, the optimal patient population should be selected 
based on patient characteristics and technical issues. To evaluate the clinical relevance of 
[11C]docetaxel PET scans, these scans need to be performed in patients who are planned 
for docetaxel therapy. In addition, a non-invasive IDIF needs to be validated, as arterial 
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blood sampling, which is required for quantification of [11C]docetaxel kinetics, is too 
invasive and too cumbersome for clinical practice. To this end, a large arterial blood 
structure, e.g. the ascending aorta, needs to be located in the same field of view as the 
tumor. For adequate validation of an IDIF, patients should be physically able to undergo 
venous and arterial sampling from two different arms simultaneously. In this respect, 
most breast cancer patients will not be able to participate, as both injury and infection of 
the arm are significant risk factors for developing lymph edema after sentinel lymph node 
biopsy and axillary lymph node dissection (35). Considering these issues, patients with 
lung cancer seem most eligible for validation of [11C]docetaxel PET, as patients with 
advanced NSCLC are eligible for docetaxel therapy (29,30,32). In addition, a tumor in 
the lungs is located in the same field of view as the ascending aorta, making it possible 
to validate a non-invasive IDIF for [11C]docetaxel. 
 
5.0 Lung cancer 
 
5.1 Epidemiology 
Worldwide, lung cancer is the most common cause of cancer related death among men 
and women (36). Every year, approximately 1.2 million new cases of lung cancer are 
diagnosed globally and 1.1 million patients die of this disease (37). It has been 
determined that tobacco smoking is the main cause of lung cancer, probably accounting 
for 85% of all lung cancer cases (38-40). In non-smokers, genetic factors, asbestos, 
radon gas, passive smoking, and air pollution are thought to attribute to the 
development of lung cancer (41-48). Patients with lung cancer frequently present with 
symptoms such as malaise, weight loss, dyspnea, cough and hemoptoe. Lung cancer can 
be detected by chest radiography or CT, but the final diagnosis needs to be confirmed by 
histological or cytological examination. To that end, usually bronchoscopy or fine needle 
aspiration is performed.           
         
5.2 Histology                                        
The main histological types of lung cancer are NSCLC and small cell lung cancer (SCLC). 
NSCLC accounts for about 85% of cases and is subdivided in subtypes, including 
squamous cell carcinoma, adenocarcinoma, large cell carcinoma and bronchioloalveolar 
carcinoma (49). Among these NSCLC subtypes, adenocarcinoma has become the most 
prevalent subtype. SCLC represents approximately 15% of lung cancer cases (50).  
                    
5.3 Staging and survival                   
NSCLC and SCLC are staged by two different systems. For staging of NSCLC, the Tumor-
Node-Metastases (TNM) classification is used (51). This staging system takes into 
18
 
 
account size and degree of spread of the primary tumor (T), involvement of lymph nodes 
(N) and presence of distant metastases (M). Based on the TNM staging system, NSCLC 
can be categorized into stages, varying from local (I and IIA) to locally advanced (IIB 
and IIIA) and advanced disease (IIIB and IV). SCLC is staged according to a simpler 
system that is divided into limited and extensive stage of the disease (52). The prognosis 
of both NSCLC and SCLC is very poor. For NSCLC, the 5-year overall survival is 67% for 
patients with stage IA and 55% for patients with stage IIA (53). For IIIA disease, 23% of 
patients is alive five years after surgery, whereas only 1% of patients with stage IV is 
alive after five years (53). Among patients with SCLC, the 5-year overall survival is 
approximately 10% and 2% for limited and extensive disease, respectively (52).  
                                              
5.4 Treatment of lung cancer                             
Treatment of lung cancer depends on histological type, stage, and performance status. 
Treatment options include surgery, radiotherapy and chemotherapy, or a combination of 
these modalities. Early stage NSCLC (stages I and II) can be treated with curative 
surgery, whereas in general surgical interventions are not used for SCLC. Commonly, 
SCLC is treated with chemotherapy and/or radiation therapy, as this tumor type usually 
is metastatic at presentation (52). For pre-operative staging of patients with NSCLC, 
[18F]FDG PET is routinely performed in the initial staging work-up (54), as PET improves 
the rate of detection of local and distant metastases in these patients (55,56), thereby 
reducing the number of unnecessary surgeries. NSCLC patients with unresectable and 
metastatic disease usually are treated with chemotherapy. First-line chemotherapy 
consists mainly of a platinum-based doublet, such as cisplatin or carboplatin, in 
combination with a third generation cytotoxic drug such as gemcitabine, pemetrexed, 
paclitaxel or docetaxel (57,58). In addition, targeted agents have been introduced for the 
treatment of advanced NSCLC. Gefitinib and erlotinib were the first targeted agents 
approved for treatment of advanced and metastatic NSCLC (59-61). These drugs target 
the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) and have 
demonstrated proven efficacy in NSCLC patients with activated EGFR mutations (62-64). 
In 2006, another targeted drug, bevacizumab, was approved for systemic treatment of 
NSCLC (65). The anti-angiogenic drug bevacizumab is a humanized monoclonal antibody 
directed against the vascular endothelial growth factor (VEGF), which has been approved 
in combination with paclitaxel and carboplatin for first-line treatment of non-squamous 
NSCLC (65).   
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6.0 Outline of the thesis 
 
In this chapter, the rationale for PET scans using [11C]docetaxel has been introduced. In 
the following chapters, several studies are described in which this novel PET tracer was 
validated for use in lung cancer patients, with the ultimate goal to determine its potential 
clinical implications.  
 
In Chapter 2, the role of PET and radiolabeled anticancer drugs for prediction of tumor 
resistance is reviewed.  
 
In Chapter 3, tumor perfusion measurements in lung cancer patients are validated using 
[15O]H2O and a clinical PET/CT scanner. This is necessary, as tumor perfusion may be an 
important factor in the delivery of radiolabeled drugs, including [11C]docetaxel. As tumor 
perfusion may change after an intervention, test-retest variability of perfusion 
measurements is also determined in order to evaluate whether a therapy induced change 
in tumor perfusion reflects a ‘real’ change or methodological variation.  
 
Chapters 4 to 7 describe successive steps in the evaluation of [11C]docetaxel for use in 
clinical PET studies. In preparation of humans studies, the biodistribution of 
[11C]docetaxel in healthy rats is investigated in Chapter 4. In Chapter 5, biodistribution 
and radiation dosimetry of [11C]docetaxel are determined in cancer patients. Chapters 6 
and 7 describe the initial clinical validation of quantitative [11C]docetaxel studies in 
cancer patients as a tool to predict response to docetaxel therapy. In Chapter 6, the 
feasibility of quantitative [11C]docetaxel PET scans is evaluated in 34 patients with lung 
cancer. First, the optimal tracer kinetic model for [11C]docetaxel uptake in tumor tissue is 
developed using a dynamic scanning protocol and arterial sampling. Next, the use of a 
non-invasive IDIF is validated, as arterial sampling is less suited for clinical practice. 
Finally, the relationship between [11C]docetaxel kinetics and tumor perfusion, tumor size 
and premedication of dexamethasone is assessed. However, kinetics of a tracer 
(microdose) amount of [11C]docetaxel do not necessarily reflect kinetics of docetaxel 
during a therapeutic infusion. Therefore, Chapter 7 provides an assessment in lung 
cancer patients to investigate whether an [11C]docetaxel PET scan can predict tumor 
uptake of cold docetaxel during a therapeutic infusion.  
 
Within the context of combination therapy, in Chapter 8, the effects of the anti-
angiogenic drug bevacizumab on tumor perfusion and [11C]docetaxel uptake in lung 
tumors is investigated in NSCLC patients. Finally, results of all these investigations are 
summarized in Chapter 9 and future perspectives are discussed in Chapter 10.  
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Abstract: Tumour resistance to anticancer agents remains a challenge in oncological practice, because it results in expo-
sure to toxicities, unnecessary costs and, most importantly, delay of a potentially more effective treatment. Drug uptake by 
tumours may be impaired by several resistance pathways. Reasons for primary resistance may be that the drug is not de-
livered to the tumour or that its uptake by the tumour is not sufficient. Drug delivery depends on its distribution within the 
body, its bioavailability in the circulation and its transport to the tumour. Binding of drugs to circulating cells and pro-
teins, formation of inactive metabolites as well as a rapid drug clearance may limit bioavailability. Furthermore, drug de-
livery to tumours is regulated by tumour vascularisation. Finally, tumour targets such as hormone receptors and efflux 
pumps also influence drug uptake by tumours.  
The use of specific PET tracers such as radiolabelled anticancer drugs (e.g. [18F]fluoropaclitaxel and [18F]5-fluorouracil) 
provide a unique means for individualized treatment planning and drug development. Combining these specific tracers 
with other less specific tracers, such as tracers for blood flow (e.g. [15O]H2O) and efflux (e.g. [
11C]verapamil), may pro-
vide additional information on drug resistance mechanisms. Furthermore, radiolabelled anticancer agents may be valuable 
to evaluate the optimal timing of combination therapies. This review will focus on how PET can reveal different mecha-
nisms of tumour resistance and thus may play a role in drug development and prediction of tumour response. 
INTRODUCTION 
 A number of systemic anticancer agents have been intro-
duced for both curative and palliative cancer treatment. Un-
fortunately, failure of anticancer therapy can occur because 
of primary (intrinsic) or secondary (acquired, following a 
temporary initial response) resistance. Tumour resistance to 
anticancer agents remains a major challenge in oncological 
practice, because it results in exposure to toxicities, unneces-
sary costs and, most importantly, delay of a potentially more 
effective treatment. To optimise cancer treatment, primary 
resistance to anticancer drugs is increasingly measured by 
early response monitoring.  
 The arrival of new targeted therapies such as imatinib 
imposes new challenges to response evaluation criteria com-
pared to their use with conventional anticancer agents [1, 2]. 
Response Evaluation Criteria in Solid Tumours (RECIST) 
are widely used and are based on the sum of the longest di-
ameters of appointed target lesions in a transversal plane [3]. 
Since most of these novel drugs are cytostatic instead of cy-
totoxic, morphological imaging is not appropriate for meas-
uring tumour response. Objective responses may be missed 
or underestimated by RECIST, as several targeted therapies 
can cause extensive tumour necrosis [4-8] without a marked 
decrease in tumour size. However, treatment-induced necro-
sis is not part of the RECIST criteria and may even mimic 
progressive disease [6].  
*Address correspondence to this author at the VU University Medical Cen-
tre, Nuclear Medicine & PET Research, P.O. Box 7057, 1007 MB Amster-
dam, the Netherlands; Tel: + 31 20 444 3999; Fax: + 31 20 444 3090;  
E-mail: g.luurtsema@vumc.nl 
 Currently, new response criteria and imaging techniques 
are investigated to evaluate tumour response. 2-[18F]fluoro-
2-deoxy-D-glucose ([18F]FDG) positron emission tomogra-
phy (PET), which is able to measure glucose metabolism has 
an increasing role in (early) response evaluation and predic-
tion of treatment outcome [9-11]. Besides [18F]FDG, 3-
deoxy-3-[18F]fluorothymidine ([18F]FLT), which visualizes 
proliferative activity, is under investigation for evaluating 
tumour response [12, 13]. The increasing availability of PET 
scanners provides the impetus for developing molecular im-
aging probes that are more specific for various cancers and 
their therapies.  
 Effective use of anticancer agents requires that efficacy 
can be predicted early during treatment. Clinical response 
evaluation methodology is too slow and inaccurate to relia-
bly predict treatment outcome. Ideally, tumour response 
should be predicted before initiating treatment, thereby pre-
venting that patients are subjected to inadequate treatment 
with unnecessary toxicities. Although [18F]FDG and [18F]- 
FLT are promising tracers for monitoring response early 
during therapy, they are not specific enough to predict tu-
mour response to a specific anticancer agent. However, more 
specific PET tracers such as radiolabelled anticancer drugs 
provide a unique means for individualized treatment plan-
ning and drug development. Combining these specific tracers 
with other less specific tracers for blood flow (e.g. [15O]H2O) 
and efflux (e.g. [11C]verapamil) may provide additional in-
formation on drug specific resistance mechanisms.  
 This review aims to outline the current and future role of 
PET in prediction of tumour response as well as drug devel-
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opment. PET tracers for assessing different mechanisms of 
drug resistance will be reviewed. Furthermore, processes that 
influence drug delivery to tumours (biodistribution of a drug 
within the body, bioavailability in the circulation and tumour 
vascularisation) as well as processes that regulate drug up-
take by tumours (tumour pharmacokinetics, drug targets and 
efflux pumps) will be discussed.  
2. RADIOLABELLED ANTICANCER AGENTS FOR 
PET IMAGING 
 The heterogeneity of tumour response to anticancer drugs 
led to the suggestion that treatment failure might be due to 
differences in tumour pharmacokinetics. Obtaining such 
knowledge requires a non-invasive method to study drug 
pharmacokinetics in tumour tissue in vivo. The PET tech-
nique is ideally suited for such measurements. PET is able to 
monitor pharmacokinetics (measurement of drug distribution 
in tumours and normal tissue) as well as pharmacodynamics 
(measurement of efficacy) of drugs. Therefore, it has been 
attempted to radiolabel anticancer drugs, resulting in more 
specific radiotracers. 
2.1. Principles of Positron Emission Tomography  
  In contrast to morphological imaging modalities such as 
computed tomography (CT), PET is a functional and quanti-
tative imaging technique. PET is based on the use of biologi-
cally relevant compounds radiolabelled with short-lived 
positron emitting radionuclides such as carbon-11 (11C),  
nitrogen-13 (13N), oxygen-15 (15O) and fluorine-18 (18F) 
(Table 1). In clinical applications, a tracer (i.e. minute) 
amount of a labelled compound of interest (radiopharmaceu-
tical or radiotracer) is introduced into the patient, usually by 
intravenous injection. 
 A PET scanner can measure the concentration of ra-
diotracer in tissue. During its decay process, the radiotracer 
emits a positron which, after travelling a short distance (~ 
mm), encounters an electron from the surrounding environ-
ment. The two particles combine and "annihilate" each other 
resulting in the emission of two ?-rays (each 511 keV) in 
opposite directions. The acquisition of 3D images is based 
on external “in coincidence” detection of the emitted pair of 
?-rays. A valid annihilation event requires a coincidence 
between two detectors at opposite sides of the PET scanner. 
Accepted coincidences are allocated to so-called lines of 
response connecting the coincidence detectors. Counts along 
these lines of response are used to reconstruct an image of 
the distribution of radioactivity in the body. A correction for 
tissue attenuation is performed using a separate transmission 
scan or, in case of a PET-CT scanner, a CT scan [14]. For 
oncological applications, a PET-CT scanner allows for the 
combination of both anatomical (CT) and functional (PET) 
information, which significantly improves tumour localiza-
tion.  
 Other functional imaging techniques such as single 
photon emission computed tomography (SPECT) and gado-
linium-enhanced magnetic resonance imaging (MRI) are 
available to investigate compounds of interest in vivo. While 
the basic principles of SPECT are similar to those of PET, 
SPECT systems are generally less sensitive than PET sys-
tems and have a less accurate spatial resolution and attenua-
tion correction. Using gadolinium labelled compounds of 
interest, MRI could in principle be an alternative to PET. 
However, gadolinium-enhanced MRI has an inferior sensi-
tivity, does not enable absolute quantification and requires a 
considerable change of the molecular structure for gadolin-
ium labelling. Since PET has a high sensitivity and is able to 
quantify tracer concentrations in absolute units, it is superior 
for quantitative imaging.  
 
Table 1. Positron Emitters and their Half-Lifes 
Radioisotope Half-Life Positron Abundance (%) 
Carbon-11 20.4 min 100 
Nitrogen-13 10.0 min 100 
Oxygen-15 2.03 min 100 
Fluorine-18 109.8 min 97 
Iron-52 8.3 h 57 
Cobalt-55 17.5 h 77 
Copper-62 9.7 min 98 
Copper-64 12.7 h 19 
Gallium-66 9.5 h 56 
Gallium-68 68.1 min 90 
Bromine-75 98.0 min 76 
Bromine-76 16.1 h 57 
Rubidium-82 1.25 min 96 
Yttrium-86 14.7 h 34 
Zirconium-89 78.4 h 25 
Technetium-94m 53 min 72 
Indium-110m 69 min 63 
Iodine-124 4.2 days 25 
 
2.2. Positron Emitters 
 A number of positron emitters can be used for the devel-
opment of successful PET radiotracers (Table 1). 18F is the 
most widely used positron emitter. Its ability to provide high 
resolution images, relatively high labelling yields, and ac-
ceptable radiation dosimetry together with its physical half-
life (110 minutes) makes 18F a very popular positron emitter 
for clinical studies. Furthermore, 18F is widely available and 
can be used for automated routine synthesis. However, an 
important limitation of 18F is that a fluorine atom is not al-
ways present in the molecular structure. Therefore, incorpo-
ration of 18F may result in changed pharmacokinetics of the 
radiolabelled molecule as compared to the natural com-
pound.  
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 Radiotracers should be designed in such a way that their 
administration does not disturb the biochemical process un-
der investigation. It is important to realize that careful design 
and development of radiotracers is necessary to preserve 
target specificity and in vivo metabolism. For example, ra-
diolabelling 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by 
13N was not advantageous because it was converted too fast 
into [13N]N2 or [
13N]NO3 to permit differential retention in 
tumours [15, 16]. Fortunately, 11C labelling provided unique 
information on the pharmacokinetic and metabolic behaviour 
of BCNU in brain tumours [15, 17].  
 When the chemical structure of a radiotracer is identical 
to the clinically applied drug, pharmacokinetics of drug and 
radiotracer are assumed identical. 11C is an ideal nuclide for 
radiolabelling molecules of biological interest, because it can 
replace the abundantly present 12C-atom. Furthermore, the 
radiation dose of 11C is lower than that of 18F. This is due to 
a lower half-life as compared to 18F, even when corrected for 
the higher beta energy of 11C. Interestingly, both [18F]fluoro- 
paclitaxel and [11C]paclitaxel have been synthesized from the 
taxane paclitaxel [18-20]. Since the molecular structure of 
paclitaxel does not contain a fluoride atom, [11C]paclitaxel 
would be expected to provide clinically more relevant results 
than [18F] fluoropaclitaxel. Paradoxically however, only [18F] 
fluoropaclitaxel, has been used for studies in vivo [21-23]. 
This may be explained by the physical half-life of 11C (20 
minutes), which can be too short for measurement of tumour 
kinetics at late time points. 
2.3. Radiolabelled Anticancer Agents 
  In 1973, 5-fluorouracil (5-FU) was the first anticancer 
agent that was labelled with 18F [24]. Since then, pharma-
cokinetics of [18F]5-FU have been studied extensively [25-
39]. Furthermore, other conventional anticancer agents as 
well as targeted therapies such as tyrosine kinase inhibitors 
(TKIs) and monoclonal antibodies (MAbs) have been radio-
labelled with PET isotopes (Table 2). 
2.3.1. Radiolabelled Monoclonal Antibodies  
 Therapeutic MAbs represent a different class of antican-
cer agents that are targeted to receptors, antigens and growth 
factors on which the survival of tumours is dependent. Ra-
diolabelling therapeutic MAbs provides visualization and 
quantification of MAb biodistribution with PET (immuno-
PET). In choosing the most appropriate positron emitter, 
MAbs have different requirements than other anticancer 
agents. Intact MAbs have a long residence time in humans 
ranging from a few days to weeks. Therefore, the physical 
half-life of the positron emitter should be compatible with 
the time needed for a MAb or MAb fragment to achieve op-
timal tumour-to-nontumour ratios (typically 2-4 days and 2-6 
hours, respectively). Given these considerations, the follow-
ing positron emitters for labelling MAbs are under investiga-
tion: copper-64 (64Cu), yttrium-86 (86Y), bromine-76 (76Br), 
zirconium-89 (89Zr) and iodine-124 (124I). 76Br and 124I can 
be labelled directly to MAbs, while the other positron emit-
ters are coupled by indirect methods. However, the unfa-
vourable decay characteristics of many of these long-lived 
isotopes may affect PET image quality and quantitative ac-
curacy [40]. In general, radiolabelling MAbs is less difficult 
than radiolabelling other anticancer agents: MAbs are radio-
labelled by coupling isotopes (bridging), while other drugs 
are radiolablled by incorporation of a positron emitter into 
the molecule itself (exchange). This favourable characteristic 
of MAbs not only makes them promising to predict tumour 
response, but also to deliver therapeutic radioactivity by ra-
dioimmmunotherapy (RIT) [41].  
2.3.2. Ideal Labelling Position of an Anticancer Drug 
 Given the possibility of different radioactive metabolites, 
the ideal labelling position within a drug molecule should be 
considered. The effects of different labelling positions was 
investigated for 11C labelled temozolomide. The amount of 
[11C]CO2 in exhaled air was significantly higher for [4-car- 
bonyl-11C]temozolomide than for [3-N-methyl-11C]temozo- 
lomide [42]. Based on this study, it was postulated that label-
ling temozolomide in the 3-N-methyl position results in in-
corporation of the radiolabel into DNA, whereas labelling in 
the 4-cabonyl position results in loss of label as [11C]CO2 in 
expired air, prior to its incorporation in DNA.  
2.3.3. Considerations in Labelling Anticancer Drugs 
 In contrast to the relatively large number of radiolabelled 
anticancer agents that have been developed, a few studies 
have evaluated these tracers in vivo, particularly in humans. 
Complex synthesis, low radiochemical yield, low specific 
activity and low reproducibility might have been factors im-
peding further (pre-)clinical studies in vivo. Furthermore, 
this discrepancy may be explained by the formation of radio-
labelled metabolites, which complicates quantitative analy-
sis.  
 While the majority of targeted agents such as TKIs are 
administered orally on an outpatient basis, radiolabelled 
drugs are usually administered intravenously. Intravenous 
administration of the radiolabelled drug may result in differ-
ent pharmacokinetics, since orally administered drugs have 
to pass the gastrointestinal tract before entering the blood 
circulation. The development of radiolabelled anticancer 
agents for oral administration should be considered, as there 
is no principal objection against oral administration of PET 
tracers, provided the half-life is long enough.  
3. DRUG RESISTANCE 
 Drug resistance remains a significant problem that limits 
efficacy in cancer patients. Causes of resistance may be im-
paired drug delivery or an insufficient uptake by tumours. 
Drug delivery depends on distribution within the body, 
bioavailability in the circulation as well as transport into 
tumours. Bioavailability is regulated by binding to circulat-
ing cells and proteins, drug metabolism and total body clear-
ance. Furthermore, tumour vasculature controls drug deliv-
ery to tumours. In the tumour, drug pharmacokinetics and 
tumour targets such as hormone receptors regulate drug up-
take by the tumour. When drugs are substrates for efflux 
pumps, they can immediately be transported out of tumour 
cells. The following sections will elaborate on how PET 
tracers provide information on these different processes of 
tumour resistance (Fig. 1 and Table 3).  
3.1. Drug Delivery: Biodistribution  
 Biodistribution within the body influences the efficacy of 
an anticancer agent (Fig. 1A). The degree of drug uptake can 
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Table 2. Radiolabelled Anticancer Drugs for PET Studies 
Class of Drugs PET Tracer Mechanism of Action Tumour Uptake1 Predictive Value2 
[11C]BCNU4 [171, 172]  
DNA cross-linking, DNA polymerase repair, 
RNA synthesis inhibition 
Animals [173],  
Humans [15, 17, 174] 
Humans [17] 
[13N]BCNU4 [175]  
DNA cross-linking, DNA polymerase repair, 
RNA synthesis inhibition 
n.a.3 n.a.3 
[13N]cisplatin [176] 
DNA cross-linking, intercalation, DNA precursor 
inhibition, alteration of cellular membranes 
Humans [43] n.a.3 
[18F]fluorocyclophosphamide [177] DNA cross-linking Animals [44] Animals [44] 
A
lk
yl
at
in
g 
ag
en
ts
 
[11C]temozolomide [178, 179]  DNA methylation, alkylation Animals [46], humans [42] n.a.3 
[11C]daunorubicin [144, 154] 
DNA intercalation, preribosmal DNA and RNA 
inhibition, alteration of cell membranes, free 
radical formation 
Animals [145] Animals [145] 
[11C]docetaxel [180] Microtubule polymerization n.a.3 n.a.3 
[11C]paclitaxel [20] Microtubule polymerization n.a.3 n.a.3 
[18F]fluoropaclitaxel [18, 19] Microtubule polymerization 
Animals [21, 22], humans 
[23] 
Animals [22], 
humans [23] N
at
ur
al
 p
ro
du
ct
s 
[11C]vinblastine [56] 
Tubulin binding, inhibition of microtubule as-
sembly, dissolution of mitotic spindle 
Humans [56] Humans [56]  
[18F]capecitabine [181] Inhibition of thymidylate synthase n.a.3 n.a.3 
[11C]5-fluorouracil [182] Inhibition of thymidylate synthase n.a.3 n.a.3 
A
nt
im
et
ab
ol
ite
s 
[18F]5-fluorouracil [24, 183, 184] Inhibition of thymidylate synthase 
Animals [26, 27, 38, 39], 
humans [25, 28-37] 
Animals [38, 39], 
humans [29, 36] 
C
on
ve
nt
io
na
l c
yt
ot
ox
ic
 a
ge
nt
s 
T
I6
 
[11C]DACA5 [185] 
Binds DNA by intercalation and stimulates DNA 
cleavage by inhibition topoisomerase I and II 
Animals [47],  
humans [55, 122] 
n.a.3 
[18F]derivative of dasatinib [186]  Abl, Src, c-KIT Animals [186] n.a.3 
[18F]gefitinib [187] EGFR10 Animals [49] n.a.3 
[N-11C-methyl]imatinib [188] c-KIT, PDGFRs11 n.a.3 n.a.3 T
K
Is
7  
[18F]sunitinib [189] VEFGFRs12, PDGFRs10, c-KIT, flt-3 n.a.3 n.a.3 
[18F]fulvestrant [190] ER13 n.a.3 n.a.3 
SH
R
M
s8
 
[18F]fluorotamoxifen [191, 192] ER13 Humans [53] Humans [53] 
[64CU]abegrin [51]  ?v?3 intergrin Animals [51] n.a.3 
[89Zr]bevacizumab [54, 193] VEGF14 Animals [54] n.a.3 
[64CU]cetuximab [52] EGFR10 n.a.3 n.a.3 
[89Zr]cetuximab [194] EGFR10 Animals [194] n.a.3 
[68Ga]trastuzumab [48]15 HER216 Animals [48] n.a.3 
[76Br]bromo-NBI-trastuzumab [139, 
195]17 
HER216 n.a.3 n.a.3 
[89Zr]trastuzumab [138, 193] HER216 
Animals [138],  
humans [138] 
n.a.3 
T
ar
ge
te
d 
ag
en
ts
 
M
A
bs
9  
[89Zr]ibritumomab tiuxetan [41] CD20 
Animals [41] ,  
humans [41] 
n.a.3 
1 Tumour uptake, studies investigating the uptake of the labelled anticancer agent by tumours; 2 Predictive value, studies investigating the ability of the tracer to predict tumour re-
sponse; 3 n.a., to our knowledge not available; 4 BCNU, (1,3-bis(2-chloroethyl)-1-nitrosourea) (also known as carmustine); 5 DACA, N-[2-(dimethylamino)ethyl] acridine-4-
carboxamide (also known as XR5000); 6 TI, topoisomerase inhibitor; 7 TKIs, tyrosine kinase inhibitors; 8 SHRMs, selective hormone receptor modulators; 9 MAbs, monoclonal anti-
bodies; 10 EGFR, epidermal growth factor receptor; 11 PDGFR, platelet-derived growth factor receptor; 12 VEGFR, vascular endothelial growth factor receptor; 13 ER, oestrogen recep-
tor; 14 VEGF, vascular endothelial growth factor; 15 DOTA-conjugated Herceptin fragment (DCHF); 16 human epidermal growth factor receptor; 17 NBI, undecahydro-bromo-7,8-
dicarba-nido-undecaborate(1-). 
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Fig. (1). Potential processes of tumour resistance as revealed by a radiolabelled anticancer agent. The figure represents an example of a patient with a 
primary breast tumour who is injected with a radiolabelled anticancer agent. Several processes that influence tumour resistance are visualized. Drug 
delivery depends on distribution of drugs in the body (A), binding of drugs to cells and circulating proteins (B), formation of metabolites (C), and 
clearance by biliary and renal excretion. Furthermore, tumour vascularisation, which is dependent on angiogenesis and hypoxia, affect drug delivery 
(D1). Moreover, targets such as hormone receptors (D2) and efflux pumps (D3) regulate drug uptake by the tumour.  
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Table 3. Role of PET Tracers in Revealing Processes that Contribute to Drug Resistance 
Potential Process of Resistance PET Tracers Procedure Information Obtained 
Radiolabelled anticancer drugs 
Dynamic  
(whole body) PET 
Drug uptake in organs 
(e.g. brain) Biodistribution 
body (§3.1) 
Barriers prevent-
ing drug uptake  
Radiolabelled metabolites 
Dynamic (whole body) 
PET 
Uptake of metabolites in 
organs 
Binding to cells 
and proteins 
(§3.2.1) 
Radiolabelled anticancer drugs Serial blood sampling Blood plasma ratio  
Serial blood sampling Metabolites in blood Formation of 
metabolites 
(§3.2.2) 
Radiolabelled anticancer drugs Dynamic (whole body) 
PET  
Drug uptake in metabolic 
organs (e.g. liver) 
Serial blood sampling 
Clearance from  
circulating blood 
Circulating 
blood (§3.2) 
Clearance 
(§3.2.3) 
Radiolabelled anticancer drugs 
Dynamic (whole body) 
PET 
Drug uptake by liver, 
kidney, bladder 
Angiogenesis 
(§3.3.1) 
[18F]galacto-RGD, [18F]FB-RGD, 
[89Zr]bevacizumab, [64Cu]DOTA-VEGF, 
[64Cu]DOTA-VEGF(DEE), [64CU]abegrin 
PET pharmacokinetics 
Degree of tumour  
angiogenesis  
Tumour blood 
flow (§3.3.2) 
[15O]H2O, [
15O]CO2, [
62Cu]PTSM PET pharmacokinetics Tumour blood flow 
Drug 
delivery  
Tumour  
vasculature  
(§3.3) 
Hypoxia (§3.3.3) 
[18F]FMISO, [18F]FAZA, [18F]FETNIM, 
[62Cu]ATSM, [18F]FEAU 
PET pharmacokinetics Tumour hypoxia 
Tumour pharmacokinetics (§3.4) Radiolabelled anticancer drugs PET pharmacokinetics 
Drug pharmacokinetics 
in tumours 
Tumour targets (§3.5) 
[18F]gefitinib, [18F]FES,[18F]FENP, [18F]FDHT, 
[7?-18F]FMDHT, [18F]fulvestrant, 
[18F]fluorotamoxifen, [64CU]abegrin, 
[64Cu]cetuximab, [89Zr]cetuximab, 
[68Ga]trastuzumab, [76Br]bromo-NBI-trastuzumab, 
[89Zr]trastuzumab, [89Zr]ibritumomab tiuxetan 
PET pharmacokinetics Presence of drug targets Tumour 
uptake  
Drug efflux by efflux pumps (§3.6) 
[11C]colchicine, [11C]daunorubicin, 
[11C]loperamide, [94mTc]sestamibi, [11C]paclitaxel, 
[18F]fluoropaclitaxel, [11C]verapamil  
PET pharmacokinetics Presence of efflux pumps 
 
be organ specific and is dependent on physical aspects such 
as blood flow, active and passive diffusion, receptor binding 
and metabolism. A number of studies in animals and humans 
have successfully investigated biodistribution of several ra-
diolabelled anticancer drugs by sacrifice experiments [16, 
21, 38, 43-50] as well as PET imaging [21, 26, 37, 41, 49, 
51-56] (Fig. 2). In addition, serial whole-body PET scans 
may provide information on the biodistribution over time 
[57]. 
 Clinically, an anticancer drug can adequately control 
tumours in most organs of the body, but fail at specific sites 
such as brain and testis. Failure of disease control in the 
brain due to the inability of drugs to pass the blood-brain 
barrier is a common problem for anticancer agents [58, 59]. 
Biodistribution studies with the radiolabelled taxanes 
[18F]fluoropaclitaxel [21] and [11C]docetaxel [50] have re-
vealed that these drugs have low penetration in the brain, 
which is in line with clinically observed isolated tumour 
progression in the central nervous system [58]. 
 Knowledge of the biodistribution of a drug is important 
and may have implications for drug development as well as 
clinical treatment. For example, if a drug intended for brain 
tumours does not enter the brain in pre-phase I studies, 
modifications of the molecular structure of this drug should 
be attempted in order to increase cerebral uptake. Further-
more, if studies with radiolabelled drugs reveal that a drug 
does not appear to enter the brain in sufficient amounts, pre-
ventive strategies (e.g. prophylactic cranial irradiation for 
patients at high risk for brain metastases) may be applied 
[60]. 
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 Finally, the biodistribution of a drug is important to pre-
dict dose-limiting toxicities [55] and organ-protective bene-
fits [61]. High cardiac, brain, liver or vertebral body uptake 
may be indicative of potential dose-limiting toxicity to these 
organs. Such foreknowledge of toxicities is important to an-
ticipate potential toxicities in phase-I studies.  
3.2. Drug Delivery: Bioavailability  
 Knowledge of the bioavailability of a drug in the circulat-
ing blood may reveal potential mechanisms of resistance. If a 
drug appears to have a rather low bioavailability, this may 
have clinical implications for the dosing schedule of a drug: 
it may be necessary to administer a drug at higher frequen-
cies.  
3.2.1. Drug Binding 
 Tumour uptake is assumed to be driven by the free un-
bound concentration of drug in circulating blood [62]. High 
concentrations of free drug are required to guarantee its 
bioavailability, but interactions with blood constituents (e.g. 
cells and proteins) may affect their efficacy (Fig. 1B). For 
example, the cytotoxic agents cisplatin, paclitaxel and 
doxorubicin bind to albumin [63], while docetaxel and gem-
citabine can be found in erythrocytes [64]. After administra-
tion of a radiotracer, accumulation in circulating cells can 
easily be demonstrated by assessing the ratio of radioactivity 
in whole blood and plasma. Ideally, the blood:plasma ratio is 
1 [45], indicating that there is no accumulation of drug in 
circulating cells.  
3.2.2. Drug Metabolism  
 Metabolism can induce rapid breakdown of drugs, result-
ing in reduced bioavailability. Detailed information on the 
formation of metabolites for each individual drug is essen-
tial. PET studies with radiolabelled anticancer drugs can 
increase our knowledge of drug metabolism in several ways. 
From serial blood samples obtained during PET scanning, 
the fractions of radiolabelled parent drug and its radiola-
belled metabolites (Fig. 1C) can be measured using rapid 
high-performance liquid chromatography (HPLC) or liquid 
chromatography-mass spectrometry (LC-MS). If necessary, 
urine samples can also be collected and analysed.  
 Although PET lacks in vivo chemical specificity (i.e. the 
ability to distinguish radiolabelled parent drug from its radio-
labelled metabolites), it can be useful to investigate metabo-
lism by assessing radioactivity in highly metabolic organs 
such as the liver. PET can reveal whether tissue uptake in 
these organs parallels formation of metabolites and/or 
plasma clearance of radioactivity. In addition, PET studies 
investigating pharmacokinetics of several analogues of an 
anticancer drug can contribute to the selection of the most 
potent analogue based on the most favourable distribution, 
kinetics and metabolic stability [47]. In this way, PET stud-
ies have improved the understanding of the metabolism of 
several drugs [25-27, 37, 45].  
 Finally, pharmacokinetics of radiolabelled metabolites 
can be determined separately. This can be necessary to de-
velop and validate the pharmacokinetic model for the radio-
labelled parent compound or to follow the kinetics of a me-
tabolite [65]. [18F]FBAL, the radiolabelled anabolite of 
[18F]5-FU, has been isolated from rat urine and injected into 
other rats to investigate its pharmacokinetics using PET [66]. 
Obviously, a more appropriate approach for studies in hu-
mans would be to radiolabel chemically synthesized metabo-
lites of a drug.  
3.2.3. Drug Clearance  
 Drugs can be rapidly cleared from circulating blood by 
the hepatobiliary and renal systems (Fig 1A). During PET 
scanning, arterial and venous plasma sampling at several 
time points can provide information about drug clearance. 
Additionally, dynamic PET studies can provide information 
on time activity curves (TACs) in liver, kidney and bladder. 
High uptake in these organs immediately after injection of 
the radiolabelled drug may indicate rapid clearance and ex-
cretion. For most radiolabelled anticancer agents, high he-
 
 
 
 
 
 
 
 
 
 
Fig. (2). Time course of [18F]fluoropaclitaxel biodistribution in a normal male volunteer [23]. Reprinted from Nucl Med Biol, Vol. 34, 
Kurdziel et al., Imaging multidrug resistance with 4-[18F]fluoropaclitaxel, pages 823-31, copyright 2007, with permission from Elsevier.  
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patic and renal radioactivity has been measured in animal 
[16, 21, 38, 44-46, 48-50, 54] as well as human [23, 28, 30, 
32, 35, 36, 53, 55, 56] experiments.  
3.3. Drug Delivery: Tumour Vasculature 
3.3.1. Tumour Angiogenesis 
 Angiogenesis (Fig. 1D1), the formation of new blood 
vessels is essential for tumour growth and metastasis forma-
tion. Numerous stimulating and inhibitory growth factors 
regulate this complex process [67-69] in which vascular en-
dothelial growth factor (VEGF) is the key stimulator. Tu-
mour angiogenesis, especially VEGF signalling, has become 
an interesting therapeutic target and several antiangiogenic 
strategies have proven to be effective, including an anti-
VEGF MAb and several inhibitors of the tyrosine kinase 
(TK) VEGF receptor(s).  
 In general, tumours have immature vessels which are 
leaky, dilated and tortuous [68, 70]. These morphological 
abnormalities are accompanied by functional changes: in-
creased interstitial fluid pressure and decreased tumour oxy-
genation. High interstitial pressure contributes to limited 
drug penetration [71, 72], which may subsequently lead to 
drug resistance [73]. Originally, it was hypothesized that 
inhibitors of VEGF signalling would destroy tumour vascu-
lature, thereby depriving the tumour of oxygen and nutrients. 
A completely opposing theory was proposed by Jain. [70, 
74]. He suggested that VEGF inhibitors might prune imma-
ture vessels, leading to a more normalized vasculature (Fig. 
3). This theory is based on findings that the anti-VEGF MAb 
bevacizumab reduces blood flow, microvascular density, 
vascular volume and interstitial fluid pressure in tumours, 
but without a concurrent decrease in [18F]FDG uptake [75]. 
Jain ascribed the enhanced tumour response following a 
combination of bevacizumab and cytotoxic drugs to a nor-
malization effect. Inhibition of VEGF signalling in tumours 
might revert tumour vasculature to a more “normal” state 
[70, 76], i.e. less leaky, less dilated and less tortuous vessels 
with more normal basement membrane and decreased inter-
stitial fluid pressure. As a result, increased drug penetration 
would improve delivery and subsequent efficacy of chemo-
therapy. Continued or aggressive antiangiogenic therapy, 
however, may destroy tumour vessels, leading to tumour 
vasculature that is inadequate for drug and oxygen delivery. 
Therefore, exploring the normalization window is important 
to decide on the optimal timing of drug administration in 
combination schedules.  
 With the development of antiangiogenic therapies, inter-
est in imaging tumour vasculature is increasing. Many angi-
ogenic targets for PET imaging have been identified [77], 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Normal vasculature composed of mature vessels (A). Tumour vasculature is structurally and functionally abnormal, composed of 
immature vessels which are leaky, dilated and tortuous (B). Antiangiogenic therapy might prune immature vessels, leading to a more normal-
ized tumour vasculature (C). Sustained or aggressive antiangiogenic regimens may eventually prune away these vessels, resulting in a vascu-
lature that is both resistant to further treatment and inadequate for the delivery of drugs or oxygen (D). Reprinted by permission from Mac-
millan Publishers Ltd: Nature Medicine [74], copyright 2001. 
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including ?v?3 integrin [51, 78-90] and VEGF and its recep-
tors [54, 91, 92]. Although these PET tracers are at an early 
stage of development, their potential to quantitatively image 
expression of angiogenic targets may have future applica-
tions in patient stratification, drug development, and treat-
ment monitoring of antiangiogenic agents.  
 In the next two paragraphs PET tracers for assessing tu-
mour blood flow and hypoxia will be discussed. Although 
these tracers are not drug specific, they are important for 
prediction tumour response when used in combination with 
radiolabelled anticancer agents.  
3.3.2. Tumour Blood Flow 
 Tumour blood flow is an important determinant of drug 
tumour exposure, as indicated by several PET studies on 
[18F]5-FU and [11C]DACA [30, 31, 33, 55]. PET is a sensi-
tive technique to quantify tumour blood flow using [15O]- 
H2O, which can be administered either as inhaled [
15O]CO2 
[93, 94] or intravenous [15O]H2O [95-101]. Since [
15O]H2O 
is a freely diffusible tracer, its uptake specifically reflects 
tissue perfusion. However, for the same reason [15O]H2O 
cannot be used to measure vascular permeability, but other 
PET tracers such as [68Ga]transferrin [102] and [11C]methyl- 
albumin [103] are available for this purpose. [15O]H2O PET 
is a useful tool to investigate drug delivery of radiolabelled 
anticancer agents by correlating uptake of radiolabelled 
drugs with [15O]H2O perfusion data [30, 31, 33, 55] .  
3.3.3. Hypoxia 
 A consequence of abnormal tumour vasculature is that 
some tumour areas become hypoxic (Fig. 1D1) [104]. Fur-
thermore, hypoxia is considered to be caused by an impaired 
diffusion flux, as more oxygen is consumed by rapidly pro-
liferating cells. Hypoxia impairs drug delivery, and hence 
increases tumour resistance to systemic therapy [105, 106]. 
Hypoxia also induces resistance to radiotherapy, since the 
radiotherapy-induced DNA damage depends on the reaction 
of oxygen molecules with free-radicals [107]. Non-invasive 
tests to detect hypoxic areas within tumours may potentially 
have a major impact on treatment planning. For example, 
patients with highly hypoxic tumours could be directed to-
ward radiotherapy strategies with dose painting or trials with 
hypoxic cell sensitizers. Several PET tracers have been de-
veloped for imaging hypoxic regions within tumours, includ-
ing [18F]fluoromisonidazole ([18F]FMISO) [108-111], [18F]- 
fluoroazomycin  arabinoside ([18F]FAZA) [112, 113], [18F]- 
fluoroerythronitroimidazole ([18F]FETNIM) [114-116], [60Cu]- 
diacetyl-bis(N(4)-methylthiosemicarbazone) ([60Cu]ATSM) 
[117-119], and [18F]-2-fluoro-2deoxy-1beta-D-arabinofura- 
nosyl-5-ethyl-uracil ([18F]FEAU) [120]. For detailed informa-
tion on imaging of hypoxia, the reader is referred to another 
review in the current issue of Current Pharmaceutical De-
sign. When combined with radiolabelled anticancer agents, 
assessment of tumour hypoxia with PET may be of addi-
tional value to predict tumour response [108, 110, 116-119].  
3.4. Drug Uptake: Tumour Pharmacokinetics  
3.4.1. Predictive Value of Drug Uptake 
 Improved drug delivery to a tumour does not necessarily 
result in increased drug uptake. To have insight into tu-
moural drug kinetics, quantitative data on the time-activity 
pattern of radiolabelled anticancer drugs in tumours can be 
obtained using PET. The first study on [18F]5-FU, an ex-
periment in mice, demonstrated that drug-responsive tu-
mours had higher tumour-to-blood ratios of [18F]5-FU than 
drug-resistant tumours (20:1 versus 4:1) [38]. In another 
murine tumour model, carrying a 5-FU sensitive and a 5-FU 
resistant colorectal tumour xenograft in either flank, faster 
drug efflux was observed from the less responsive tumour 
xenograft [39]. In patients with liver metastases from colo-
rectal cancer, a dedicated pharmacokinetic model was devel-
oped to allow assessment of [18F]5-FU trapping using dy-
namic PET data [35]. This model was able to separate the 
total 18F pool in liver and aorta into its 5-FU and ?-fluoro-?-
alanine (FBAL) components (Fig. 4), illustrating that a suit-
able pharmacokinetic model can overcome the lack of 
chemical specificity of PET. In liver metastases from colo-
rectal cancer, it was demonstrated that patients with high 
[18F]5-FU standardized uptake values (SUV) were more 
likely to have a favourable outcome upon 5-FU treatment 
[29, 36]. A complicating factor in prediction of response was 
the varying [18F]5-FU uptake in the different metastases 
within the same patient [29, 35, 36]. Therefore, it is likely 
that in an individual patient the metastasis with the lowest 
drug uptake will determine patient outcome.  
 In addition, the predictive value of tumour uptake of 
[18F]fluorocyclophosphamide [44] and [18F]fluoropaclitaxel 
[22, 23] in animals, and [11C]BCNU [17], [18F]fluoropacli- 
taxel [23], [18F]fluorotamoxifen [53] and [11C]vinblastine 
[56] in humans has been investigated (Table 2). Although 
these studies, especially those in humans, were very limited 
in the number of subjects included, the preliminary results of 
these studies were promising; high uptake of the radiola-
belled anticancer agent appeared to be related to better tu-
mour response.  
 Special attention should be paid to the anticancer agent 
bevacizumab, an FDA approved MAb which binds to circu-
lating VEGF, preventing VEGF from binding to its receptor. 
Although VEGF circulates through the whole body, it has 
been shown that [89Zr]bevacizumab has higher uptake in 
tumours than in normal tissue [54]. This local deposition of 
[89Zr]bevacizumab in tumours reflects the high VEGF levels 
around tumours. It would be interesting to investigate effects 
of VEGFR TKIs, e.g. sunitinib or sorafenib, on local tumour 
deposition of [89Zr]bevacizumab, as administration of 
VEGFR TKIs is known to result in an increase of circulating 
VEGF. In a human xenograft model in mice, Ebos et al. 
[121] have demonstrated that the sunitinib-induced increase 
in VEGF levels had two origins, namely the human tumour 
(measured by human VEGF) and the mouse itself (measured 
by mouse VEGF). At present, the exact mechanism of the 
VEGFR TKI-induced increase of VEGF levels is still un-
clear. Future studies with [89Zr]bevacizumab may reveal the 
site of VEGF production in the body. 
 It is unknown whether tumour uptake of every radiola-
belled anticancer agent is representative of its clinically ob-
served efficacy, as several factors can confound the assess-
ment of tumour uptake using PET: high background levels 
adjacent to the tumour and uptake of radiolabelled metabo-
lites. Furthermore, tumour cells could be relatively more 
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sensitive to anticancer drugs and their active metabolites 
than normal cells, a phenomenon that cannot be solely de-
fined by tumour uptake. Larger studies in humans are neces-
sary to assess whether PET with radiolabelled anticancer 
agents can be used in routine clinical practice to individual-
ize treatment.  
3.4.2. Tracer Dose Versus Therapeutic Dose 
 Assessment of pharmacokinetics of drugs in vivo may be 
performed following administration of the radiolabelled drug 
alone (tracer dose with high specific activity) or mixed with 
cold (non-radioactive) drug (therapeutic dose with low spe-
cific activity). Preferably, tumour response should be pre-
dicted before initiating active treatment to prevent exposure 
to unnecessary toxicities. The administration of a radiola-
belled tracer dose may be valuable for this purpose. How-
ever, it should be investigated whether the distribution of a 
tracer dose is representative for a therapeutic dose. A few 
studies have explored the effects of a therapeutic dose on the 
kinetics of the radiolabelled tracer.  
 Therapeutic doses decreased [18F]5-FU [33] and [11C]vin- 
blastine [56] uptake by the liver and myocardial and splenic 
uptake of [11C]DACA [55, 122]. Tumour uptake of tracer 
doses of [18F]fluorocyclophosphamide [44] and [18F]fluo- 
ropaclitaxel [21] was not affected by the therapeutic dose, 
while the therapeutic dose increased [11C]DACA uptake by 
tumours [55, 122]. These studies demonstrated that the effect 
of the therapeutic dose on the tracer dose is highly dependent 
on the chosen drug. For determination of pharmacokinetics, 
a comparison between tracer and therapeutic dose should be 
performed for any new radiolabelled anticancer agent.  
3.5. Targets for Treatment: Tumour Receptors  
 Treatment failure can occur when a tumour lacks the tar-
get at which an anticancer drug is aimed (Fig. 1D2). Cur-
rently, immunohistochemistry assays are the basis for deter-
mining the status of tumour receptors to predict tumour re-
sponse. For example, the status of hormone receptors (oes-
trogen and progesterone) and human epidermal growth factor 
receptor 2 (HER2) is critical in the management of patients 
with breast cancer. Although immunohistochemistry is very 
cost-effective, it may have disadvantages in metastatic dis-
ease. Immunohistochemistry is usually performed on tissue 
from one tumour site (e.g. primary tumour or one metastatic 
site), because obtaining biopsies from all lesions is not pos-
sible. Non-invasive PET may be of additional value in as-
sessing the receptor status in all metastases.  
 Several tumour types have their own tumour specific 
targets. The neuro-endocrine tumour (NET) can express so-
matostatin receptors. Both unlabelled and radiolabelled so-
matostatin analogues have demonstrated clinical efficacy. 
Although, somatostatin receptor scintigraphy with Oc-
treoScan has been recommended as the best imaging tech-
nique for NETs, PET tracers for somatostatin receptors have 
been developed [123-128]. Given the superior resolution and 
sensitivity of PET, these latter tracers could be promising for 
treatment planning of neuro-endocrine tumours.  
 Hormone receptors are often over-expressed in breast 
cancer and prostate cancer. Several selective hormone recep-
tor modulators (SHRMs) such as tamoxifen and fulvestrant 
have proven to be effective in these cancer types. Numerous 
positron emitting tracers have been developed to image hor-
mone receptors: [18F]fluoroestradiol ([18F]FES) [129-131] 
for oestrogen receptors, 21-[18F] fluoro-16?-ethyl-19-norpro- 
gesterone ([18F]FENP) [132] for progesterone receptors, and 
16?-[18F]fluoro-5?-dihydrotestosterone ([18F]FDHT) [133, 
134] and [7?-18F]fluoro-17?-methyl-5?-dihydrotestosterone 
([7?-18F]FMDHT) [135] for androgen receptors. In breast 
cancer, the uptake value of [18F]FES was predictive of re-
sponse to hormonal therapy [129, 131].  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Formation of metabolites from 5-fluorouracil (5-FU).  
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 Amplification of the HER2 gene, a member of the erbB 
family, is present in approximately 25%-30% of breast can-
cer patients [136, 137] and is an adverse prognostic factor. 
The addition of trastuzumab to chemotherapy has signifi-
cantly improved the survival of HER2 positive breast cancer 
patients. Therapeutic MAbs have been developed against 
other members of the erbB family receptors. The epidermal 
growth factor receptor (EGFR) is over-expressed in many 
cancers and cetuximab has been approved for treatment of 
several cancers with EGFR expression, e.g. colorectal cancer 
and head and neck cancer. Currently, several PET tracers  
of trastuzumab and cetuximab are under investigation [48, 
52, 138, 139]. A high correlation was found between [64Cu] 
cetuximab uptake and EGFR expression [52].  
 Finally, radiolabelling TKIs may have a role in imaging 
receptors. However, uptake values of [18F]gefitinib, the posi-
tron emitter of the EGFR TKI gefitinib, did not correlate 
with EGFR expression levels of functional status. This was 
caused by a high non-specific cellular uptake [49], which is a 
common problem for PET receptor tracers. To determine 
whether tracer uptake is due to specific binding, the receptor 
can be saturated with unlabelled drug before administration 
of the tracer. Although TKIs have been named as targeted 
agents, they are known to have multiple targets. This charac-
teristic makes positron emitters of these drugs inappropriate 
for pharmacokinetic studies of specific receptors, but may 
still be valuable to investigate drug pharmacokinetics for 
drug development and prediction of tumour response. Addi-
tional reviews on imaging tumour targets can be found in 
other contributions to this issue of Current Pharmaceutical 
Design.  
3.6. Drug Efflux  
3.6.1. Multidrug Resistance Phenotype 
 On exposure to an anticancer agent, tumours may be-
come cross-resistant to a number of structurally and func-
tionally unrelated drugs. Multidrug resistance (MDR) in-
cludes a large number of anticancer agents such as etoposide, 
dactinomycin, anthracyclines, vinca alkaloids and paclitaxel. 
The MDR phenotype usually is a multifactorial phenomenon 
and many physiological mechanisms can neutralize the ac-
tion of anticancer agents. Known examples are decreased 
topoisomerase II enzyme levels, increased glutathione and 
glutathione S-transferase levels in tumours and the presence 
of efflux pumps (Fig. 1D3). The most clearly defined mecha-
nism of the MDR phenotype occurs as a result of the ampli-
fication of the MDR1 gene, which encodes the transmem-
brane glycoprotein, P-glycoprotein (Pgp) [140, 141]. This 
protein belongs to the ATP-binding cassette (ABC) family. 
ABC transporters are membrane proteins that utilize energy 
derived from the hydrolysis of ATP to drive transport of 
compounds over biological membranes. Three other ABC 
transporter proteins are known to contribute to the MDR 
phenotype: the protein associated to the multidrug resis-
tance-associated protein (MRP1), the canalicular multis-
pecific organ anion transporter (cMOAT) or MRP2, and the 
breast cancer resistance protein (BCRP).  
 Most of the mechanisms involved in MDR have first 
been described in normal tissues. Pgp plays an important role 
in the protection of cells from toxins. Pgp expression in 
normal tissue is variable and high levels are found at the 
blood-brain barrier, the proximal tubules of the kidney, the 
intestinal lumen and the biliary surface of hepatocytes [142, 
143]. High levels in the blood-brain barrier may explain the 
relatively high failure rate of anticancer agents in the brain.  
 Nowadays, several detection assays such as polymerase 
chain reaction, Northern blotting, Western blotting and im-
munohistochemistry are available to detect the MDR pheno-
type. However, these techniques have some known limita-
tions. Serial tumour biopsies are not generally performed for 
ethical reasons, resulting in lack of information on the MDR 
phenotype during and following treatment with anticancer 
drugs. Furthermore, assessment of mRNA and protein ex-
pression does not necessarily provide information on the 
functionality of MDR efflux pumps. It is evident that the 
MDR phenotype is not defined by expression of ABC trans-
porter proteins, but by the functional transport capacity of 
these efflux pumps.  
3.6.2. PET Imaging of the Multidrug Resistance Phenotype  
 PET studies can show in vivo functionality of MDR 
pumps and give quantitative information on Pgp-mediated 
pharmacokinetics [144-147]. In SPECT studies with [99mTc]-
sestamibi it was possible to predict tumour response to drugs 
affected by the MDR phenotype [148, 149]. These promising 
results have stimulated the development of PET tracers to 
image the MDR phenotype. Parallel to the SPECT tracer 
[99mTc]sestamibi, the PET tracer [94mTc]sestamibi has shown 
lower accumulation in drug-resistant tumours than in drug-
sensitive tumours [150]. In the development of PET tracers 
for MDR imaging, incorporation of conventional PET radi-
onuclides into drugs, that are known to interact with MDR, is 
a frequently used approach. Employing this strategy, various 
PET tracers including [11C]verapamil [146, 151], [11C] 
colchicine [152, 153], [11C]daunorubicin [144, 145, 154], 
[11C]loperamide [155], [11C] paclitaxel and [18F]fluoropacli- 
taxel [18-20] have been developed and applied to investigate 
the blood-brain barrier [147, 156, 157] as well as tumours 
[21, 23, 144, 145, 153]. For [11C]colchicine, a 2-fold differ-
ence between [11C]colchicine accumulation in sensitive and 
resistance tumours was observed [153]. In vitro experiments 
in ovarian carcinoma cell lines (A2780) and its Pgp express-
ing counterpart (A2780AD) demonstrated that the accumula-
tion of [11C]verapamil and [11C]daunomycin were a 5-fold 
and 16-fold higher in A2780 than in 2789AD, respectively 
[144]. [18F]fluoropaclitaxel was also able to differentiate bet- 
ween drug-sensitive and drug-resistant tumours in mice [23].  
 Pgp blockade with inhibitors such as cyclosporine A, 
PSC833 and tariquidar can give quantitative information on 
Pgp-mediated pharmacokinetics. Administration of cyclo- 
sporine increased tumour uptake of [18F]fluoropaclitaxel in 
MCF-7 breast cancer xenografts [21] as well as [11C]vera- 
pamil and [11C]daunomycin uptake in Pgp expressing small 
cell lung cancer [145].  
 Although effects of Pgp inhibitors on MDR have been 
disappointing in treatment of cancer patients [158], early 
diagnosis of MDR may serve to improve the efficacy of the 
chemotherapeutic intervention and the quality of life of pa-
tients. Furthermore, PET can be used to develop better in-
hibitors of MDR for clinical use.  
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4. BIOMODULATION 
4.1. Principles  
 Drug resistance to anticancer cancer agents has stimu-
lated research into approaches to increase the response rate. 
The ultimate goal of enhancing anti-tumour activity can be 
achieved by pharmacological manipulation of an anticancer 
drug by another compound, an approach that is named bio-
modulation. PET and its radiolabelled anticancer drugs can 
contribute to the rational development of biomodulation 
strategies by exploring whether tumour uptake of a radiola-
belled drug can be increased by biomodulating agents. Fur-
thermore, these studies can provide information on the ef-
fects of the biomodulator on plasma and organ pharmacoki-
netics as well as tumour blood flow [31, 33].  
4.2. Improving Drug Delivery 
 Limited drug penetration is an important mechanism of 
tumour resistance of anticancer drugs [72, 73]. Several drugs 
have been investigated to increase the delivery of radiola-
belled anticancer agents. PET studies using both [15O]H2O 
and [18F]5-FU have demonstrated that nicotinamide, car-
bogen as well as interferon-alpha were able to increase tu-
mour perfusion, while a decrease was observed with N-
phosphonacetyl-L-aspartate (PALA) [31, 33]. Moreover, 
administration of PALA and interferon-alpha induced 
changes in plasma, tumour and liver pharmacokinetics of 
[18F]5-FU [33]. Blood flow and tumour TACs increased 
upon interferon-alpha administration, whereas they de-
creased when PALA was administered. Although nicotina-
mide and carbogen administration increased perfusion and 
[18F]5-FU delivery to colorectal cancer metastases, these 
effects did not increase [18F]5-FU retention [31]. Interest-
ingly, tumour perfusion and consequently drug delivery may 
rely on organ specific perfusion. Moreover, biomodulators 
may affect organ perfusion selectively [159].  
 The induction of hypertension is another approach to 
improve drug delivery to tumours [160]. Treatment with 
angiotensin II, a drug that induces hypertension, resulted in a 
selective increase in [15O]H2O and [
62Cu]pyruvaldehyde bis-
(N4-methyl)thiosemicarbazone ([62Cu]PTSM) tumour blood 
flow without increasing blood flow in normal tissue [161-
163]. This phenomenon is due to a lack of autoregulation in 
tumour vessels [160]. Inhibitors of VEGF signalling are 
known to induce hypertension [164, 165], possibly due to 
peripheral vasoconstriction [166, 167]. PET studies with 
[15O]H2O are of interest to explore whether antihypertensive 
medication will abrogate the change in tumour blood flow 
and drug delivery induced by treatment with VEGF(R) in-
hibitors.  
 As mentioned before, therapy targeted against VEGF 
signalling may improve drug delivery [168] by normaliza-
tion of tumour vasculature [70]. Optimal scheduling of 
antiangiogenic therapy combined with chemotherapy re-
quires knowledge of the time window during which vessels 
become normalized. PET studies with [15O]H2O and radiola-
belled anticancer agents may be able to reveal effects of 
antiangiogenic treatment on drug uptake. Following antian-
giogenic treatment, an increase in tumour uptake of radiola-
belled agents may be expected as a result of better drug 
penetration and decreased interstitial fluid pressure. Since 
rapid changes in vascular parameters are seen during treat-
ment with VEGF(R) inhibitors [169], optimal timing of drug 
administration may be within hours after administrating a 
VEGF(R) inhibitor.  
4.3. Influencing Drug Metabolism  
 Rapid and extensive drug metabolism may limit the 
availability of a drug. Therefore, approaches have been in-
vestigated to decrease drug metabolism. The effects of enilu-
racil, an inhibitor that suppresses catabolism of 5-FU by in-
activating dihydropyrimidine dehydrogenase (DPD) (Fig. 4), 
have been explored using [18F]5-FU PET [25-27, 37]. Ca-
tabolism of 5-FU into anabolite fluorouridine-5’-monophos- 
phate (FUMP) and catabolite ?-fluoro-?-alanine (FBAL) can 
result in the loss of up to 80% of systemically administered 
drug [170]. Administration of eniluracil in patients decreased 
[18F]5-FU uptake in normal liver, indicating inactivation of 
DPD in the liver. Uptake in kidneys also decreased, while 
there was a large increase in plasma uracil and unmetabo-
lised [18F]5-FU. The uptake of radioactivity in tumours in-
creased, possibly as a result of improved tumour uptake of 
[18F]5-FU, its radiolabelled anabolites [66] or both [37].  
4.4. Further Considerations  
 Remarkably, clinical efficacy of biomodulation is not 
necessarily reflected by changes in tumour pharmacokinetics 
as measured by PET. Although combining 5-FU with folic 
acid has proven to be clinically effective, administration of 
folic acid did not cause any changes in the clearance and 
tumour pharmacokinetics of [18F]5-FU [33]. It is possible 
that improved clinical efficacy of biomodulation is not al-
ways mirrored by increased tumour retention of the antican-
cer agent, e.g. when the biomodulator has cytotoxic capaci-
ties and does not change the tumour pharmacokinetics of the 
investigated drug. In that case, PET should be seen as a tool 
that can reveal limitations of biomodulation strategies due to 
unforeseen disadvantages of pharmacokinetics. Moreover, 
the discrepancy between clinical efficacy and observed PET 
pharmacokinetics may be attributable to the inability of PET 
to discriminate between the radiolabelled parent drug and 
radiolabelled metabolite. Finally, poor reproducibility may 
cause conflicting results.  
 Before initiating paired biomodulation studies, repro-
ducibility of a specific radiotracer method should be as-
sessed. When small modulation effects are expected, high 
test-retest reproducibility is required. Only tracer doses, 
which are considered therapeutically ineffective, are suitable 
for biomodulation studies in the same patient. Otherwise, the 
effects of a therapeutic dose during the first PET scan (be-
fore biomodulation) may affect the results of the second PET 
scan (after biomodulation).  
 The promising role of PET to assess effects of biomodu-
lation strategies and to optimize the timing of treatment 
schedules highlights the need for tracer dose reproducibility 
studies.  
5. CONCLUSIONS 
 Development of personalised medicine for cancer is 
closely linked to techniques that can predict tumour response 
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to anticancer agents. Currently, a few PET studies with ra-
diolabelled anticancer agents have successfully investigated 
the predictive value of these tracers, indicating the promising 
role of radiolabelled anticancer agents for individualized 
treatment planning. For patient selection, PET may be of 
additional value as compared to immunohistochemistry, be-
cause it is drug specific, and can be used to assess drug up-
take in all tumour lesions and normal tissues non-invasively, 
quantitatively and over time (four dimensional). Further-
more, radiolabelled anticancer agents may contribute to 
morphological imaging techniques (e.g. CT) to monitor tu-
mour response: when the uptake of a radiolabelled anticancer 
agent decreases during treatment with the (unlabelled) agent, 
this may be the first sign of acquired tumour resistance. Drug 
resistance is a multifactorial phenomenon and radiolabelled 
anticancer agents can help to reveal several resistance path-
ways.  
 Integration of radiolabelled anticancer agents into selec-
tion of cancer patients may alter and improve therapeutic 
management, prevent unnecessary morbidity, and lead to 
substantial cost savings and, most importantly, better patient 
outcome. Furthermore, it is envisaged that PET studies with 
radiolabelled anticancer agents may be important for optimi-
sation and development of combined treatment schedules by 
investigating the optimal timing of drug administration.  
 However, PET studies with radiolabelled anticancer 
agents are expensive. The development of radiolabelled anti-
cancer agents takes time (especially in case of a complex 
synthesis) and requires special facilities (e.g. presence of a 
cyclotron) and highly qualified personnel. Furthermore, 
(pre)clinical evaluation of a new radiotracer can be logisti-
cally complex and the development of an appropriate phar-
macokinetic model can be challenging.  
 Despite these disadvantages, costs of PET studies could 
outweigh the costs of passing drugs through phase 1 and 2, 
since the potency of an anticancer agent would be known 
early during development. PET can speed up drug develop-
ment by providing valuable information on the biodistribu-
tion, bioavailability and pharmacokinetics of a new drug. 
More studies are warranted to investigate the promising role 
of PET with radiolabelled anticancer agents in drug devel-
opment and individualized treatment planning. 
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Quantiﬁcation of tumor perfusion using radioactive water
(H215O) and PET is a promising method for monitoring treatment
with antiangiogenic agents. However, use of dynamic H215O
scans together with a fully 3-dimensional clinical PET/CT scan-
ner needs to be validated. The purpose of the present study
was to assess validity and reproducibility of dynamic H215O
PET/CT scans for measuring tumor perfusion and validate
the quantitative accuracy of parametric perfusion images.
Methods: Eleven patients with non–small cell lung cancer were
included in this study. Patients underwent 2 dynamic H215O
(370 MBq) PET scans on the same day. During the ﬁrst scan,
arterial blood was withdrawn continuously. Input functions were
derived from blood sampler data and the ascending aorta as
seen in the images themselves (image-derived input function
[IDIF]). Parametric perfusion images were computed using a
basis function implementation of the standard single-tissue-
compartment model. Volumes of interest (VOIs) were delineated
on low-dose CT (LD-CT) and parametric perfusion images.
Results: VOIs could be accurately delineated on both LD-
CT and parametric perfusion images. These parametric per-
fusion images had excellent image quality and quantitative
accuracy when compared with perfusion values determined
by nonlinear regression. Good correlation between perfusion
values derived from the blood sampler input function and IDIF
was found (Pearson correlation coefﬁcient, r 5 0.964; P ,
0.001). Test–retest variability of tumor perfusion was 16%
and 20% when delineated on LD-CT and parametric perfusion
images, respectively. Conclusion: The use of ascending
aorta IDIFs is an accurate alternative to arterial blood sam-
pling for quantiﬁcation of tumor perfusion. Image quality
obtained with a clinical PET/CT scanner enables generation
of accurate parametric perfusion images. VOIs delineated on
LD-CT have the highest reproducibility, and changes of more
than 16% in tumor perfusion are likely to represent treatment
effects.
Key Words: tumor perfusion; PET-CT; radioactive water; lung
cancer; parametric perfusion images
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Angiogenesis, or formation of new blood vessels, is
essential for tumor growth, tumor progression, and develop-
ment of metastases (1,2). Many proangiogenic factors reg-
ulate this process, with vascular endothelial growth factor
being the most important. Consequently, it has been shown
that antiangiogenic therapy, particularly when targeting the
vascular endothelial growth factor signaling pathway, pro-
vides a survival beneﬁt in patients with solid malignancies
including non–small cell lung cancer (NSCLC) (3–9).
Response evaluation of antiangiogenic drugs, however,
remains a challenge, because response to antiangiogenic
therapy is not necessarily reﬂected by drug-induced changes
in tumor size (10–13). Therefore, new imaging tools are
needed to assess the efﬁcacy of antiangiogenic drugs to select
cancer patients who may beneﬁt from those agents early dur-
ing treatment.
Previous studies have shown that quantiﬁcation of tumor
perfusion using radioactivewater (H215O) and PET is a promis-
ing method to monitor antiangiogenic treatment (14–18). The
short half-life of 15O enables serial measurements within a sin-
gle scan session. Because contrast between tumor and back-
ground in H215O images usually is low, these scans often are
followed by a second PET scan using, for example, 18F-FDG
(19) or 3-deoxy-3-18F-ﬂuorothymidine (18F-FLT) (20). These
additional scans are required to deﬁne appropriate regions of
interest, which subsequently are copied onto theH215O images.
To date, most PET scanners are combined with CT, which
enables tumor localization on a low-dose CT (LD-CT) scan.
In addition, these scanners allow for 3-dimensional (3D) PET
with much lower doses of H215O (,400 MBq) than that (.1
GBq) usually administered in the case of older stand-alone
2-dimensional (2D) PET scanners. At present, however, PET/
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CT has primarily been used for whole-body 18F-FDG studies
using, at best, a semiquantitative approach for analyzing data.
Only a few studies have addressed full quantiﬁcation of tracer
kinetics using a 3D PET/CT scanner.
Although test–retest variability of H215O perfusion studies
has been reported previously for a stand-alone 2D scanner,
those results are not necessarily valid for a state-of-the-art
3D PET/CT scanner because of the higher scatter fraction of
the PET/CT device. On the other hand, the superior image
quality of 3D PET/CT provides the potential of performing
analyses at the voxel level, thereby generating parametric
perfusion images.
The aims of the present study were to validate the use of
an image-derived input function (IDIF) in the case of 3D
acquisitions, assess the accuracy of parametric perfusion
images, and assess test–retest variability of tumor perfusion
measured using a state-of-the-art PET/CT scanner.
MATERIALS AND METHODS
Patients
Between September 2008 and May 2009, 11 patients (9 men, 2
women; mean age 6 SD, 59 6 12 y) with advanced-stage NSCLC
participated in this prospective study. Inclusion criteria were 18 y of
age or older, life expectancy of at least 12 wk, a malignant lesion of
at least 1.5 cm in diameter in the chest, Karnofsky performance
status scale score greater than 60%, thrombocyte count more than
100 · 109 L21, and hemoglobin more than 6.0 mmolL21. Exclusion
criteria included patients who were claustrophobic, pregnant, or lac-
tating; had metal implants (e.g., pacemakers); used coumarin deriv-
atives or inhibitors of thrombocyte aggregation; were undergoing
concurrent treatment with experimental drugs; or had participated
in a clinical trial with any investigational drug within 30 d before
study entry. Before inclusion, each patient signed a protocol-speciﬁc
informed consent form that had been approved by the Medical Ethics
Review Committee of the VU University Medical Center.
Scanning Protocol
Studies were performed on a Gemini TF-64 PET/CT scanner
(Philips) (21). This scanner has an axial ﬁeld of view of 18 cm,
divided into 45 contiguous planes. Ten of 11 patients underwent 2
H215O scans on the same day. Patients received an indwelling
radial artery catheter for arterial blood sampling and a venous
catheter for tracer injection. Patients were positioned supine in
the scanner bed, with both tumor and aortic arch in the center
of the axial ﬁeld of view. Elastic body-restraining bandages were
used to minimize movement during scanning. After a 50-mAs LD-
CT scan for attenuation correction, a 10-min dynamic scan was
started simultaneously with an intravenous injection of 370 MBq
of H215O (22) (5 mL at 0.8 mLs21), followed by 35 mL of saline
(2 mLs21). Data were normalized, and all appropriate corrections
were applied for dead time, randoms, scatter, and attenuation.
Each emission scan was reconstructed into 26 frames (1 · 10, 8
· 5, 4 · 10, 2 · 15, 3 · 20, 2 · 30, and 6 · 60 s) using the 3D row-
action maximum-likelihood reconstruction algorithm with a
reconstructed resolution of 6.5 mm.
Arterial Blood Sampling
To compare the use of an IDIF with the blood sampler input
function (BSIF), arterial blood was sampled during the ﬁrst scan.
Arterial blood was withdrawn continuously at a rate of 5 mLmin21
during the ﬁrst 5 min and 1.7 mLmin21 thereafter, using an online
detection system (23). In addition, at 5, 8, and 10 min after injection,
10 mL arterial blood samples were collected manually. These samples
were counted in awell-counter thatwas cross-calibrated against thePET
scanner and were subsequently used to calibrate the online blood curve.
Input Functions
Volumes of interest (VOIs) (diameter, 1 cm) were drawn over the
ascending aorta in approximately 10 consecutive image planes of
the frame in which the ﬁrst pass of the bolus was best visualized.
Projection of the resulting VOI onto all image frames yielded the
arterial time–activity curve or IDIF CA(t). Applying a similar
approach to the right ventricular cavity and pulmonary artery pro-
vided a time–activity curve for the pulmonary circulation CV(t).
Blood sampler data were corrected for delay and dispersion by
ﬁtting the early part of the sampler curve to the ascending aorta
time–activity curve, convolved with a single exponential dispersion
function and including a delay parameter. The sampler curve was
subsequently shifted and corrected for dispersion using these ﬁtted
delay and dispersion constants. The resulting delay- and dispersion-
corrected sampler curve was calibrated using the manually drawn
samples, ﬁnally providing the BSIF.
Parametric Images
Parametric perfusion images were generated using IDIFs and a
basis function implementation of the standard single-tissue-
compartment model (24–26), applying corrections for both arterial
and pulmonary artery blood volumes (27):
CPETðtÞ5ð1 VA  VVÞ  F  CAðtÞ  e
F
VT
t1VACAðtÞ1VVCVðtÞ;
Eq. 1
where F represents perfusion, VA arterial blood volume, VV pul-
monary circulation blood volume, and VT the distribution volume
or partition coefﬁcient of water in tumor tissue. In the present
study, 30 logarithmically spaced precomputed basis functions with
F/VT values ranging from 0.1 to 2 min21 were used. Parametric
perfusion images were postsmoothed with a gaussian ﬁlter of
10 mm in full width at half maximum.
Deﬁnition of Tumor VOIs
All LD-CT images were converted to ECAT 7 format. Tumor
VOIs were drawn on the LD-CT image by an experienced nuclear
medicine physician unaware of patients’ histories and outcomes,
using the CAPP software package (CTI/Siemens). On parametric
perfusion images, focally enhanced perfusion other than physiologic
perfusion was interpreted as potentially malignant. VOIs were
deﬁned by the same nuclear medicine physician using software
developed in-house, applying a semiautomatic threshold technique
(50% of the maximum pixel value with correction for local back-
ground) (28).
Data Analysis
All tumor VOIs were projected onto the dynamic H215O
images, thereby generating tumor time–activity curves. In addi-
tion, VOIs deﬁned on parametric perfusion images were copied
to parametric VT images. Using nonlinear regression (NLR),
tumor time–activity curves were ﬁtted to the standard single-
tissue-compartment model for H215O (Eq. 1) with or without
(i.e., VV set to 0) correction for pulmonary circulation blood
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volume, yielding F and VT. Perfusion values obtained using BSIF
and IDIF were compared for CT-based VOIs. The need to include
a correction for pulmonary circulation blood volume in the model
was assessed for CT-based VOIs using the Akaike and Schwartz
criteria (29,30). The quantitative accuracy of parametric images
was validated by comparing (unweighted) average VOI perfusion
and distribution volume values directly extracted from the para-
metric images to tumor perfusion and distribution volume
obtained by NLR of the corresponding tumor time–activity curve.
Correlations were explored using the Pearson correlation coefﬁ-
cient. Level of agreement between test and retest values was
determined using an intraclass correlation coefﬁcient (ICC) with a
2-way randommodel. The Bland and Altman method (31) was used to
analyze the difference between the 2 measurements and to test the
repeatability of each measurement. The repeatability coefﬁcient was
calculated as 1.96 times the SD of the differences. For comparison, the
repeatability coefﬁcient is also given as a percentage of the average
value of the 2 measurements. For correlation and test–retest analyses,
only the primary tumor in each patient was used, whereas only IDIF-
based values were entered into test–retest analyses.
RESULTS
Delineation of Tumors
Eleven primary tumors and 7 mediastinal metastases
were in the ﬁeld of view of the dynamic scan. Ten of 11
primary tumors could be delineated on the LD-CT scan
(Supplemental Table 1; supplemental materials are avail-
able online only at http://jnm.snmjournals.org), whereas 1
could not be deﬁned because of postobstruction atelectasis,
which could not be distinguished from the primary tumor.
In addition, 3 of 7 mediastinal metastases could be delin-
eated on the LD-CT scan. On the parametric perfusion
images, fewer lesions could be deﬁned than on the LD-
CT scan (11 vs. 13 VOIs; Supplemental Table 2).
IDIF Versus Arterial Sampling
Arterial sampling was successfully performed, except for
1 patient in whom online sampling was difﬁcult because of
formation of a thrombus in the line of the detection system.
Therefore, this patient was excluded from BSIF analyses.
The IDIF curve was isomorphic to the BSIF curve (Fig. 1).
However, the IDIF peak was sharper because of dispersion
in the blood-sampling system. A high correlation between
IDIF and blood sample activity concentrations was found
(r 5 0.954; P , 0.001). Tumor perfusion and VT based on
the ascending aorta IDIF showed high correlations with
corresponding values based on arterial sampling (r 5
0.964 and 0.835, respectively; P , 0.001). In addition,
agreement between BSIF- and IDIF-based tumor perfusion
and distribution volume values was high, with ICCs of
0.956 (95% conﬁdence interval [CI], 0.819–0.990) and
0.850 (95% CI, 0.491–0.964), respectively. Figure 2
presents scatter and Bland–Altman plots of tumor perfusion
derived using ascending aorta IDIF vs. BSIF.
Pulmonary Blood Volume Correction
In 9 of 11 patients, VOIs for pulmonary blood volume
correction were deﬁned in both the pulmonary artery and
the right ventricular cavity. In 1 patient, VOIs could be
deﬁned only in the pulmonary artery because the right
ventricular cavity was not in the ﬁeld of view. In another
patient, both the pulmonary artery and the right ventricle
were outside the ﬁeld of view, and the superior caval vein
was used instead. In all delineated lesions (n 5 24), Akaike
and Schwarz analyses showed better ﬁts when a pulmonary
blood volume parameter was included, but its inclusion did
not affect absolute values of tumor perfusion (correlation
between tumor perfusion with and without pulmonary
blood volume parameter: r 5 1.000; P , 0.001).
Validation of Parametric Images
Perfusion and distribution volumes as determined di-
rectly from the parametric images, using an ascending aorta
IDIF, were compared with those obtained using the NLR
of Equation 1 to the VOI time–activity curve. Correlation
(F: r 5 0.979; VT: r 5 0.950; P , 0.001) and agreement
(F: ICC, 0.979; 95% CI, 0.917–0.995; VT: ICC, 0.949; 95%
CI, 0.791–0.988) between parametric images and NLR
were excellent. Figure 3 shows scatter and Bland–Altman
plots of tumor perfusion values as determined directly from
the parametric images versus values determined by NLR
of tumor time–activity curves. Furthermore, parametric
images clearly showed increased perfusion in the tumor
(Fig. 4).
Test–Retest Reproducibility
When VOIs were deﬁned on the LD-CT scan, tumor
perfusion, distribution volume, and tumor size showed good
reproducibility, with ICCs of 0.997 (95% CI, 0.986–0.999),
0.880 (95% CI, 0.560–0.972), and 0.998 (95% CI, 0.993–
FIGURE 1. Typical example of IDIF based on ascending aorta and
corresponding BSIF (not corrected for dispersion) derived from
same dynamic dataset.
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1.000), respectively (Table 1). When VOIs were deﬁned on
parametric perfusion images, reproducibility of tumor per-
fusion was comparable (ICC, 0.980; 95% CI, 0.915–0.996).
For parametric-based VOIs, the ICCs for tumor size and
distribution volume were 0.811 (95% CI, 0.367–0.954) and
0.871 (95% CI, 0.532–0.969), respectively. In addition, per-
fusion values directly taken from parametric perfusion
images showed good reproducibility, with an ICC of 0.977
(95% CI, 0.901–0.995). Distribution volumes taken directly
from parametric VT images, using VOIs deﬁned on perfusion
images, showed slightly better reproducibility (ICC, 0.908;
95% CI, 0.649–0.979) than VT values calculated using NLR.
Figure 5 shows Bland–Altman plots of tumor perfusion val-
ues for CT- and parametric-based VOIs. The repeatability
coefﬁcient of tumor perfusion was 16% and 20% when
delineated on LD-CT and parametric perfusion images,
respectively (Table 1).
Correlation Between CT- and Parametric-Based VOIs
In 8 of 10 primary tumors, tumor perfusion was higher
for parametric-based VOIs than for CT-based VOIs (0.296
0.23 mLcm23min21 vs. 0.35 6 0.17 mLcm23min21;
mean 6 SD). Nevertheless, correlation between both sets
of perfusion data was high (r 5 0.835; P 5 0.003).
DISCUSSION
In this study, the use of low-dose dynamic H215O scans for
assessment of tumor blood ﬂow using a clinical, fully 3D
PET/CT scanner was evaluated. In NSCLC patients, the LD-
CT scan enabled delineation of appropriate VOIs, which
makes additional PET scans with 18F-FDG or 18F-FLT for
delineation of VOIs obsolete, resulting in decreased radiation
burden and scanning time. In addition, quantitative H215O
PET/CT tumor perfusion measurements had excellent repro-
ducibility. Image quality obtained with the relatively low
dose of 370 MBq of H215O (compared with the usual dose
of 1,100 MBq for 2D scanners) was such that accurate para-
metric perfusion images with good statistics could be pro-
duced. On the basis of the present results, changes in tumor
perfusion of more than 16% in CT-based VOIs or 20% in
parametric-based VOIs are likely to reﬂect treatment effects.
For quantiﬁcation of perfusion, an arterial input function
is needed. This can be obtained using either arterial
sampling or an IDIF. Arterial sampling is invasive and
limits clinical applicability. On the other hand, IDIFs are
prone to partial-volume effects and can be used only when a
large structure containing arterial blood is visible in the
ﬁeld of view. In the present study, noninvasive IDIFs of the
FIGURE 2. Scatter (A) and Bland–Altman
(B) plots of tumor perfusion derived using
ascending aorta IDIF vs. BSIF. Solid line
(A) represents linear ﬁt through data points.
Dotted lines (B) represent 6 1.96 · SD val-
ues. Difference was absolute change
between test and retest scans, and mean
perfusion was mean tumor perfusion of test
and retest scans.
FIGURE 3. Scatter (A) and Bland–
Altman (B) plots of tumor perfusion values
directly from parametric images vs. perfu-
sion values determined by NLR of tumor
time–activity curves, using 50% isocontour
VOIs deﬁned on parametric perfusion
images. Parametric images were generated
using IDIFs. Solid line (A) represents linear ﬁt
through data points. Dotted lines (B) repre-
sent 6 1.96 · SD values. Difference was
absolute change between test and retest
scans, and mean perfusion was mean tumor
perfusion of test and retest scans.
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ascending aorta were compared with arterial concentrations
obtained using invasive BSIFs. Resulting tumor perfusion
values agreed well with each other (Fig. 2), indicating that
use of ascending aorta IDIFs is a valid noninvasive alterna-
tive to arterial blood sampling. Although manual IDIF def-
inition is time-consuming, automated IDIF deﬁnition has
recently been shown to be feasible for myocardial perfusion
imaging with H215O (32) and may similarly be applied for
quantiﬁcation of tumor perfusion in the thorax.
Inclusion of a pulmonary blood volume parameter in Equa-
tion 1 resulted in improved ﬁts, whereas tumor perfusion
values were not affected signiﬁcantly. Because blood vessels
of the pulmonary circulation are erroneously depicted as
areas with high perfusion in parametric images when no
pulmonary blood volume parameter is applied, inclusion of
a pulmonary blood volume parameter also improves the qual-
ity of parametric images. Consequently, the application of
this parameter facilitates delineation of tumors that are close
to large blood vessels on parametric images.
In contrast to a stand-alone 2D PET scanner (20), the
present 3D PET/CT scanner did produce parametric perfu-
sion images of good quality. This can be explained by
differences in noise-equivalent count rates. During the ﬁrst
pass of 370 MBq of H215O, the observed noise-equivalent
count rate was 5 times higher than that during the ﬁrst pass
of 1,100 MBq of H215O on the stand-alone 2D PET scanner
used previously (20). This difference is mainly due to the
much lower random coincidence rate on the 3D PET/CT
scanner, because of its narrower coincidence time window
(6 vs. 12 ns) and the use of lutetium yttrium orthosilicate
instead of bismuth germinate crystals.
As can be seen from Figure 3, measured perfusion was
variable between different tumors, as is in line with pre-
vious studies investigating perfusion in lung cancer (19,20).
In addition, reproducibility of perfusion measurements
using the present 3D PET/CT scanner was comparable to
the results of a previous study in NSCLC patients on a
stand-alone 2D PET scanner (20). In that study, an addi-
tional 18F-FLT PET scan was used for delineation of
lesions, and changes of more than 18% in tumor perfusion
and 32% in distribution volume were likely to represent
biologic effects (20). The reproducibility of distribution
volume, however, was better using a 2D PET scanner than
using CT-based values of the PET/CT scanner, which had a
reproducibility of 47%. However, the reproducibility of dis-
tribution volume was better than for CT-based VOIs and
more comparable to the previous study for VOIs deﬁned on
parametric perfusion images.
FIGURE 4. PET/CT images of primary
tumor in 54-y-old man (patient 6) with meta-
static NSCLC. Parametric perfusion image
(A; 10 mm in full width at half maximum ﬁlter)
shows increased perfusion in primary tumor
in left upper lobe. B and C represent corre-
sponding CT and PET/CT fusion images,
respectively.
TABLE 1
Reproducibility of Tumor Measurements Using Dynamic H215O PET/CT Scans
Repeatability coefﬁcient
Measurement ICC 95% CI Absolute value Relative value (%)
Tumor perfusion (F)
CT-based VOI, NLR 0.997 0.986–0.999 0.030 mLcm23min21 15.8
Parametric VOI, NLR*,† 0.980 0.915–0.996 0.074 mLcm23min21 19.9
Direct parametric VOI*,‡ 0.977 0.901–0.995 0.084 mLcm23min21 40.9
Volume of distribution (VT)
CT-based VOI, NLR 0.880 0.560–0.972 0.20 mLcm23 47.3
Parametric VOI, NLR*,† 0.871 0.532–0.969 0.19 mLcm23 37.0
Direct parametric VOI*,‡ 0.908 0.649–0.979 0.17 mLcm23 36.8
Tumor size
CT-based VOI 0.998 0.993–1.000 14.2 cm3 27.3
Parametric VOI* 0.811 0.367–0.954 29.5 cm3 98.6
*Parametric perfusion images with 10-mm ﬁlter were used.
†Values were obtained by projecting parametric-based VOI onto dynamic H215O images.
‡Values were obtained by direct extraction from parametric image.
n 5 9 lesions.
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When compared with parametric-based VOIs, application
of CT-based VOIs resulted in larger tumor volumes with
lower perfusion values. Delineation of lesions on the LD-CT
scan results in average perfusion values over the whole CT
volume, which may include nonvital necrotic tissue (Fig. 6).
Parametric perfusion images, on the other hand, preserve
spatial information and enable visual assessment of a perfu-
sion image, allowing selective delineation of well-perfused
parts in heterogeneous tumors. In addition, delineation on a
PET scan with a second tracer such as 18F-FDG or 18F-FLT
(20) may facilitate the identiﬁcation of vital tumor tissue,
giving perfusion only in metabolically active or only in
highly proliferative tumor tissue, respectively.
Although dynamic H215O PET/CT measurements are
feasible, there are 2 practical limitations to use in NSCLC
patients. First, the image quality of an LD-CT scan may be
too low to adequately distinguish tumor from mediastinal
structures. In addition, high (physiologic) perfusion in post-
obstruction atelectasis may even mirror tumor perfusion on
parametric perfusion images. In such cases, a diagnostic CT
scan with a higher radiation dose or an additional 18F-FDG
PET scan may be required to deﬁne lesions accurately.
Second, quantiﬁcation of tumor perfusion within the thorax
may be affected by respiration, resulting in respiration-
averaged images with lower perfusion values. Pulmonary
gating might overcome this issue but remains a challenge
when used in combination with dynamic scans.
Several methods are available to delineate VOIs on
H215O PET/CT scans, including LD-CT, parametric perfu-
sion images, and even PET scans with a second tracer.
However, it is currently not clear which delineation method
best characterizes treatment-induced changes in tumor per-
fusion, especially in the case of spatially varying heteroge-
neous responses. Therefore, studies are warranted that
compare the predictive value of these different delineation
methods in patients treated with antiangiogenic agents.
CONCLUSION
In NSCLC patients, it is feasible to assess tumor perfusion
using dynamic H215O PET on a clinical PET/CT scanner. In
this case, the use of an ascending aorta time–activity curve as
the input function is an accurate alternative to arterial blood
sampling. The high image quality allows generation of para-
metric perfusion images with good statistics. Tumors can
conveniently be delineated on both LD-CT and parametric
perfusion images, but CT-based VOIs result in the highest
reproducibility of tumor perfusion.
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FIGURE 5. Bland–Altman plots of tumor
perfusion based on delineation on LD-CT
scan (A) and parametric perfusion images
(B). Dotted lines represent 6 1.96 · SD val-
ues. Difference was percentage change
between test and retest scans, calculated
by subtracting values of morning scans from
those of afternoon scans; mean perfusion
was mean tumor perfusion of test and retest
scans.
FIGURE 6. PET/CT images of primary
tumor in 73-y-old man (patient 3) with meta-
staticNSCLC. Parametric perfusion image (10
mm in full width at half maximum ﬁlter) shows
high perfusion in peripheral zone of tumor (A;
arrow) but low perfusion in central region. B
and C represent corresponding CT and PET/
CT fusion images, respectively. Because of
dispersion, high perfusion is erroneously
shown in descending aorta (*).
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Dear Sir,
With interest we read the study by Cho et al [1], evaluating
the usefulness of FDG PET/CT for differentiating malig-
nant endobronchial lesions with distal atelectasis from
benign bronchial stenosis. In this retrospective study, they
adequately demonstrated the additional value of FDG PET/
CT in this challenging clinical problem. Besides differen-
tiation of endobronchial lesions, accurate discrimination
between malignant tumours and atelectatic lung tissue can
facilitate the definition of radiotherapy target volumes. As a
result, the size of radiotherapy fields can be decreased [2],
potentially reducing radiotherapy-induced side-effects.
For these purposes, the PET technique may be of
additional value to discriminate the obstructive lesion from
the atelectatic lung tissue. Although Cho et al [1]
mentioned different patterns of FDG uptake in atelectatic
lung tissue, we wonder whether the FDG uptake in the
obstructive lesions could be adequately distinguished from
the FDG uptake in the atelectatic lung tissue. As FDG
uptake is dependent on perfusion for its delivery to tissue,
variation in tissue vascularity may contribute to variable
FDG uptake in obstructive atelectasis. In a previous PET/
CT study, we quantified tumour perfusion in lung cancer
patients using radiolabelled water ([15O]H2O) [3]. The
measured perfusion values in atelectatic lung tissue differed
significantly as compared with perfusion values in malig-
nant tumours. Figure 1 shows an example of a patient with
relatively high perfusion in atelectatic lung tissue as
compared with the malignant tumour. These observations
suggest that perfusion measurements may have additional
value to discriminate atelectatic lung tissue from malignant
lesions. Therefore, we believe that additional perfusion
measurements of atelectatic lung tissue may improve
diagnosis and radiotherapy planning of malignant endo-
bronchial lesions.
A reply to this letter can be found at doi:10.1007/s00330-011-2170-y.
A. A. M. van der Veldt (*) :M. Lubberink :A. A. Lammertsma
Department of Nuclear Medicine & PET Research,
VU University Medical Center,
P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
e-mail: aam.vanderveldt@vumc.nl
E. F. Smit
Department of Pulmonary Diseases,
VU University Medical Center,
Amsterdam, The Netherlands
Eur Radiol (2011) 21:2148–2149
DOI 10.1007/s00330-011-2172-9
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[11C]DocetaxelandPositronEmission
Tomography for Noninvasive
Measurements of Docetaxel Kinetics
To the Editor: We read with great interest the article by
Bradshaw-Pierce and colleagues (1) reporting a physiologically
based pharmacokinetic (PBPK) model for docetaxel. Because
docetaxel is frequently used for the treatment of several cancers,
more often, recently, in combination with other anticancer
agents, a comprehensive technique to evaluate the effects of
other agents on docetaxel pharmacokinetics and pharmacody-
namics is required. In view of this development, the PBPK
model for docetaxel by Bradshaw-Pierce and colleagues is of
great value. This model was developed based on measurements
of docetaxel concentrations in plasma and some tissues of mice
by using liquid chromatography–tandem mass spectrometry.
We would like to point out, however, that the method
used might not be ideal for collecting the data to develop a
PBPK model. Although liquid chromatography–tandem mass
spectrometry is a sensitive technique for measuring docetaxel
levels in plasma and tissue, for the latter measurements it can
only be applied to animals because an extensive number of
biopsies in humans is too invasive. Second, to develop a
PBPK model, organ volumes and organ blood flow need to
be fixed to predefined values. Furthermore, only a limited
number of organs can be investigated and the validity of the
model depends on an appropriate selection of these organs
(before experimentation). For example, in the study by
Bradshaw-Pierce and co-workers, the spleen was not selected.
Uptake of docetaxel in spleen, however, is high, therefore,
the spleen should be taken into account in developing the
PBPK model. Finally, with liquid chromatography–tandem
mass spectrometry, it might be difficult to achieve high
extraction efficiency for tissue (extraction efficiency from
tissues was only 40-90%), resulting in potential inaccuracies
in the PBPK model (e.g., systematic errors up to 200%
between simulation and measured data in the study by
Bradshaw-Pierce and colleagues).
Another technique to measure drug concentrations in tissue
is positron emission tomography (PET). Using this noninvasive
technique, it is possible to quantify pharmacokinetics and
pharmacodynamics in vivo in animals and humans (2). Over
the years, several therapeutic drugs have been labeled with
short-lived positron-emitting radionuclides. Note that with this
imaging modality, only tracer doses of the radiolabeled drug
need to be administered, making it possible to predict and
evaluate a dose in the same animal or human. PET measure-
ments do not require assumptions about organ volumes and
organ blood flow. In addition, the number of organs that can
be investigated is not limited because a whole-body scan can
easily be done. Furthermore, PET has high accuracy and
sensitivity (picomolar level).
To investigate tracer kinetics of docetaxel, we have labeled this
drug with carbon-11 at high specific activity (>18.5 GBq/Amol;
ref. 3). This enables sensitive and appropriate measurements of
[11C]docetaxel uptake in tissues. Using [11C]docetaxel, we have
done a preliminary biodistribution study in healthy male Wistar
rats at 5, 15, 30, and 60 min and found that the spleen had the
highest uptake followed by urine, lung, and liver. Brain and
testes showed the lowest uptake. Within less than 5 min,
[11C]docetaxel had already cleared from blood and plasma by
>99%. Because docetaxel binds intracellulary to tubulin,
knowledge of the uptake of docetaxel in the separate organs of
the intracellular component (e.g., heart, liver, spleen, lung, but
also tumor tissue) is required. We agree with Bradshaw-Pierce
and co-workers that this will contribute to a better understand-
ing of the toxicity and tumor response of docetaxel. We believe,
however, that PET is a more accurate and sensitive technique for
measuring docetaxel kinetics. Therefore, we have embarked on
[11C]docetaxel PET studies in animals and humans with
advanced solid tumors with the ultimate goal of predicting
response to docetaxel therapy in individual patients.
Astrid A.M. van der Veldt
Adriaan A. Lammertsma
N. Harry Hendrikse
Department of Nuclear Medicine and
PET Research, VU University Medical Center,
Amsterdam, the Netherlands
F2007 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-07-1626
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Abstract
Purpose Docetaxel is an important chemotherapeutic agent
used for the treatment of several cancer types. As radio-
labelled anticancer agents provide a potential means for
personalized treatment planning, docetaxel was labelled
with the positron emitter 11C. Non-invasive measurements
of [11C]docetaxel uptake in organs and tumours may
provide additional information on pharmacokinetics and
pharmacodynamics of the drug docetaxel. The purpose of
the present study was to determine the biodistribution and
radiation absorbed dose of [11C]docetaxel in humans.
Methods Biodistribution of [11C]docetaxel was measured in
seven patients (five men and two women) with solid
tumours using PET/CT. Venous blood samples were
collected to measure activity in blood and plasma. Regions
of interest (ROI) for various source organs were defined on
PET (high [11C]docetaxel uptake) or CT (low [11C]
docetaxel uptake). ROI data were used to generate time-
activity curves and to calculate percentage injected dose
and residence times. Radiation absorbed doses were
calculated according to the MIRD method using
OLINDA/EXM 1.0 software.
Results Gall bladder and liver demonstrated high [11C]
docetaxel uptake, whilst uptake in brain and normal lung
was low. The percentage injected dose at 1 h in the liver
was 47±9%. [11C]docetaxel was rapidly cleared from
plasma and no radiolabelled metabolites were detected.
[11C]docetaxel uptake in tumours was moderate and highly
variable between tumours.
Conclusion The effective dose of [11C]docetaxel was
4.7 μSv/MBq. As uptake in normal lung is low, [11C]
docetaxel may be a promising tracer for tumours in the
thoracic region.
Keywords [11C]docetaxel . Biodistribution .
Radiation dose . Cancer . PET/CT
Introduction
Tumour resistance to chemotherapy remains a major
challenge, because it results in unnecessary toxicity and
costs and, most importantly, delay in initiating potentially
more effective treatment. In the last decade, there has been
growing interest in molecular imaging for tumour response
monitoring at an early stage during treatment. For example,
glucose metabolism as measured by the commonly used
positron emission tomography (PET) tracer 2-[18F]fluoro-2-
deoxy-D-glucose ([18F]FDG) has been accepted as a
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surrogate end-point for the evaluation of new drugs in
oncology [1]. However, [18F]FDG PET can only measure
tumour response after treatment has already been started by
comparing a response scan with the corresponding baseline
scan. Ideally, response to anticancer drugs should be
predicted before initiating therapy. Anticancer agents that
are labelled with a positron emitter may be promising
tracers for predicting treatment outcome before initiating
treatment [2]. A few studies have suggested that radio-
labelled anticancer agents may provide a unique means for
personalized treatment planning in cancer patients [2], but
more studies are needed to substantiate this concept. In
addition, radiolabelled anticancer agents may contribute to
drug development and the rational development of combi-
nation therapy strategies by exploring whether drug
pharmacokinetics can be modulated by other agents. The
anticancer drug docetaxel has been radiolabelled with 11C
[3–5]. Docetaxel belongs to the taxanes, one of the most
active classes of cytotoxic agents, and has been approved
for the treatment of several cancer types, including breast,
prostate and lung cancer [6]. Docetaxel acts by disrupting
the microtubular network which results in the inhibition of
mitosis in cells. In spite of this effective mechanism of
action in tumours, the efficacy of docetaxel treatment in
cancer patients is not optimal. Appropriate selection of
patients and addition of biomodulating agents may improve
efficacy of docetaxel therapy. PET using [11C]docetaxel
may be valuable, as it allows for measurement of docetaxel
uptake in tumours and for investigating effects of other
agents on this uptake. In preparation for kinetic studies in
cancer patients, the purpose of the present study was to
determine biodistribution and radiation absorbed doses of
[11C]docetaxel in humans.
Materials and methods
Patients
Patients with advanced solid tumours, due to undergo
chemotherapy, were eligible for this study. Inclusion criteria
were: 18 years of age or older, malignant lesion of at least
1.5 cm in diameter within the chest as measured by Response
Evaluation Criteria in Solid Tumors (RECIST) [7], life
expectancy of at least 12 weeks, Karnofsky performance
status scale>60%, platelets>100×109/l and haemoglobin>
6.0 mmol/l. Exclusion criteria included previous treatment
with taxanes, claustrophobia, pregnant or lactating patients,
patients having metal implants (e.g. pacemakers), use of
coumarin derivatives or inhibitors of platelet aggregation,
use of drugs that are inhibitors of or substrates for P-
glycoprotein (Pgp), concurrent treatment with experimental
drugs and participation in a clinical trial with any
investigational drug within 30 days prior to study entry.
The study was approved by the Medical Ethics Review
Committee of the VU University Medical Center. Five male
and two female patients with a mean age (± SD) of 63±
10 years and a mean body weight (± SD) of 78±15 kg (range:
66–94 kg) were included in the study. All patients were
diagnosed with metastatic cancer including non-small cell
lung cancer (NSCLC) (n=5), malignant pleural mesothelio-
ma (n=1) and prostate cancer (n=1). Prior to inclusion, each
patient signed a protocol-specific informed consent.
Synthesis of [11C]docetaxel
[11C]docetaxel was synthesized according to Good Manu-
facturing Practice (GMP) standards as described in detail
previously [4, 5]. For the preparation of the precursor, the drug
docetaxel was obtained from Green Plantchem Company Ltd.
(Hangzhou, China). Briefly, the 11C isotope was introduced in
the side chain by a [11C]tert-butoxycarbonylation of the free
amine of docetaxel, and [11C]docetaxel was produced with a
decay-corrected overall radiochemical yield of 10±1% prior to
purification. The mean specific activity at time of injection
was 7±5 GBq/μmol.
Scan protocol
Patients were asked to fast over midnight before scanning.
A light breakfast before 8.00 a.m. and water and tea were
allowed. Due to the fact that only sub-pharmacological
(tracer) doses of [11C]docetaxel were administered, no side
effects were expected. The Medical Ethics Review Com-
mittee, however, required that dexamethasone be given to
prevent potential allergic reactions. Two dosages of 4 mg
dexamethasone were given; one in the evening and the
other in the morning before [11C]docetaxel administration.
Whole-body scans were performed on a Gemini TF-64
PET/CT scanner (Philips Medical Systems, Best, The
Netherlands) [8]. Each patient was positioned on the
scanner bed using elastic body-restraining bandages to
minimize body movement during the scans. Following a
50 mAs low-dose CT (LD-CT) scan, a mean (± SD) single
bolus of 178±79 MBq [11C]docetaxel (dissolved in a
maximum volume of 12 ml saline) was injected intrave-
nously and four serial whole-body PET scans from head to
mid-thigh were acquired over a 1-h period with progressive
increase of scan durations per bed position of 0.5, 1, 1.5
and 2 min, respectively. The axial field of view of the
scanner is 18 cm and a 50% overlap between bed positions
is applied in whole-body scans, resulting in an average of
11 bed positions per scan. Resulting mean durations of the
four consecutive whole-body PET scans were 6.9±1.2,
12.6±2.3, 18.3±3.3 and 24.0±4.3 min, respectively. One
patient was able and willing to undergo a fifth whole-body
Eur J Nucl Med Mol Imaging (2010) 37:1950–1958 1951
70
scan with duration of 2.5 min per bed position. Data was
normalized and all appropriate corrections were applied for
dead time, randoms, scatter, attenuation and scanner
calibration, and whole-body scans were corrected for decay
relative to the start of each scan. Images were reconstructed
using time-of-flight ordered subsets expectation maximiza-
tion (TF-OSEM).
Analysis of blood samples
After each whole-body scan, a venous blood sample (7 ml)
was collected for measuring blood and plasma concen-
trations as well as radiolabelled metabolites. To avoid
contamination of activity remaining in the catheter, 3–5 ml
blood was withdrawn prior to each sample and the line was
flushed with 2 ml saline after sampling, as described
previously [9]. A cross-calibrated gamma counter was used
to determine activity concentrations and plasma to whole
blood ratios. The presence of radiolabelled metabolites in
plasma was assessed using solid phase extraction (SPE)
combined with high-performance liquid chromatography
(HPLC) using offline detection.
Region of interest definition
PET and LD-CT images were converted to ECAT 7 format
and regions of interest (ROIs) were drawn using CAPP
software (CTI/Siemens, Knoxville, TN, USA) to obtain
mean activity concentration in each region at each of the
four time points. For organs with activity concentrations
clearly exceeding background levels [liver, gall bladder,
upper large intestine (ULI), urinary bladder, heart wall,
bone marrow in vertebrae], ROIs were defined on the PET
scan with the highest tracer uptake (Fig. 1) using a 50%
isocontour. For organs with lower tracer uptake (brain,
lung, spleen, kidney) that could easily be identified on the
LD-CT scan, ROIs were drawn manually on the LD-CT
scan and subsequently copied to the PET scans (Fig. 2). For
each patient, a ROI of one tumour of at least 1.5 cm in
diameter that could easily be identified on the LD-CT scan
was determined. All ROIs were projected onto all scans. As
the volume of the urinary bladder increased during
scanning, bladder ROIs were separately drawn on each
PET image except for the first image. The bladder ROI of
the second image was projected onto the first PET scan.
Calculation of [11C]docetaxel uptake
ROIs were used to generate time-activity curves (TAC) for
each source organ. The time of measurement of each
individual organ in each scan was calculated based on the
organ position in the whole-body image and the total
duration of that scan. All organ TACs were then corrected
for decay relative to the time of injection of the tracer. To
assess biodistribution, the mean standardized uptake value
(SUV) normalized to body weight and the percentage
injected dose (%ID) in each organ were calculated at each
time point. For organs with ROIs covering less then the
entire organ (ULI, myocardial wall, red marrow), the
percentage of injected activity per cm3 was multiplied with
the organ volumes of the adult male reference phantom,
scaled with the ratio of the patient’s weight and the
reference man weight [10, 11]. Since bones not containing
active marrow were not visible in the images, all activity in
vertebrae ROIs was assumed to be in red marrow. For
tumours, the maximum SUV (SUVmax) was calculated.
Residence time and absorbed dose calculations
For each organ, TACs were uncorrected for decay and
residence times were computed as the trapezoidal sum of
the TAC with the assumption that, after the last time point,
activity decreased only by physical decay (i.e. no biological
clearance after the last time point). Residence time for the
remainder of the body was calculated as the total body
residence time without voiding (one divided by the decay
constant) minus the sum of the residence times of all
defined organs. Residence times for each patient were
Fig. 1 For organs with activity clearly exceeding background (e.g.
liver) ROIs were defined on the PET scan with the highest uptake.
PET/CT fusion image (a) and PET image (b) demonstrate high [11C]
docetaxel uptake in liver. The liver ROI as determined on the PET
image is presented in green (b)
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entered into the OLINDA/EXM 1.0 software package [12]
to compute absorbed doses using the adult male reference
phantom. Since the small intestine (SI) was difficult to
delineate in both PET and LD-CT images due to the
vicinity to the liver and the poor contrast of the LD-CT
images, the ICRP 30 GI [13] tract model was used to
estimate residence times in SI and lower large intestine
(LLI) based on those found for ULI. According to this
model, ratios of SI to ULI and LLI to ULI residence times
are 8.45 and 0.039, respectively, for 11C-labelled tracers
[12]. OLINDA/EXM 1.0 provides effective dose values
according to ICRP 60 [14] and does not provide effective
dose values according to the latest definition (ICRP 103,
[15]). Therefore, effective doses according to ICRP 103
were calculated manually using target organ doses as
reported by OLINDA/EXM 1.0 and ICRP 103 weighting
factors. Since not all target organs are included in
OLINDA/EXM 1.0 (skin, salivary glands, oesophagus),
the sum of weighting factors was 0.94 and effective dose
values were divided by 0.94 [16].
Results
Biodistribution
Figure 3 shows the typical biodistribution of [11C]docetaxel
over time, as obtained from the four sequential PET
acquisitions over about 1 h. Liver, gall bladder, intestine
and urinary bladder were visually identified as organs with
relatively high activity, whilst [11C]docetaxel uptake in
brain and normal lung was low. Between the third and
fourth PET scans, [11C]docetaxel uptake in gall bladder and
intestine was still increasing. Figure 4 shows TACs for
various organs [%ID versus time post-injection (p.i.)].
Percentage ID at 1 h p.i. was highest in liver (47±9%) and
gall bladder (7.2±3.6%), with 35% of all disintegrations
occurring in the liver. The highest peak activity concentrations
were measured in gall bladder (SUVmean 96±49), liver
(SUVmean 24±3) and ULI (SUVmean 9±6), whereas concen-
trations were smallest in brain (SUVmean 0.05±0.03) and
lung (SUVmean 0.7±0.2).
Fig. 2 For organs with lower tracer uptake (e.g. lung), ROIs were
drawn on the LD-CT scan and subsequently copied onto the PET
scans. PET/CT fusion image (a) and PET image demonstrate low
[11C]docetaxel uptake in lungs. The lung ROIs were drawn on the CT
image (b) and projected onto the PET image (c). The lung ROIs as
determined on the LD-CT scan are presented in green (b, c)
Fig. 3 Maximum intensity pro-
jections of the biodistribution of
[11C]docetaxel in a 71-year-old
male patient with metastatic
malignant pleural mesothelioma.
The four successive whole-body
PET scans (0–6, 8–19, 23–39
and 42–63 min p.i.) demonstrate
high liver uptake at all time
points and low uptake in brain
and normal lung. On the fourth
scan, [11C]docetaxel uptake is
observed in intestine
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Blood clearance
[11C]docetaxel was rapidly cleared from the blood pool and
within 30 min %ID/ml was less than 0.001, as shown in
Fig. 5. After the first PET scan, plasma values were higher
than those of whole blood, but after the second scan and
onwards whole blood values were higher. No radiolabelled
metabolites were detected in plasma, with the HPLC
chromatogram showing a single peak due to [11C]docetaxel
itself. Recovery of radioactivity in the HPLC analysis was
94±5%.
Safety
Patients did not report any side effect or discomfort after
the [11C]docetaxel injection and during the imaging
procedure.
Radiation dosimetry
Table 1 summarizes average organ residence times calcu-
lated from the whole-body images of the seven patients.
Organ absorbed dose estimates are displayed in Table 2.
Estimated radiation absorbed doses were highest in liver
and gall bladder wall at 35.2±6.6 and 34.6±9.9 μGy/MBq,
respectively. Based on these results, the mean effective dose
for [11C]docetaxel was estimated at 4.7±0.2 μSv/MBq.
Tumour uptake
[11C]docetaxel uptake was observed in tumours. Figure 6
shows a patient with [11C]docetaxel uptake in a mediastinal
metastasis of a malignant pleural mesothelioma. In each
patient, one tumour was selected for further analysis,
consisting of primary NSCLC (n=3), mediastinal lymph
Fig. 4 Decay-corrected TACs of [11C]docetaxel (%ID versus time p.i.) (n=7) in a liver, b ULI and gall bladder, c brain, lung, heart contents and
myocardial wall, and d urinary bladder, spleen, kidney and red marrow. Vertical bars indicate standard deviation
1954 Eur J Nucl Med Mol Imaging (2010) 37:1950–1958
73
node metastasis of NSCLC (n=1), supraclavicular lymph
node metastasis of NSCLC (n=1), mediastinal lymph node
metastasis of malignant pleural mesothelioma (n=1) and
lung metastasis of prostate cancer (n=1).The TACs for
these seven tumours are shown in Fig. 7. The highest
measured SUVmax was 5.1.
Discussion
In the present study, the biodistribution of [11C]docetaxel
was measured in seven patients with metastatic solid
tumours using whole-body PET/CT scans, and radiation
absorbed doses were estimated. The LD-CT scan was of additional value to identify organs with low [11C]docetaxel
uptake. Uptake of [11C]docetaxel appeared to be highest in
gall bladder and liver, whilst uptake in normal lung and
brain was very low. Furthermore, [11C]docetaxel uptake in
tumours was moderate and highly variable between
different tumours. The results of the present study showed
promising biodistribution and radiation dosimetry of [11C]
docetaxel. For a typical administration of 370 MBq [11C]
docetaxel, the estimated dose is 1.7 mSv, which is within
the 1–10 mSv range of effective doses that are acceptable
for volunteers in biomedical research [17]. The tracer was
rapidly cleared from the blood pool which resulted in
images of high quality and reliable statistics for quantifica-
tion. The main route of elimination of the tracer was the
hepatobiliary pathway which contributed to a relatively
high radiation burden to gall bladder and liver. During the
successive PET scans, extensive hepatic uptake and
subsequent excretion into gall bladder and intestine were
observed (Fig. 3). The SUVmean of [
11C]docetaxel was
highest in gall bladder, which is also the dose-limiting organ
for [11C]docetaxel. For an administration of 370 MBq, the
Fig. 5 Decay-corrected TACs of [11C]docetaxel (%ID/ml versus time
p.i.) in plasma and whole blood
Table 2 Radiation absorbed dose estimates for [11C]docetaxel
Target organ μGy/MBq (mean±SD)
Adrenals 4.1±0.2
Brain 0.5±0.1
Breast 1.6±0.1
Gall bladder wall 34.6±9.9
Lower large intestine wall 2.1±0.3
Small intestine 9.5±3.8
Stomach 2.6±0.1
Upper large intestine wall 5.1±1.2
Heart wall 6.0±1.0
Kidney 10.7±1.5
Liver 35.2±6.6
Lung 4.1±1.0
Muscle 1.9±0.2
Ovary 2.4±0.3
Pancreas 4.0±0.1
Red marrow 3.2±0.2
Bone surface 3.1±0.3
Skin 1.3±0.2
Spleen 7.4±2.3
Testis 1.3±0.3
Thymus 1.8±0.2
Thyroid 1.4±0.3
Urinary bladder wall 3.1±1.1
Uterus 2.3±0.3
Total body 2.9±0.0
Effective dose (μSv/MBq) 4.7±0.2
Table 1 Average (± SD) organ residence times for [11C]docetaxel
uptake (n=7)
Organ Organ residence time (h)
Brain 0.0008±0.0003
Gall bladder 0.0124±0.0045
Small intestine 0.0243±0.0133
Upper large intestine 0.0029±0.0016
Lower large intestine 0.0001±0.0001
Heart contents 0.0046±0.0016
Heart wall 0.0032±0.0006
Kidney 0.0085±0.0016
Liver 0.2047±0.0401
Lung 0.0095±0.0038
Red marrow 0.0128±0.0018
Spleen 0.0041±0.0015
Urinary bladder 0.0023±0.0015
Remainder of body 0.2002±0.0421
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absorbed dose to the gall bladder wall is 12.8±3.7 mGy.
This equals 26% of the maximum allowed dose of 50 mGy
to a single organ for a single administration to an adult
research subject [18]. The high liver uptake of [11C]
docetaxel suggests extensive metabolism of the tracer. The
fact that no radioactive metabolites were measured in plasma
shows that if radioactive metabolites are produced, none of
these enter the bloodstream during the course of the PET
scan and, consequently, none are transported to tumours. In
fact, radioactivity was nearly completely cleared from
plasma within the first 20 min. This does not rule out the
presence of re-circulating non-radiolabelled metabolites in
plasma, as has been observed in earlier studies with
therapeutic doses of cold docetaxel [19].
Uptake in all organs except gall bladder and ULI reached a
plateau within 10 min after injection, after which %ID
remained nearly constant during the rest of the scan. Therefore,
further clearance according to physical decay only appears to
be a valid assumption. During the fourth PET scan (∼60 min
after injection), uptake in gall bladder and ULI was still
increasing, indicating that the absorbed dose of [11C]docetaxel
in gall bladder and intestine might be underestimated. In the
patient who underwent a fifth whole-body scan, however, gall
bladder and ULI uptake decreased rapidly during the last
scan. Inclusion of this fifth scan resulted in a decreased
effective dose (4.0 vs 4.1 mSv/MBq), although giving a small
increase in absorbed dose to the gall bladder (Fig. 8). This
indicates that exponential extrapolation according to physical
decay after the fourth measurement yields conservative
effective dose values. The use of more and faster whole-
body scans within the first hour after injection, as has been
published for similar studies with other tracers [20, 21],
would not have led to major differences in the results because
of the near constant uptake in most organs.
Fig. 7 Decay-corrected TACs of [11C]docetaxel for seven different
tumours (SUVmax versus time p.i.) including mediastinal metastasis of
malignant pleural mesothelioma (a), metastasis of NSCLC (b, d),
primary tumour of NSCLC (c, e, f) and lung metastasis of prostate
cancer (g)
Fig. 6 PET/CT images of [11C]docetaxel in a 71-year-old male patient with metastatic malignant pleural mesothelioma. Mediastinal metastasis
(arrow) on CT scan (a) with [11C]docetaxel uptake on PET scan (b) and on PET/CT fusion image (c)
Fig. 8 Total activity (non-decay-corrected) in gall bladder in a single
patient who underwent an additional fifth whole-body scan. Solid lines
show the interpolated data from which the trapezoidal integral was
computed, assuming physical decay after the fourth whole-body scan,
whereas dashed lines show the integral after inclusion of the fifth
whole-body scan
1956 Eur J Nucl Med Mol Imaging (2010) 37:1950–1958
75
As most anticancer agents are eliminated by liver,
extensive hepatic clearance and subsequent excretion into
the gall bladder and intestine may also be expected for
other radiolabelled anticancer drugs. Due to the resulting
high background and low contrast in the abdomen, the
value of these radiolabelled anticancer drugs for tumours in
the abdominal and pelvic region may be limited.
Paclitaxel, another taxane, has been radiolabelled with
18F [22, 23]. To our knowledge, the radiation absorbed dose
of [18F]fluoropaclitaxel has not been reported yet. Limited
data on the biodistribution of [18F]fluoropaclitaxel in
humans [24], however, appeared to be comparable with
the present biodistribution data of [11C]docetaxel. Follow-
ing intravenous administration of [18F]fluoropaclitaxel,
PET scans were performed in three healthy volunteers.
High [18F]fluoropaclitaxel uptake was observed in liver,
gall bladder and intestine, whilst uptake in brain and lung
appeared to be low. Seventy-five minutes after injection,
[18F]fluoropaclitaxel had been cleared from liver and
subsequently excreted into intestine. When comparing
biodistribution and pharmacokinetics of [18F]fluoropacli-
taxel and [11C]docetaxel, it is important to realize that the
chemical structure of [11C]docetaxel is identical to that of
clinically used, non-labelled docetaxel, whilst [18F]fluoro-
paclitaxel is not identical to paclitaxel itself [22]. Introduc-
tion of a fluoride atom into the paclitaxel molecule
effectively creates a different chemical structure and may
result in a molecule with different pharmacokinetic and
pharmacodynamic characteristics as compared to the
paclitaxel molecule that is usually administered for the
treatment of patients.
The present biodistribution results for [11C]docetaxel are
in line with three clinical observations in cancer patients
who are treated with docetaxel. First, the extensive hepatic
clearance of [11C]docetaxel indicates that caution is
warranted when treating patients with liver dysfunction.
Indeed, in patients with clinical chemistry findings sugges-
tive of mild to moderate liver function impairment [SGOT
and/or SGPT > 1.5 × upper limit of normal (ULN),
concomitant with alkaline phosphatase > 2.5 × ULN], total
body clearance of the drug docetaxel is known to be
lowered significantly. Second, [11C]docetaxel uptake in
bone marrow may mirror neutropenia, which was the dose-
limiting toxicity in previous phase I clinical trials of
docetaxel [25]. Third, [11C]docetaxel uptake in brain was
low. The blood-brain barrier is likely to be the major cause
of this poor uptake. An important component of the blood-
brain barrier is Pgp [26, 27], which acts as a drug efflux
pump and for which docetaxel is a substrate [28]. This is
reflected by the limited efficacy of systemic treatment with
docetaxel for tumours or metastases in the brain [29]. In
addition, Pgp-mediated efflux in the blood-testis barrier is
known to maintain low drug concentrations in the testis
[30]. Indeed, visual inspection of the [11C]docetaxel PET
images did not reveal any [11C]docetaxel uptake in the
testicular region, indicating that [11C]docetaxel uptake in
the testis is probably low.
Although not the primary aim of this study, [11C]
docetaxel uptake was also measured in tumours. Tumour
uptake was highly variable, which may mirror differential
sensitivity of tumours to docetaxel treatment. Studies with
other radiolabelled anticancer agents such as [18F]5-
fluorouracil (FU) and [18F]fluorotamoxifen [2] have shown
that higher uptake of these radiolabelled agents in tumours
appeared to be related to better tumour response. Radio-
labelled anticancer agents could potentially predict treatment
outcome and may contribute to individualized treatment
planning. As patients in the present study were not scheduled
to undergo docetaxel treatment, further studies are warranted
to investigate whether tumour uptake of [11C]docetaxel is
predictive of outcome of docetaxel therapy. As background
uptake of [11C]docetaxel in the chest is low, it may be a
useful tracer to predict docetaxel efficacy for tumours in the
thoracic region, such as lung and breast cancer.
Conclusion
The highest uptake of [11C]docetaxel was measured in gall
bladder and liver, whilst uptake in brain and lung was very
low. Administration of [11C]docetaxel was safe with a mean
effective dose of 4.7 μSv/MBq. [11C]docetaxel uptake in
tumours was moderate and highly variable between
different tumours.
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Abstract
Purpose: Tumor resistance to docetaxel may be associated with reduced drug concentrations in tumor
tissue. Positron emission tomography (PET) allows for quantification of radiolabeled docetaxel
([11C]docetaxel) kinetics and might be useful for predicting response to therapy. The primary objective
was to evaluate the feasibility of quantitative [11C]docetaxel PET scans in lung cancer patients. The
secondary objective was to investigate whether [11C]docetaxel kinetics were associated with tumor
perfusion, tumor size, and dexamethasone administration.
Experimental Design: Thirty-four lung cancer patients underwent dynamic PET–computed tomogra-
phy (CT) scans using [11C]docetaxel. Blood flow was measured using oxygen-15 labeled water. The first 24
patients were premedicated with dexamethasone. For quantification of [11C]docetaxel kinetics, the optimal
tracer kinetic model was developed and a noninvasive procedure was validated.
Results: Reproducible quantification of [11C]docetaxel kinetics in tumors was possible using a non-
invasive approach (image derived input function). Thirty-two lesions (size4 cm3) were identified, having
a variable net influx rate of [11C]docetaxel (range, 0.0023–0.0229mLcm3min1). [11C]docetaxel uptake
was highly related to tumor perfusion (Spearman’s r ¼ 0.815; P < 0.001), but not to tumor size
(Spearman’s r ¼ 0.140; P ¼ 0.446). Patients pretreated with dexamethasone showed lower
[11C]docetaxel uptake in tumors (P¼ 0.013). Finally, in a subgroup of patients who subsequently received
docetaxel therapy, relative high [11C]docetaxel uptake was related with improved tumor response.
Conclusions: Quantification of [11C]docetaxel kinetics in lung cancer was feasible in a clinical setting.
Variable [11C]docetaxel kinetics in tumors may reflect differential sensitivity to docetaxel therapy. Our
findings warrant further studies investigating the predictive value of [11C]docetaxel uptake and the effects
of comedication on [11C]docetaxel kinetics in tumors. Clin Cancer Res; 17(14); 4814–24. 2011 AACR.
Introduction
Docetaxel belongs to the family of taxanes, a class of drugs
that binds to microtubules and subsequently induces cell
cycle arrest and apoptosis (1). Docetaxel is widely used for
systemic therapy of several solid malignancies, including
lung cancer (2). However, clinical failure of docetaxel ther-
apy remains a major problem, and often patients are sub-
jected to therapy-related toxicity without gaining benefit. As
response to anticancer drugs is, at least in part, thought to
depend on achieving sufficient drug levels in tumor tissue,
assessment of docetaxel uptake in tumors in vivo may be
useful to understand treatment failure in patients.
To this end, docetaxel was labeled with the short-lived
positron emitting radionuclide carbon-11, resulting in
[11C]docetaxel with an identical molecular structure as
the drug docetaxel itself (3, 4). Using [11C]docetaxel and
positron emission tomography (PET), microdosing studies
can be carried out to monitor pharmacokinetics and phar-
macodynamics of docetaxel noninvasively in patients. In a
previous safety study, [11C]docetaxel showed high accu-
mulation in liver (5, 6), whereas concentrations in the chest
were low (6). These biodistribution data indicate that
[11C]docetaxel may be a suitable PET tracer for measuring
docetaxel kinetics in thoracic tumors.
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To assess whether a microdose [11C]docetaxel scan can
be used to predict response to docetaxel therapy, quanti-
fication of [11C]docetaxel uptake in tumor tissue is needed.
This, in turn, requires the development of a tracer kinetic
model, describing tumor [11C]docetaxel kinetics in relation
to the time course in arterial plasma (delivery). Arterial
blood sampling, however, is less suited for routine clinical
studies. Dynamic PET scans of the chest provide the pos-
sibility to noninvasively generate an image derived input
function (IDIF) based on the time course in, for example,
the ascending aorta. As the accuracy of an ascending aorta
IDIF depends on the biodistribution of a tracer, this pro-
cedure needs to be validated also for [11C]docetaxel.
Uptake of docetaxel in a tumor depends, at least in
part, on its delivery through the circulation, which may
be regulated by both drug exposure and tumor perfu-
sion. Docetaxel exposure is reflected by clearance of
[11C]docetaxel from blood. Tumor perfusion can be mea-
sured using oxygen-15 labeled water ([15O]H2O), which is
a freely diffusible PET tracer (7). Tumor size may also affect
docetaxel delivery, as central necrotic areas with reduced
tumor perfusion may develop with increasing tumor
size (8).
In addition, efflux pumpsmay affect the concentration of
radiolabeled drugs in tumors. Docetaxel is a substrate for
the efflux transporter ABCB1 (formerly known as P-glyco-
protein or MDR1; ref. 9). In this respect, the glucocorticoid
dexamethasone, which is given as standard premedication
to prevent several docetaxel-induced toxicities (10, 11), is
of particular interest, because dexamethasone is a potent
inducer of this efflux transporter (12). Accordingly, pre-
medication with dexamethasone may affect docetaxel
kinetics in tumors.
The primary objective of the present study was to eval-
uate the feasibility of quantitative PET studies with
[11C]docetaxel in patients with lung cancer. As mentioned
above, this required development of the optimal tracer
kinetic model for quantification of [11C]docetaxel kinetics
in lung cancer patients and validation of the use of a
noninvasive procedure to enable implementation in rou-
tine clinical practice. The secondary objective was to
explore whether [11C]docetaxel kinetics were associated
with tumor perfusion, tumor size, and administration of
premedication with dexamethasone. Finally, as a limited
number of patients were actually scheduled for docetaxel
therapy, a preliminary assessment of the relationship
between [11C]docetaxel uptake and response to docetaxel
therapy was possible.
Patients and Methods
Patients
Thirty-four patients (23 males and 11 females; median
age 62 years; range 32–74 years) with advanced-stage
cancer were prospectively enrolled prior to planned sys-
temic therapy. Thirty-two patients were diagnosed with
non-small cell lung cancer and two with malignant
mesothelioma. Criteria for enrollment in the study were
18 years of age or older, a malignant lesion of at least
1.5 cm in diameter within the chest, life expectancy of at
least 12 weeks, Karnofsky performance status scale >60%,
thrombocyte count >100  109L1, and hemoglobin >6.0
mmolL1. Exclusion criteria included previous treatment
with taxanes, claustrophobia, pregnancy or lactation, metal
implants (e.g., pacemakers), use of coumarin derivatives or
inhibitors of thrombocyte aggregation, use of inhibitors or
substrates of the efflux transporter ABCB1, concurrent
treatment with experimental drugs, and participation in
a clinical trial with any investigational drug within 30 days
prior to study entry. When patients were scheduled for
docetaxel therapy, computed tomography (CT) scans were
carried out at baseline and every cycle or every two cycles of
treatment to assess clinical response according to Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1
(13). The study was approved by the Medical Ethics Review
Committee of the VU University Medical Center. Prior to
inclusion, each patient signed a protocol-specific informed
consent.
Synthesis of radiopharmaceuticals
[15O]H2O and [
11C]docetaxel were synthesized accord-
ing to Good Manufacturing Practice (GMP) standards as
described previously (3, 4, 14). Docetaxel was obtained
from Green PlantChem Company Ltd., which was used to
synthesize the precursor of [11C]docetaxel. [11C]docetaxel
itself was produced with a decay-corrected overall radio-
chemical yield of 10  1% prior to purification. The
median specific activity at time of injection was 2.0
GBqmmol1 (range: 1.0–37.3 GBqmmol1).
Scanning protocol
Studies were conducted on a Gemini TF-64 PET-CT
scanner (Philips Medical Systems; ref. 15). This scanner
has an axial field of view of 18 cm, divided into 45
contiguous planes. All patients underwent a dynamic
Translational Relevance
Docetaxel is an effective drug for the treatment of
patients with several advanced malignancies including
breast cancer, prostate cancer, and lung cancer. How-
ever, a number of patients will not benefit from doc-
etaxel therapy. Tumor resistance to docetaxel may be
associated with reduced drug concentrations in tumor
tissue. Positron emission tomography (PET) is a non-
invasive technique that can be used to quantify kinetics
of radiolabeled docetaxel ([11C]docetaxel) in tumors.
The present study shows the feasibility and potential
clinical relevance of quantitative [11C]docetaxel PET
studies in patients with lung cancer. In the future,
microdosing studies using [11C]docetaxel may be used
to predict benefit from docetaxel in individual patients.
In addition, PET imaging with [11C]docetaxel may be
useful for evaluating effects of other drugs on docetaxel
delivery to tumors and to optimize drug scheduling.
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[11C]docetaxel PET–CT scan. Eight patients underwent a
second [11C]docetaxel scan to assess test–retest reproduci-
bility of measurements. The second [11C]docetaxel scan
was carried out approximately 4 hours after the first.
Twenty-eight patients underwent an additional PET scan
using [15O]H2O to measure tumor perfusion.
Patients were asked to fast from midnight before scan-
ning. A light breakfast at 08.00 hours or a light lunch at
12.00 hours, and water and tea were allowed until PET
scanning. In the first 24 patients, dexamethasone (8 mg
p.o.) was given to prevent potential allergic reactions. As
none of these patients did experience any side-effects, the
Medical Ethics Review Committee allowed dexamethasone
administration to be discarded in subsequent patients.
All patients received two venous catheters, one for tracer
injection, the other for blood sampling. In addition, 17
patients received an indwelling radial artery catheter for
arterial blood sampling during the dynamic [11C]docetaxel
scan. Patients were positioned supine on the scanner bed
with both tumor and aortic arch located inside the axial
field of view of the scanner. Elastic body-restraining ban-
dages were used to minimize movement during scanning.
Following a 50 mAs low-dose CT scan for attenuation
correction, a 10 minutes dynamic scan was started simul-
taneously with an intravenous injection of 370 MBq
[15O]H2O (5 mL at a rate of 0.8 mLs1), followed by a
35mL saline flush (rate 2 mLs1). At least 20minutes after
administration of [15O]H2O, which has a half-life of 2
minutes, a 60-minute dynamic scan was started simulta-
neously with an intravenous injection of [11C]docetaxel
(median dose 335 MBq; range 133–385 MBq; dissolved
in a maximum volume of 12 mL saline, at a rate of
0.8 mLs1), followed by 35 mL saline (rate 2 mLs1).
Data were normalized and all appropriate corrections
were applied for dead time, decay, randoms, scatter, and
attenuation. Using the 3-dimensional row action maxi-
mum likelihood reconstruction algorithm (3D RAMLA),
[15O]H2O and [
11C]docetaxel scans were reconstructed
into 26 (1  10, 8  5, 4  10, 2  15, 3  20, 2 
30, and 6 60 s) and 36 (1 10, 8 5, 4 10, 2 15, 3
20, 2 30, 6 60, 4 150, 4 300, and 2 600 s) frames,
respectively.
Blood sampling
In the first 17 patients, arterial blood sampling was
carried out during [11C]docetaxel scanning.Using an online
detection system (16), arterial blood was withdrawn con-
tinuously at a rate of 5 mLmin1 during the first 5 minutes
and 1.7 mLmin1 thereafter. Twenty-nine minutes after
injection, online sampling was discontinued to minimize
the total amount of blood to be taken. In addition, both
10mL arterial and venous samples were collectedmanually
at 2.5, 5, 10, 15, 20, 30, 40, and 60 minutes postinjection.
Prior to each sample, 3–5 mL blood was discarded and
the line was flushed with 2 mL saline after each sample.
Blood samples were analyzed for blood and plasma con-
centrations and potential radiolabeled metabolites of
[11C]docetaxel as described in the Supplementary Data.
Input functions
Blood sampler data of [11C]docetaxel were corrected for
delay relative to the time-activity curve of the ascending
aorta. The resulting delay-corrected sampler curve was
calibrated using the manually drawn arterial blood sam-
ples. Plasma/whole blood ratios derived from the manual
blood samples were fitted to a sigmoid function. Finally,
the blood sampler input function (BSIF) was obtained by
multiplying the delay-corrected and calibrated sampler
curve with this sigmoid function.
IDIFs were derived for both [15O]H2O and
[11C]docetaxel scans. An IDIF of the ascending aorta has
been validated for several PET tracers including [15O]H2O
(17) and it is considered to be a noninvasive alternative to
arterial sampling. Hence, volumes of interest (VOI) of 1 cm
diameter were drawn over the ascending aorta in approxi-
mately 10 consecutive image planes of the frame in which
the first pass of the bolus was best visualized. Projection of
these VOIs onto all image frames yielded the arterial time-
activity curve CA(t). A similar approach was used for right
ventricular cavity and pulmonary artery, thereby providing
a time-activity curve for the pulmonary circulation CV(t)
(17). For [11C]docetaxel, the plasma IDIF was obtained by
multiplying CA(t) with a sigmoid function describing the
plasma/whole blood ratio over time. The correction for
plasma/whole blood ratio was based on either arterial or
venous sampling.
Delineation of tumors
Tumors were defined on the low-dose CT scans by an
experienced nuclear medicine physician (E.F.C.) who was
blinded to patients’ history and outcome. To this end, all
low-dose CT images were converted to ECAT 7 format
and tumor VOIs were drawn using the CAPP software
package (CTI/Siemens). Finally, these VOIs were pro-
jected onto the dynamic images of the corresponding
[15O]H2O and [
11C]docetaxel scans, thereby generat-
ing tumor time-activity curves for [15O]H2O and
[11C]docetaxel.
Analysis of tumor perfusion
Kinetic analysis of data was carried out using dedicated
programs written within the software environment
Matlab (The MathWorks Inc.). The standard single-tissue
compartment model was used to derive tumor perfusion
from [15O]H2O kinetics, applying corrections for both
arterial and pulmonary artery blood volume (18):
CTðtÞ ¼ ð1 VA  V V Þ  F  CAðtÞ  e
F
VT
t
þ VACAðtÞ þ V V CV ðtÞ
where CT(t) represents measured tissue [
15O]H2O con-
centration as function of time, F perfusion, VA arterial
blood volume, VV pulmonary circulation blood volume,
and VT the volume of distribution or partition coefficient
of water.
Using nonlinear regression, tumor time-activity curves
were fitted to this single-tissue compartment model using
van der Veldt et al.
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IDIF as arterial input function (17). The correction for
pulmonary circulation blood volume was included, as it
improved the quality of the fits without affecting tumor
perfusion values (17).
Analysis of [11C]docetaxel kinetics in tumors
To develop a kinetic model and validate the use of a
noninvasive procedure for quantification of [11C]docetaxel
data, only lesions with a volume 4 cm3 were considered.
The generated time-activity curves of arterial blood and
tumor tissue were entered into the analysis (Fig. 1). First,
nonlinear regression analysis was applied to fit the tumor
time-activity curves of [11C]docetaxel to a two-tissue rever-
sible (4 rate constants) and a two-tissue irreversible (3 rate
constants) compartment model, both including a blood
volume parameter and using the BSIF derived plasma input
function. Akaike and Schwarz criteria (19, 20) were used to
determine which model best described [11C]docetaxel
kinetics in tumors.
The two-tissue compartment model (Fig. 1) describes the
total tissue signal (CT) by the following equation:
CTðtÞ ¼ C1ðtÞ þ C2ðtÞ
where C1(t) and C2(t) are concentrations in 1st and 2nd
compartment, respectively. Kinetics in both compartments
are given by the following differential equations:
dC1ðtÞ
dt
¼ K1CpðtÞ  ðk2 þ k3ÞC1ðtÞ þ k4C2ðtÞ
dC2ðtÞ
dt
¼ k3C1ðtÞ  k4C2ðtÞ
where CP is arterial plasma concentration, K1 the rate
constant for transport from plasma to tumor, k2 the rate
A
B
C
Blood sampler
0
300
250
200
150
100
50
0 2 4 6 8 10
Time (min)
A
ct
iv
ity
 (k
Bq
.
m
L–
1 )
BSIF
0
300
250
200
150
100
50
0 2 4 6 8 10
K1
k2
k3
k4
Time (min)
CP C1 C2
Blood Tumor tissue
A
ct
iv
ity
 (k
Bq
.
m
L–
1 )
IDIF
0
20
15
10
5
0
2 4 6 8 10
Time (min)
A
ct
iv
ity
 (k
Bq
.
m
L–
1 )
Tumor
Aorta VOI Tumor VOI Data acquisition
Tim
e–activity curves
Kinetic m
odel
Figure 1. Compartmental modeling of dynamic [11C]docetaxel PET scans. A, arterial concentrations of [11C]docetaxel were obtained from arterial blood
sampling or an IDIF. For the latter, VOIs were drawn over the ascending aorta in a frame in which the first pass of the bolus was best visualized. In addition, a
tumor VOI was defined on the low-dose CT scan. Finally, aorta VOI and tumor VOI were projected onto the dynamic images of the corresponding
[11C]docetaxel scan, thereby generating time-activity curves. B, time-activity curves of arterial blood and tumor tissue were entered into two-tissue
compartment modeling. To this end, either BSIF or IDIF was entered into the analysis as arterial input function. C, schematic diagram of a two-tissue
compartment model. The concentration (C) in the tumor consists of [11C]docetaxel in compartments 1 (C1) and 2 (C2), representing free and bound
[11C]docetaxel, respectively. Kinetics of [11C]docetaxel in tumor tissue is regulated by input from plasma (CP) and four kinetic rate constants K1, k2, k3, and k4.
K1 is the rate constant describing transport from plasma to tumor, k2 is the rate constant for clearance from tumor to plasma, and k3 and k4 are kinetic
rate constants describing exchange between the two tumor compartments. For the irreversible two-tissue compartment model k4 ¼ 0. VOI, volume of
interest; BSIF, blood sampler derived input function; IDIF, image derived input function.
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constant for clearance from tumor to plasma, and k3 and k4
kinetic rate constants describing exchange between 1st and
2nd compartment.
For the irreversible two-tissue compartment model, k4 is
0. In this case the net influx rate constant Ki can be
calculated:
Ki ¼ K1  k3
k2 þ k3
In case of irreversible uptake, both robustness and sim-
plicity of the Ki estimation can be improved by using the
Patlak method (21). The Patlak plot is a linearization of the
compartmental equations, and is given by:
CTðtÞ
CpðtÞ ¼ Ki 
Ð t
0 CpðtÞ  dt
CpðtÞ þ V0;
where the intercept V0 represents the initial volume of
distribution. Ki is now given by the slope of the linear part
of the curve.
The schematic diagram in Supplementary Fig. S1 illus-
trates the various steps that were carried out to develop a
simplified procedure suitable for clinical implementation of
[11C]docetaxel studies. After validation of a simplified
kinetic analysis (i.e., Patlak analysis), use of IDIF was com-
paredwithuseofBSIF.Next, theuseofdiscrete venous rather
than arterial samples to correct IDIF for the time course of
the plasma/whole blood ratio was investigated. Finally, the
least invasive procedure was used to determine test–retest
variability of [11C]docetaxel quantification in tumors.
[11C]docetaxel clearance
To determine the effect of dexamethasone on blood
kinetics of [11C]docetaxel, the clearance of [11C]docetaxel
was calculated using the following equation:
Clearance ¼ DÐ
CpðtÞ  dt BSA
where the injected does (D) of [11C]docetaxel is divided by
the integral of the plasma time-activity curve multiplied by
the body-surface area (BSA).
Statistics
Statistical analysis was carried out using SPSS software
(SPSS for Windows 16.0, SPSS, Inc.). Correlations were
explored using the Spearman’s correlation coefficient. Level
of agreement was assessed using the intraclass correlation
coefficient with a 2-way randommodel and Bland–Altman
analysis (22). TheMann–Whitney test was used to compare
between groups.
Results
[11C]docetaxel kinetics in blood
Initially, the plasma/whole blood ratio was >1, but it
rapidly decreased to values <1 from 15 minutes onward
(Supplementary Fig. S2A). There was high correlation
between plasma/whole blood ratios obtained from arterial
and venous sampling (Spearman’s r ¼ 0.970; P < 0.001;
n¼ 169). In all patients, there was rapid systemic clearance
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Figure 2. A, PET image of
[11C]docetaxel uptake at 10–60
minutes post injection showing a
mediastinal metastasis with
increased [11C]docetaxel uptake
(arrow). B, corresponding CT
image. C, PET-CT fusion image.
D, representative time-activity
curve in the corresponding tumor.
E, Patlak-plot of [11C]docetaxel in
the corresponding tumor. Ki, net
influx rate constant; CT, measured
PET activity in tumor; CP,
measured plasma activity in
arterial blood.
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of radioactivity from blood (Supplementary Fig. S2B). This
precluded reliable high performance liquid chromatogra-
phy (HPLC) measurements of radiolabeled metabolites of
[11C]docetaxel beyond 15 minutes after injection. Over the
first 15 minutes, HPLC chromatograms did not reveal any
radiolabeled metabolites and no radioactivity was mea-
sured in the solid-phase-extraction-rinsing fraction. Due to
this rapid clearance of [11C]docetaxel, calibration of the
BSIF was not reliable at time points > 10 minutes after
injection. Therefore, only the first 10 minutes of data were
used for further analysis.
Quantification of [11C]docetaxel kinetics in tumors
[11C]docetaxel accumulated in lung cancer lesions
(Fig. 2). Fig. 2D shows a representative time-activity curve
of [11C]docetaxel in lung cancer. In the 17 patients who
underwent arterial blood sampling, a total of 15 lesions
had a volume 4 cm3. As a result, 15 lesions were eligible
for validation of a simplified method for the analysis of
[11C]docetaxel PET/CT scans. According to both Akaike
and Schwarz criteria, the irreversible two-tissue compart-
ment model was the kinetic model of choice for 14 out of
15 lesions.
The irreversible behavior of [11C]docetaxel kinetics was
confirmed by Patlak plots, which became linear soon
after injection (Fig. 2E). The Patlak method showed the
most robust values for Ki, whereas the individual micro-
parameters K1, k2, and k3 showed relative large standard
errors, which are due to noise levels of tissue tracer
kinetics.
Validation of a less invasive procedure
Patlak andnonlinear regression analyses of [11C]docetaxel
data produced comparable Ki values (Spearman’s r¼ 0.979;
P < 0.001; Fig. 3A). Therefore, the more robust and faster
Patlak method was used in further analyses. Although Ki
valueswere lower for ascendingaortaderived IDIF than those
for corresponding BSIF (Fig. 3B), correlation between
both sets of Ki values was high (Spearman’s r ¼ 0.946;
P < 0.001). Use of venous and arterial samples to correct
IDIF for plasma/whole blood ratios resulted in comparable
Ki values (Spearman’s r¼ 0.986; P < 0.001; Fig. 3C). Accord-
ing to the Patlak method, the median Ki values
were 0.011 mLcm3min1 (range, 0.003–0.024
mLcm3min1), 0.008 mLcm3min1 (range, 0.003–
0.019 mLcm3min1), and 0.008 mLcm3min1 (range,
0.003–0.021 mLcm3min1) for BSIF, IDIF using arterial
samples and IDIF using venous samples, respectively.
Finally, using IDIF (with plasma/whole blood correc-
tions based on venous samples) in the test–retest analysis
showed good reproducibility for Ki (Fig. 3D) with an
intraclass correlation coefficient of 0.952 (95% confidence
interval: 0.781–0.990), an absolute repeatability coefficient
of 0.003 mLcm3min1 and a relative repeatability coef-
ficient of 29%. These results indicate that an IDIF, together
with venous blood samples, could be used as a noninvasive
arterial input function. Consequently, arterial sampling
could be discarded in the following patients. Finally,
venous samples were used to quantify tumor uptake of
[11C]docetaxel in all 34 patients.
Correlation with tumor perfusion
In the 28 patients who underwent an additional PET scan
with [15O]H2O, a total of 27 lesions (20 primary tumors
and 7 metastases) with a size 4 cm3 could be defined on
the low-dose CT scan. In these lesions, tumor perfusion was
variable with a median perfusion of 0.281 mLcm3min1
(range, 0.052–0.904 mLcm3min1). A significant asso-
ciation between Ki of [
11C]docetaxel and tumor perfusion
was found (Spearman’s r ¼ 0.815; P < 0.001; Fig. 4).
Correlation with tumor size
Overall, 32 lesions (22 primary tumors and 10 metas-
tases) could be identified on the corresponding low-dose
CT scans. In these lesions, the Ki of [
11C]docetaxel was
variable (range, 0.0023–0.0229 mLcm3min1) with a
median Ki of 0.0092 mLcm3min1. Although the size
of the lesions was highly variable (median size, 20 cm3;
range, 5–485 cm3), therewas no association between tumor
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size and Ki of [
11C]docetaxel (Spearman’s r ¼ 0.140;
P ¼ 0.446) or tumor perfusion (Spearman’s r ¼ 0.139;
P ¼ 0.491).
Effects of dexamethasone on [11C]docetaxel kinetics
As premedication with dexamethasone was required in
the first 24 patients and discontinued thereafter, it was
possible to investigate potential effects of dexamethasone
administration on [11C]docetaxel kinetics in tumors (size
4 cm3). Dexamethasone treated patients had significantly
lower Ki values (median Ki, 0.0072 mLcm3min1; range,
0.0023–0.0208 mLcm3min1) than patients not pre-
treated with dexamethasone (median Ki, 0.0118
mLcm3min1; range, 0.0051–0.0229 mLcm3min1;
Mann–Whitney, P ¼ 0.013; Fig. 5A).
Althoughtumorperfusionwas somewhat lower inpatients
pretreated with dexamethasone (median perfusion, 0.265
mLcm3min1; range, 0.052–0.725 mLcm3min1) as
compared with patients who were not pretreated with dex-
amethasone (median perfusion, 0.396 mLcm3min1;
range, 0.093–0.904 mLcm3min1), this difference did
not reach statistical significance (Mann–Whitney, P ¼
0.093; Fig. 5B).However, whenKiwas normalized for tumor
perfusion, therewasnodifferencebetweenpatientswhowere
pretreated with dexamethasone and patients who were not
pretreated (Mann–Whitney, P ¼ 0.297). When analyzed
separately, the association between Ki of [
11C]docetaxel
and tumor perfusion still persisted in both patients treated
(Spearman’s r ¼ 0.785; P ¼ 0.001) and not treated
(Spearman’s r ¼ 0.552; P ¼ 0.063) with dexamethasone.
Furthermore, dexamethasone administration did not affect
[11C]docetaxel clearance from plasma. The median plasma
clearance during the first 10 minutes of data was 8.24
mLs1m2 (range, 6.09–12.40 mLs1m2) and 8.27
mLs1m2 (range, 6.32–9.44mLs1m2) in patientswith
and without dexamethasone premedication, respectively
(Mann–Whitney, P ¼ 0.724; Fig. 5C).
[11C]docetaxel kinetics and clinical outcome
Seven non-small cell lung cancer patients were scheduled
for docetaxel therapy following this PET study. Three of
those were treated simultaneously with platinum-
based agents. All patients received premedication with
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dexamethasone prior to PET scanning. When smaller
tumors were also included, a total of 12 lesions could be
identified in the field of view of the PET scan. In these
lesions, the median tumor size was 3 cm3 (range, 1–334
cm3) with a median [11C]docetaxel Ki of 0.0073
mLcm3min1 (range, 0.0023–0.0228 mLcm3min1).
In the first evaluation, the median change in the longest
diameter of these lesions was 4% (range, 6% to 100%).
The Ki of [
11C]docetaxel was negatively associated with the
change in tumor size (Spearman’s r¼ 0.803; P ¼ 0.002).
Tumors with a Ki value > 0.0073 mLcm3min1 had a
significantly better response than tumors with a lower Ki
value (Mann–Whitney, P ¼ 0.007). Figure 6 shows an
example of a patient with stable disease and another
patient with progressive disease. The change in tumor size
was not significantly affected by additional treatment with
platinum-based agents (Mann–Whitney, P ¼ 0.073).
Discussion
Docetaxel is an effective drug for the treatment of
patients with several cancers, including non-small cell lung
cancer (23, 24). However, tumor resistance to docetaxel
therapy remains a major challenge. Quantitative
[11C]docetaxel PET studies may provide insight in kinetics
of docetaxel in tumors and therefore contribute to appro-
priate selection of cancer patients for docetaxel therapy.
Using a state of the art validation approach, the present
study shows the feasibility and reproducibility of quanti-
tative PET studies with [11C]docetaxel in patients with lung
cancer. Tumor kinetics of [11C]docetaxel were irreversible
and associated with tumor perfusion. Patients pretreated
with dexamethasone showed significantly lower
[11C]docetaxel uptake in tumors, whereas no difference
in [11C]docetaxel clearance was measured in these patients.
In the few patients who were subsequently treated with
docetaxel, [11C]docetaxel uptake in tumors seemed to be
associated with treatment outcome.
[11C]docetaxel showed fast kinetics, reflected by the
rapid clearance of radioactivity from blood. Consequently,
only 10 minutes of blood data could be used, as input
functions were not reliable at later times. In addition, 10–
15 minutes after injection already more than 50% of the
total administered activity was located in the liver. Rapid
clearance of [11C]docetaxel from blood and high
[11C]docetaxel uptake in liver likely reflect extensive meta-
bolism of docetaxel. Nevertheless, no radiolabeled meta-
bolites of [11C]docetaxel were detected, obviating the need
to correct the arterial input function for radiolabeled meta-
bolites. In the liver microsomes, docetaxel is metabolized
mainly by the cytochrome P450 enzyme CYP3A4 (25).
Hepatic transformation and subsequent biliary excretion
into feces is known to account for80% of the elimination
of an administered therapeutic dose (26). In addition, active
effluxbyABCB1 in intestine andbiliary systemrepresents an
alternative pathway of docetaxel elimination (27).
Ki of [
11C]docetaxel in lung cancer was variable and
highly related to tumor perfusion, but not to tumor size.
Figure 6. Computed tomography
images of 2 patients with
metastatic non-small cell lung
cancer who were treated with
docetaxel. A–B, example of a
patient with relatively high
[11C]docetaxel uptake
(Ki ¼ 0.0151 mLcm3min1) in
recurrent disease (arrow), which
showed stable disease (B) as
compared with baseline (A). C–D,
example of a patient with relatively
low [11C]docetaxel uptake
(Ki ¼ 0.0050 mLcm3min1) in
the primary tumor (arrow), which
showed rapid progression with
increased atelectasis within
2 months (D) as compared with
baseline (C).
A B
C D
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Tumor perfusion also was variable, which may reflect
interindividual differences in tumor vasculature. The tumor
vasculature itself may also limit [11C]docetaxel delivery to
tumors, as it is structurally and functionally abnormal,
consisting of leaky and dilated vessels that result in
increased interstitial fluid pressure and reduced drug pene-
tration (28). Limited drug penetration in tumors is an
important mechanism of tumor resistance to docetaxel
therapy. A previous study in tumor xenografts showed that
docetaxel accumulation was limited to the first 100 mm
around a blood vessel, with little drug reaching a distance
of 100 to 150 mm (29). Although a larger tumor size may
result in reduced perfusion in the central part, consequently
leading to lower average perfusion values, no associations
between tumor size and [11C]docetaxel kinetics or tumor
perfusion were found.
The high correlation between tumor perfusion and
[11C]docetaxel uptake suggests that tumor uptake of
[11C]docetaxel primarily depends on tumor perfusion.
Consequently, administration of drugs that change tumor
perfusion, e.g., antiangiogenic agents, may have signifi-
cant effects on docetaxel delivery to tumors, possibly
affecting its efficacy. The methodology developed here,
measuring both perfusion and docetaxel kinetics, pro-
vides a noninvasive means to investigate effects of anti-
angiogenic drugs on both tumor perfusion and docetaxel
delivery. This, in turn, may lead to optimized scheduling
of drugs, thereby enhancing antitumor efficacy of com-
bination therapy.
Next to tumor perfusion, intracellular binding of
[11C]docetaxel to tubulin may determine [11C]docetaxel
kinetics in tumors. The taxane docetaxel acts by binding to
the beta-tubulin subunit of the microtubules, promoting
tubulin assembly into microtubules, stabilizing them, and
inhibiting depolymerization to free tubulin (2). Tumor cells
can alter the tubulin isotype, thereby reducing docetaxel
binding (30) with subsequent lower Ki values of
[11C]docetaxel.
Apart from those parameters that regulate uptake of
[11C]docetaxel in tumor tissue, efflux from tumor cells
may be another determinant of [11C]docetaxel kinetics,
especially because docetaxel is a substrate for the drug efflux
transporter ABCB1 (9). This efflux transporter is a member
of the ATP binding cassette family and may contribute to
multidrug resistance in tumors by actively eliminating drugs
from cancer cells (31). The lowerKi values of [
11C]docetaxel
measured in patients treated with the ABCB1 inducer dex-
amethasone may reflect the importance of ABCB1 for
[11C]docetaxel kinetics in tumors. In addition, antivascular
effects of dexamethasone may contribute to the lower Ki
values of [11C]docetaxel, because dexamethasone is known
to decrease total blood volume in tumors (32). The non-
significant difference in perfusion-normalized Ki values
suggests that reduced tumor perfusion may contribute to
lower [11C]docetaxel uptake in dexamethasone pretreated
patients. Although dexamethasone potentially increases
[11C]docetaxel clearance by inducingboth intestinal ABCB1
(12) and CYP3A4 activity (33), dexamethasone adminis-
tration was not associated with higher [11C]docetaxel
plasma clearance. As calculated Ki values of [
11C]docetaxel
were corrected for the activity in plasma, the present
explorative analysis suggests that dexamethasonemay affect
[11C]docetaxel kinetics in tumors. To date, conflicting
results have been reported on the antitumor effects of
dexamethasone in addition to docetaxel (34, 35). Because
dexamethasone is administered routinely as premedication
for docetaxel,more studies are required to further clarify the
effects of dexamethasone and its scheduling on perfusion
and docetaxel kinetics in tumors.
PET using radiolabeled anticancer drugs may be valu-
able for predicting outcome prior to start of treatment
and, as such, it may be an important tool for individua-
lized treatment planning. Human PET studies with radi-
olabeled anticancer drugs (36), including F-18 labeled
5-fluorouracil ([18F]5-FU; ref 37 and 38) and tamoxifen
([18F]fluorotamoxifen; ref. 39), have shown that high
tumor concentrations of the radiolabeled drug were asso-
ciated with improved tumor response. Although the
present study was not designed to predict tumor response
to docetaxel therapy, the finding in the limited
number of docetaxel-treated patients suggests that vari-
able [11C]docetaxel kinetics in tumors may reflect differ-
ential sensitivity to docetaxel therapy. Ideally, only
patients scheduled for docetaxel treatment should have
been selected for the present study. In the present valida-
tion study, however, three cannulas including one for
arterial sampling were required and therefore also
patients scheduled for other therapies were included.
The noninvasive approach developed in this study now
provides a means to investigate the relationship between
[11C]docetaxel uptake and response to docetaxel treat-
ment in larger cohorts of lung cancer patients and in
patients with other tumors located in the thoracic region
such as locally advanced breast cancer. Although micro-
dosing prevents patients from drug-induced toxicities
associated with therapeutic doses, it has potential limita-
tions, as the kinetic behavior of tracer and therapeutic
doses differ. Therefore, further PET studies using
[11C]docetaxel during docetaxel therapy are also needed
to assess whether tumor kinetics are dose dependent.
In conclusion, full quantification of [11C]docetaxel
kinetics in lung cancer patients using a noninvasive
PET based approach is feasible. Tumor kinetics of
[11C]docetaxel were highly variable and strongly related
to tumor perfusion. In addition, uptake of [11C]docetaxel
in tumors was reduced in patients pretreated with dexa-
methasone. Variable [11C]docetaxel kinetics in tumors may
reflect differential sensitivity to docetaxel therapy. The
findings of this study warrant further clinical studies inves-
tigating the predictive value of initial [11C]docetaxel uptake
and the effects of comedication on docetaxel kinetics in
tumors.
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SUPPLEMENTARY METHODS 
 
Analyses of blood samples 
Blood samples were analyzed for blood and plasma concentrations and potential 
radiolabeled metabolites of [11C]docetaxel. Whole blood (0.5 mL) was weighted in 
duplicate and 0.05 mL 10% Triton X-100 solution was added. After centrifuging the 
remaining whole blood (5 min; room temperature; 4000 rpm), plasma was harvested 
and 0.5 mL plasma was weighted in duplicate, again adding 0.05 mL 10% Triton X-100 
solution. A well-counter (Wallac 1480 Wizard, Perken Elmer, Zaventem, Belgium), cross-
calibrated against the PET scanner, was used to determine activity concentrations.  
 
For metabolite analysis, a high performance liquid chromatography (HPLC) system, as 
described previousl (1,2), was used. The HPLC column used was a Phenomenex Luna 5u 
C18 100A 250 x 10.00 mm (Phenomenex, Torrance, CA, USA). Components for solid 
phase extraction (SPE) columns (4.7 x 50 mm) were purchased from Jones 
Chromatography (Hengood, England). tC18 specification silica stationary phase, used in 
the SPE columns, was obtained from commercially available Sep-Pak® cartridges (Waters 
Corporation, Milford, MA, USA). Harvested plasma was rinsed, using a Millipore GV filter 
(Millipore, Molsheim, France). The HPLC loop was loaded with a plasma sample that was 
eluted onto the SPE column, using a 0.01 M di-ammonium hydrogen phosphate solution 
with a flow of 0.5 mL·min-1 for a period of 4 min. The flow was then gradually increased 
to 3 mL·min-1 for a period of 30s and kept at 3 mL·min-1 for an additional 220s to rinse 
polar plasma components from the SPE column. The phosphate fraction was collected 
and weighted. Amounts of ~ 1.5 mL of this eluate were weighted and counted for 
radioactivity, resulting in the polar metabolite fraction [counts per minute (CPM)·g-1] if 
activity was measured. Trapped activity was then eluted from the SPE column with a 
mixture of 65/35 acetonitril/ammoniumacetate 5mMol, pH 4.1 onto the HPLC column 
with a flow of 1.8 mL·min-1 for a period of 20 min. The eluate was collected in fractions of 
30s that were counted using a gamma counter to generate an HPLC plot. A weighted 
aliquot of the plasma was also counted for calculating recovery. 
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic diagram illustrating the various analyses that were performed to validate a 
less invasive procedure for analysis of [11C]docetaxel kinetics in lung cancer patients. 
TAC, time-activity curve; BSIF, blood sampler derived input function; IDIF, image derived 
input function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  
(A) Mean (o) ± SD (vertical error bars) of arterial plasma/whole blood ratios as function of time for 
seventeen patients. The solid line represents the best fit of these ratios to a sigmoid function.  
(B) Mean whole blood and plasma time-activity curves of seventeen patients.  
P/W ratio, plasma/whole blood ratio; normalized activity, activity concentration normalized to the 
area under the curve of the corresponding whole blood curve.  
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SUMMARY
Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical beneﬁt in cancer
patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal
tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this
concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission
tomography (PET) and radiolabeled docetaxel ([11C]docetaxel). In NSCLC, bevacizumab reduced both
perfusion and net inﬂux rate of [11C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical
relevance of these ﬁndings is notable, as there was no evidence for a substantial improvement in drug
delivery to tumors. These ﬁndings highlight the importance of drug scheduling and advocate further studies
to optimize scheduling of anti-angiogenic drugs.
INTRODUCTION
Angiogenesis is a critical component for growth and metastatic
spread of tumors (Hanahan and Weinberg, 2000; Carmeliet,
2000). Vascular endothelial growth factor (VEGF), which is over-
expressed in many human malignancies, is a key regulator of
tumor angiogenesis, inducing proliferation, differentiation, and
migration of endothelial cells (Ferrara et al., 2003). Consequently,
numerous drugs have been developed to target the signaling
pathways of VEGF and its receptors (VEGFR; Ferrara andKerbel,
2005).
Bevacizumab is a humanized monoclonal antibody that
targets circulating VEGF and subsequently prevents binding of
VEGF to its receptors (Ferrara et al., 2004). Except for metastatic
renal cell cancer (Yang et al., 2003), clinical efﬁcacy of single-
agent bevacizumab treatment has been very limited in the
majority of advanced malignancies (Reese et al., 2001; Cobleigh
et al., 2003). Combined with chemotherapy, however, additional
value was shown in colorectal (Hurwitz et al., 2004), breast (Miller
et al., 2007), and non-small cell lung cancer (NSCLC; Sandler
et al., 2006).
In the past years, the normalization theory proposed by Jain
(2001) has gained widespread acceptance for explaining
additional antitumor effects of inhibitors of VEGF signaling,
when combined with cytotoxic drugs. It is hypothesized that
anti-angiogenic drugs normalize structurally and functionally
abnormal tumor vasculature, thereby reducing interstitial ﬂuid
pressure, improving drug penetration, and subsequently
Signiﬁcance
Optimal scheduling of anti-angiogenic drugs is important for improving efﬁcacy of combination therapy in patients with
advanced-stage cancer. In this study, effects of the anti-angiogenic drug bevacizumab on delivery of chemotherapy to
non-small cell lung cancer (NSCLC) were investigated using positron emission tomography and 11C-labeled docetaxel.
Bevacizumab induced a rapid and signiﬁcant reduction in delivery of chemotherapy to tumors in NSCLC patients. The study
provides a framework for investigating effects of anti-angiogenic drugs on drug delivery to tumors in vivo. In addition, it high-
lights the importance of drug scheduling and advocates further studies to optimize scheduling of anti-angiogenic drugs.
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enhancing efﬁcacy of cytotoxic drugs. Exploration of the
normalization window may be crucial for optimizing drug
scheduling in order to improve clinical efﬁcacy. To date,
however, no clinical studies have been reported on the effects
of anti-angiogenic agents on drug delivery in cancer patients.
Positron emission tomography (PET) is a noninvasive imaging
technique that can be used to monitor drug pharmacokinetics
and pharmacodynamics in vivo by radiolabeling drugs of interest
with short-lived positron emitting radionuclides (Gambhir, 2002).
Previously, the cytotoxic drug docetaxel, a taxane targeting the
microtubular network, has been radiolabeled with the radionu-
clide C-11 ([11C]docetaxel; van Tilburg et al., 2004), enabling
in vivo quantiﬁcation of docetaxel kinetics in lung cancer (Van
der Veldt et al., 2011). In the latter study, feasibility of noninvasive
PET measurements using radiolabeled water ([15O]H2O) and
[11C]docetaxel was demonstrated and uptake of [11C]docetaxel
in lung tumors was found to be associated with tumor perfusion,
measured using [15O]H2O.
The purpose of the present study was to investigate the
effects of anti-angiogenic drugs on tumor perfusion and
[11C]docetaxel delivery in patients with advanced-stage NSCLC
using PET. To this end, bevacizumab was selected, as it is the
most selective inhibitor of VEGF signaling among currently
approved anti-angiogenic drugs. It was hypothesized that
bevacizumab improves drug delivery by normalizing tumor
vasculature, which should be reﬂected by a more homogeneous
distribution of perfusion and [11C]docetaxel delivery. A
secondary objective of this study was to investigate (systemic)
effects of bevacizumab on (1) circulating VEGF levels in plasma;
(2) cardiovascular parameters, including blood pressure,
cardiac output, and microcirculation in muscle and skin; (3)
systemic exposure of [11C]docetaxel; and (4) perfusion and
[11C]docetaxel uptake in normal tissues. For the latter, the
thyroid gland and the vertebral body were selected. The thyroid
gland is known to be highly sensitive to VEGF inhibition (Kamba
et al., 2006), whereas the vertebral body may reﬂect effects of
bevacizumab on [11C]docetaxel uptake in bone marrow.
Figure 1. Tumor Measurements in 10 NSCLC
Patients at Baseline and after Administration of
Bevacizumab
Horizontal bars represent median values.
(A) Perfusion (F).
(B) Volume of distribution of water (VT).
(C) F/VT.
(D) Net rate of inﬂux (Ki) of [
11C]docetaxel.
*p value < 0.05; **p value < 0.01.
RESULTS
Bevacizumab Induces Rapid Reduction
in Tumor Perfusion
To investigate the effect of anti-VEGF therapy
on tumor perfusion (F), PET scans using
[15O]H2O, which is a freely diffusible tracer
(Hoekstra et al., 2002; Wilson et al., 1992),
were performed at baseline and 2 hr, 5 hr, and
4 days after bevacizumab administration. Five
hours after bevacizumab administration, there
was a signiﬁcant reduction in tumor perfusion, which persisted
until day 4 (Figures 1A and 2A). In three out of eight patients,
tumor perfusion already decreased 2 hr after the end of bevaci-
zumab infusion. Accordingly, tumor perfusion showed median
percentage changes of 8% (range39 to +15%; N = 9; p value =
0.889), 20% (range, 39 to 7%; N = 8; p value = 0.012),
and 38% (range, 55 to 4%; N = 10; p value = 0.005) at
2 hr, 5 hr, and 4 days after bevacizumab administration, respec-
tively. In addition, the volume of distribution of water (VT),
a measure of the (viable) fraction of tissue that is able to
exchange [15O]H2O, was decreased at 4 days after bevacizumab
administration (Figure 1B), with a median percentage change
of 7% (range, 52 to +2%; N = 10; p value = 0.022). Individu-
ally, eight out of ten patients showed a reduction in volume of
distribution of water. Although both perfusion and volume of
distribution of water showed an overall decrease, the reduction
in perfusion was more severe, as illustrated by a signiﬁcant
decrease in the ratio of tumor perfusion over volume of distribu-
tion (F/VT; (Figure 1C). Collectively, these ﬁndings indicate that
the decrease in tumor perfusion is not due to a reduction in
tumor tissue, which was conﬁrmed by an unchanged tumor
volume on subsequent computed tomography (CT) scans.
Bevacizumab Decreases the Net Inﬂux Rate of
[11C]docetaxel in Tumors
To determine whether delivery of chemotherapy is affected by
bevacizumab, PET scans using [11C]docetaxel were performed
at baseline and 5 hr and 4 days after bevacizumab administra-
tion. Kinetics of [11C]docetaxel in tumor tissue are irreversible
and can be quantiﬁed using Patlak graphical analysis, providing
the net inﬂux rate constant (Ki) of [
11C]docetaxel in tumor
tissue (Patlak et al., 1983; Van der Veldt et al., 2011). Prior
to bevacizumab infusion, tumors showed a variable Ki of
[11C]docetaxel (median Ki, 0.0132 ml$cm
3$min1; range,
0.0054–0.0247 ml$cm3$min1; N = 10). After administration of
bevacizumab, median Ki of [
11C]docetaxel signiﬁcantly
decreased (Figures 1D and 2B), resulting in amedian percentage
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change of 22% (range, 51 to 4%; N = 9; p value = 0.008)
and 34% (range, 61 to 16%; N = 10; p value = 0.005) at
5 hr and 4 days, respectively. In line with the decrease in
the volume of distribution of water, the distribution volume of
[11C]docetaxel, which can be obtained from the Patlak plot,
also showed a decline on day 4 with a median percentage
change of 14% (range, 24 to + 20%; N = 10; p value =
0.052). Before administration of bevacizumab, [11C]docetaxel Ki
was associated with tumor perfusion (Spearman’s r = 0.626;
N = 10; p value = 0.053). As two patients had one missing scan
(either [11C]docetaxel PET or [15O]H2O PET), this correlation
could not be evaluated at 5 hr. At 4 days, the correlation between
[11C]docetaxel Ki and perfusion showed a slight decrease
(Spearman’s r 0.564; N = 10; p value = 0.090).
Tumor Heterogeneity of [11C]docetaxel Uptake
Is Not Affected by Bevacizumab
As it is assumed that normalization of tumor vasculature results
in a more homogenous distribution of perfusion and drug
delivery, spatial distributions of tumor perfusion, volume of
distribution of water, and [11C]docetaxel Ki were analyzed on
a voxel-by-voxel basis using histogram analysis. For the Ki of
[11C]docetaxel, only the median kurtosis of the histograms
showed a trend toward an increase from 2.60 at baseline to
3.11 (N = 9; p value = 0.051) and 2.97 (N = 10; p value = 0.059)
at 5 hr and 4 days, respectively, whereas standard deviation
and kurtosis of the other histograms (F and VT) did not change.
When histogram analysis was applied to separately analyze
tumor center and rim, larger tumors showed lower perfusion
and lower values of [11C]docetaxel Ki in the center than in the
rim. When all primary tumors were analyzed, median baseline
values, however, were not signiﬁcantly different (N = 10; p value =
0.739 and 0.579, respectively). At 5 hr and 4 days after bevacizu-
mab administration, mean, median, minimum, and maximum
values of tumor perfusion and [11C]docetaxel Ki showed the
same degree of reduction (p value < 0.05) in the whole tumor,
as in the center and the rim separately. In addition, the volume
of distribution of water showed a signiﬁcant decrease in both
center and rim at 4 days (N = 10; p value < 0.05). Standard devi-
ation and kurtosis of all histograms (F, VT, and [
11C]docetaxel Ki)
did not change in the center and the rim, except for a decreased
standard deviation of perfusion in the center at 5 hr (N = 8;
p value = 0.028). Furthermore, changes in perfusion, volume of
distribution of water, and [11C]docetaxel Ki were not associated
with baseline tumor volumes. Collectively, these results indicate
that bevacizumab induces an overall decrease in perfusion,
volume of distribution of water, and [11C]docetaxel Ki in tumors
without signiﬁcantly affecting tumor heterogeneity.
Decrease in [11C]docetaxel Delivery to Tumors Is
Accompanied by Rapid Reduction in Circulating VEGF
Plasma levels of circulating VEGF were measured to evaluate
whether the rapid decrease in [11C]docetaxel Ki in tumors was
supported by a rapid decrease in free VEGF. As VEGF is mainly
transported by platelets (Verheul et al., 1997), circulating VEGF
was assessed in both platelet-poor and platelet-rich plasma.
At 3 hr, administration of bevacizumab resulted in a signiﬁcant
decrease in circulating VEGF in platelet-rich plasma (N = 7;
p value = 0.018; Figure 3). In the majority of patients, free
VEGF in plasma was completely neutralized within 3 hr and
seemed to recover in part after 4 days. Comparable changes
in VEGF levels were measured in platelet-poor plasma.
A Reduction in [11C]docetaxel Delivery to Tumors Is Not
Associated with Cardiovascular Parameters
Because arterial hypertension and cardiotoxicity are commonly
reported side effects associated with inhibitors of VEGF/
VEGFR-2 signaling (Chen and Cleck, 2009), it was investigated
whether the rapid decrease in tumor perfusion and [11C]doce-
taxel Ki was accompanied by early onset cardiovascular
changes. A single infusion of bevacizumab did not affect systolic
and diastolic blood pressure during the ﬁrst 4 days (Figures 4A
and 4B). Median cardiac output as derived from ﬁrst pass
dynamic [15O]H2O PET scans (Knaapen et al., 2008), however,
showed a trend toward a reduction at day 4 (from 6.9 l$min1
to 6.0 l$min1; N = 9; p value = 0.051; Figure 4C). As inhibitors
of VEGF/VEGFR-2 signaling may induce so-called rarefaction
(Mourad et al., 2008), that is, a reduction in the number of arteri-
oles or capillaries within vascular beds of various tissues (e.g.,
muscle and skin), muscle perfusion in the erector spinae, as
well as capillary density in the skin, were measured. Muscle
perfusion was obtained from the [15O]H2O images, whereas nail-
fold capillaries in the dorsal skin of the third ﬁnger were examined
using a capillary microscope (Serne´ et al., 2001). Perfusion in the
erector spinae muscle and capillary density in the skin did not
change during the ﬁrst 4 days after administration of
Figure 2. PET-CT Images of a 51-Year-Old Woman
with Metastatic Non-Small Cell Lung Cancer
(A) Parametric perfusion images obtained at baseline
and at 5 hr and 4 days after bevacizumab administration.
In the whole tumor, the mean perfusion changed from
0.875ml$cm3$min1 at baseline to 0.765ml$cm3$min1
at 5 hr and 0.535 ml$cm3$min1 at 4 days.
(B) Patlak images of [11C]docetaxel uptake obtained at
baseline and at 5 hr and 4 days after bevacizumab
administration. In the whole tumor, the mean Ki of
[11C]docetaxel changed from 0.0205 ml$cm3$min1 at
baseline to 0.0193 ml$cm3$min1 at 5 hr and
0.0127 ml$cm3$min1 at 4 days.
F, perfusion; Ki, net inﬂux rate constant.
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bevacizumab (Figures 4D, 4E, and 4F). Of note, [11C]docetaxel Ki
in muscle tissue (median Ki, 0.0072 ml$cm
3$min1; range,
0.0029–0.0104 ml$cm3$min1) was lower than that in tumor
tissue (N = 10; p value = 0.002). The Ki of [
11C]docetaxel in
muscle tissue was neither associated with perfusion nor affected
by bevacizumab.
Bevacizumab Increases Systemic Exposure
of [11C]docetaxel
To investigate whether decreased [11C]docetaxel Ki in tumor
tissue was associated with a change in systemic exposure of
[11C]docetaxel, plasma clearance of [11C]docetaxel was deter-
mined. Four days after bevacizumab administration, plasma
clearance of [11C]docetaxel was signiﬁcantly decreased (N = 10;
p value = 0.037), as reﬂected by a shift to the right of the plasma
curves (Figure 5). Consequently, bevacizumab increased thedura-
tionof [11C]docetaxel exposurebya reduction inplasmaclearance.
However, this increased systemic exposure of [11C]docetaxel did
not result in increased [11C]docetaxelaccumulation in tumor tissue,
as the retention index of [11C]docetaxel still decreased after
bevacizumabadministration (from0.0155ml$cm3$min1atbase-
line to 0.0109 ml$cm3$min1 at day 4; N = 10; p value = 0.005).
Bevacizumab Decreases Thyroid Perfusion
Because normal vessels of the thyroid gland are known for their
extensive capillary regression after anti-VEGF therapy (Kamba
et al., 2006), thyroid perfusion was also determined using para-
metric perfusion images. In four out of ten patients, the primary
tumorwas located in the upper lobes, enabling adequate analysis
of thyroid perfusion at baseline and day 4. Four days after beva-
cizumab administration, median perfusion in the thyroid gland
showed a decrease (from 1.316 ml$cm3$min1 at baseline to
0.585 ml$cm3$min1 at day 4; p value = 0.068), whereas the
volume of distribution of water did not change (p value = 0.273).
[11C]docetaxel Uptake in Bone Marrow Is Not Affected
by Bevacizumab
As [11C]docetaxel shows high uptake in bone marrow (Van der
Veldt et al., 2010b) and anti-VEGF therapy can block rapid
induction of viable circulating endothelial progenitor cells from
bone marrow and can inhibit taxane-induced bone marrow
colonization in tumors (Shaked et al., 2008), the effects of beva-
cizumab on [11C]docetaxel uptake in bone marrow was also
evaluated. To this end, perfusion and [11C]docetaxel Ki were
determined in the vertebral body. Perfusion values were signiﬁ-
cantly lower in the vertebral body than in tumors (N = 10; p value=
0.003), whereas Ki values of [
11C]docetaxel were signiﬁcantly
higher than those in tumors (N = 10; p value < 0.001; Figure 6).
In contrast to tumor tissue, there was no association between
[11C]docetaxel Ki and perfusion in the vertebral body (Spear-
man’s r = 0.285; N = 10; p value = 0.425). Perfusion and
[11C]docetaxel Ki did not change after bevacizumab administra-
tion (Figure 6).
DISCUSSION
Current strategies combining anti-angiogenic therapy with cyto-
toxic agents have shown proven efﬁcacy in cancer patients,
including those with advanced-stage NSCLC (Sandler et al.,
2006). Pretreatment with anti-angiogenic drugs may transiently
normalize abnormal tumor vasculature (Batchelor et al., 2007)
and thereby contribute to improved delivery of subsequent
chemotherapy, enhancing efﬁcacy (Jain, 2005). Investigating
this process of vasculature normalization in vivo is a major
challenge, which is mainly restricted to imaging studies.
Whereas conventional imaging studies, such as CT and mag-
netic resonance imaging, have concentrated on changes in
tumor perfusion, the present concept of PET imaging using a
radiolabeled drug to study drug delivery in patients after anti-
VEGF therapy has not been reported yet. The humanized mono-
clonal antibody bevacizumab induced an overall decrease in
both perfusion and Ki of [
11C]docetaxel in tumor tissue within
a few hours after bevacizumab administration, a decrease
that persisted for at least four days. These ﬁndings represent
physiological changes in tumors, as measured changes were
beyond the known test-retest variability (van der Veldt et al.,
2010a and 2011). The large range of changes in perfusion and
[11C]docetaxel uptake is most likely due to interpatient differ-
ences in tumor response to bevacizumab and partly due to
differences in interval between end of bevacizumab infusion
and PET scans. Nevertheless, the results indicate a decrease
in perfusion and [11C]docetaxel uptake in tumor tissue of all
patients. Based on these data, it can be concluded that anti-
VEGF therapy is not able to improve drug delivery to tumors
but rather has the opposite effect.
Results of the present study are at variance with those ob-
tained by Willett et al. (2004), where improved drug delivery in
rectal cancer was postulated partly based on human imaging
studies. Tumor perfusion, as determined by dynamic contrast-
enhanced CT scanning decreased, whereas the standardized
uptake value of 20-deoxy-20-[18F]ﬂuoro-D-glucose ([18F]FDG)
remained unchanged at 12 days after bevacizumab administra-
tion. However, kinetics of [18F]FDG are fundamentally different
from those of anticancer drugs, as [18F]FDG reﬂects glucose
metabolism. In the present study, however, the decrease in
standard deviation of tumor perfusion in the center of the
tumor at 5 hr and the increase in kurtosis of [11C]docetaxel
histograms may reﬂect a more homogenous distribution as
Figure 3. Platelet-rich Plasma Levels of VEGF in Seven Individual
Patients at Baseline and after Administration of Bevacizumab
Vascular endothelial growth factor levels were corrected for platelet count and
are expressed in pg$ml1 per 200,000 platelets$ml1. Horizontal bars represent
median values.
*p value < 0.05.
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a result of certain normalization of tumor vasculature. Neverthe-
less, these possible changes in tumor heterogeneity did not
result in improved drug delivery, as bevacizumab infusion
caused a rapid and overall reduction in [11C]docetaxel Ki in
tumors. In addition, drug uptake may be further impaired by
development of tumor necrosis, associated with extensive
vascular damage, which usually develops after anti-VEGF
therapy. Although it is not possible to deﬁne necrotic areas on
low-dose CT, development of necrotic areas was possibly re-
ﬂected by a reduction in the distribution volume of water after
4 days, despite an unchanged total tumor volume on low-dose
CT.
Apart from tumor parameters, systemic effects after admin-
istration of bevacizumab were evaluated. The rapid changes
in tumor perfusion and [11C]docetaxel Ki were associated with
an immediate reduction in plasma levels of VEGF, indicating
an immediate inhibition of VEGF signaling in the whole body.
This rapid neutralization of circulating VEGF also induced a
decrease in perfusion of the thyroid gland, whereas perfusion
and [11C]docetaxel Ki in the vertebral body and muscle tissue
were not affected. In addition, Ki values of [
11C]docetaxel in the
vertebral body and muscle tissue were essentially different
from that in tumor tissue and were not related to perfusion in
these normal tissues. These ﬁndings imply that tumor tissue
shows a difference in sensitivity to VEGF inhibition (Kamba
et al., 2006) and in drug delivery as compared with normal
tissues. Among the cardiovascular parameters, only cardiac
output showed a decrease at day 4, whereas blood pressure
and capillary density did not change during the ﬁrst 4 days after
Figure 4. Cardiovascular Variables in Ten NSCLC
Patients at Baseline and after Administration of
Bevacizumab
Horizontal bars represent median values.
(A) Systolic blood pressure (SBP).
(B) Diastolic blood pressure (DBP).
(C) Cardiac output.
(D) Perfusion (F) in muscle tissue.
(E) Nailfold capillary density.
(F) Nailfold capillary density during venous occlusion (VO).
bevacizumab infusion. These ﬁndings indicate
that the rapid and signiﬁcant changes in
perfusion and [11C]docetaxel Ki in tumors are
not caused by immediate development of
hypertension, microvascular rarefaction, or a
rapid reduction in cardiac output. Conse-
quently, it can be concluded that the decrease
in perfusion and [11C]docetaxel Ki in tumors
can be attributed to rapid inhibition of VEGF
signaling in tumors. As the decrease in perfu-
sion and [11C]docetaxel uptake in tumors is
probably too rapid to be solely ascribed to
inhibition of tumor angiogenesis, vasoconstric-
tive effects of anti-angiogenic drugs on tumor
vessels, particularly those from the host,
should be considered as a potential underlying
mechanism. In this regard, inhibition of endo-
thelial nitric oxide synthesis by VEGF inhibitors
may be an important factor (Dhaun and Webb, 2010; Syrigos
et al., 2011; Ng et al., 2007). Although plasma clearance of
[11C]docetaxel decreased slightly after bevacizumab administra-
tion, signifying prolonged duration of [11C]docetaxel exposure,
this decrease in clearance appeared to be too limited to result
in an overall increase in [11C]docetaxel uptake, that is, retention
index, by tumors.
Bevacizumab was selected to investigate the effects of anti-
angiogenic agents, as it is the most selective inhibitor of VEGF
signaling among presently approved anti-angiogenic drugs,
and it does not have multiple targets like most tyrosine kinase
inhibitors. In addition, the long terminal half-life of 17–21 days
(Ferrara et al., 2004) enables sequential measurements after
a single administration of bevacizumab. The study was conduct-
ed in patients with advanced-stage NSCLC, as noninvasive
PET-CT measurements using [15O]H2O and [
11C]docetaxel
were previously found to be feasible in this patient group (Van
der Veldt et al., 2011). As a result, [11C]docetaxel measurements
could be repeated in individual patients who acted as their own
control. Although both docetaxel and bevacizumab are active
agents for the treatment of advanced lung cancer (Sandler
et al., 2006; Kudoh et al., 2006), single-agent bevacizumab is
not considered effective for the treatment of NSCLC patients.
Consequently, ethically it was not acceptable to prolong the
study with PET measurements at later time points. In addition,
the localization of the lung tumors did not enable invasive
measurements of interstitial ﬂuid pressure (Curti et al., 1993) or
sequential biopsies for additional histopathological analyses.
Furthermore, use of tracer amounts of docetaxel (microdoses)
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may be a potential limitation of the present study, as it is conceiv-
able that the effects of bevacizumab on [11C]docetaxel delivery
in tumors may not hold true for pharmacological drug concentra-
tions. However, use of repeated therapeutic doses mixed with
the radiolabeled drug, instead of microdoses, will obscure
bevacizumab-induced effects, as cytotoxic drugs themselves
also affect both tumor perfusion (Dunnwald et al., 2008) and
interstitial ﬂuid pressure (Griffon-Etienne et al., 1999) and may
modulate the speciﬁc targets of the drug under study (Shalli
et al., 2005). In a separate study, in which [11C]docetaxel was
given at tracer concentrations and during infusion of a thera-
peutic dose, albeit was possible to predict tumor uptake of
(therapeutic) docetaxel from the tumor kinetics of (tracer)
[11C]docetaxel (data not shown), indicating that the present
bevacizumab-induced decrease in [11C]docetaxel uptake in
tumors is likely to represent changes in tumor uptake of thera-
peutic doses of docetaxel.
The results of the present study pose a number of important
issues relevant to anti-angiogenic drugs administered in combi-
nation with other anticancer drugs. In human tumors, bevacizu-
mab induced a rapid decrease in perfusion and [11C]docetaxel
uptake. It is conceivable that other inhibitors of the VEGF
signaling pathways may produce similar effects. In addition, it
is likely that these effectsmay persist during continued treatment
with these drugs. Therefore, administration of anti-angiogenic
drugs can be considered after administration of the other anti-
cancer agents, as the immediate decrease in tumor perfusion
should decrease clearance of drugs from tumors. Hence,
preclinical studies are warranted to investigate this concept for
scheduling of anticancer drugs. To improve scheduling of
combination therapy, other potential mechanisms need to be
investigated to understand the synergistic effects with anti-
angiogenic drugs. In this regard, it is important to explore the
effects of anti-angiogenic drugs on proliferative activity of tumor
cells (Ortholan et al., 2010) and their environment, such as
mobilization of bone marrow-derived circulating endothelial
progenitor cells (Shaked et al., 2008) and acute release of
cytokines from the tumor microenvironment (Gilbert and He-
mann, 2010).
The results of the present study may explain why several
clinical trials have failed to show the additional value of anti-
angiogenic drugs in speciﬁc populations of cancer patients.
Clearly, more clinical studies are needed to assess whether
administration schedules affect response and outcome of com-
bination strategies. To this end, the optimal design to prove
clinical relevance of drug scheduling would be a randomized
controlled trial in which cancer patients are randomized to
different administration schedules.
In conclusion, the results of this human study indicate a rapid
and signiﬁcant reduction in perfusion and [11C]docetaxel uptake
in NSCLC after administration of bevacizumab. The clinical rele-
vance of these ﬁndings is notable, as the present study did not
provide evidence for a substantial improvement in drug delivery
to tumors but rather showed the opposite effect. These ﬁndings
highlight the importance of drug scheduling and advocate further
studies to optimize scheduling of anti-angiogenic drugs.
EXPERIMENTAL PROCEDURES
Patient Selection
Between October 2009 and September 2010, ten patients (six men and four
women; median age 58 years; range, 47–70 years) with advanced-stage
NSCLC were prospectively enrolled. Patients participated in this study prior
to their scheduled therapy. The study was approved by the Medical Ethics
Review Committee of the VU University Medical Center, Amsterdam. All
patients signed a protocol-speciﬁc informed consent form prior to study
enrollment.
Inclusion criteria were the following: age R18 years; a malignant lesion
R1.5 cm in diameter within the chest; life expectancy of at least 12 weeks;
Eastern Cooperative OncologyGroup performance status <3;R4weeks since
any prior surgery or radiotherapy; no previous acute toxicities (>1) in accor-
dance with Common Terminology Criteria for Adverse Events v3.0 (CTCAE);
adequate organ function [hemoglobin R6.0 mmol∙l1; absolute neutrophil
countR1.53 109/l; absolute platelet count >1003 109/l; total serum bilirubin
%1.5 upper limit of normal (ULN); aspartate aminotransferase and alanine
aminotransferase%2.5 x ULN (in case of liver metastases% 5 x ULN); alkaline
phosphatase%2.5 x ULN; serum creatinine%1.5 ULN or creatinine clearance
R60 ml∙min1; normal serum calcium; urine dipstick for proteinuria <2+]; and
use of effective contraception.
Exclusion criteria were the following: squamous lung cancer; history of R
grade 2 hemoptysis; cavitary lesion; tumor invading major blood vessels;
newly diagnosed and untreated central nervous system metastases; any
unstable systemic disease (including but not limited to clinically signiﬁcant
cardiovascular disease and uncontrolled hypertension); major surgery or
signiﬁcant traumatic injury <28 days before study entry; prior treatment with
taxanes or bevacizumab; concurrent treatment with other anticancer agents
or experimental drugs; use of inhibitors or substrates of the efﬂux transporter
ABCB1; serious nonhealing wound or ulcer; a history of documented hemor-
rhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use of
aspirin (>325 mg per day); planned radiotherapy or major surgery; pregnancy
or lactation; metal implants (e.g., pacemakers); and claustrophobia.
Study Design
Patients received a single infusion of bevacizumab (15 mg$kg1, infused over
90 min). In the week prior to this infusion, patients underwent a dynamic PET-
CT study with both [15O]H2O and [
11C]docetaxel. At 5 hr and 4 days after infu-
sion of bevacizumab, the PET-CT protocol was repeated. In addition, 2 hr after
infusion of bevacizumab, patients underwent an additional dynamic PET-CT
scan with [15O]H2O. Sequential scans were possible because of the short
half-lives of oxygen-15 and carbon-11, which are 2.0 and 20.3 min, respec-
tively. Initially, the last time point for PET measurements was set at day 7.
However, recruitment of patients seemed difﬁcult, as patients were not willing
Figure 5. Plasma Clearance of [11C]docetaxel at
Baseline and after Administration of Bevacizumab
(A) Example of plasma activity curves of [11C]docetaxel in
a patient at baseline and after 5 hr and 4 days following
bevacizumab administration. Plasma activity curves are
divided by injected dose (ID).
(B) Plasma clearance of [11C]docetaxel in 10 NSCLC
patients at baseline and after administration of bev-
acizumab.
Horizontal bars represent median values.
*p values < 0.05.
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to postpone their planned chemotherapy for more than a few days. Hence, the
protocol was amended and the last time point was set at day 4. Adverse events
were graded in accordance with CTCAE v3.0. After the last PET-CT study,
patients started with their scheduled therapy. In accordance with the guide-
lines of the Medical Ethics Review Committee of the VU University Medical
Center, the total radiation burden of the study was estimated at <10 mSv.
As efﬁcacy was not an endpoint of the present study, response evaluation
and data collection for survival were not performed.
Synthesis of Radiopharmaceuticals
The radiosyntheses of [15O]H2O and [
11C]docetaxel were performed in accor-
dance with good manufacturing practice (GMP) standards (Jackson et al.,
1993; van Tilburg et al., 2004 and 2008). Docetaxel, obtained from Green
PlantChem Company (Hangzhou, China), was chemically modiﬁed and used
as precursor in the synthesis of [11C]docetaxel. 11C-labeled docetaxel was ob-
tained with an isolated decay-corrected radiochemical yield of 10 ± 2% and
a radiochemical purity of >98%. [11C]docetaxel has an identical molecular
structure as the drug docetaxel. The identity of [11C]docetaxel was conﬁrmed
by comparison of retention times on high-performance liquid chromatography
with authentic docetaxel.
Scanning Protocol
Imaging studies were performed on a state-of-the-art three-dimensional (3D)
PET-CT scanner (Gemini TF-64, Philips Medical Systems, Best, The Nether-
lands; Surti et al., 2007). This scanner has an axial ﬁeld of view of 18 cm,
divided into 45 contiguous planes. All patients underwent PET-CT scans
with [15O]H2O and [
11C]docetaxel at baseline and at day 4. Nine patients
underwent a [15O]H2O PET-CT scan at 2 hr and eight patients underwent
combined [15O]H2O and [
11C]docetaxel PET-CT scans at 5 hr, whereas one
patient underwent a single [11C]docetaxel PET-CT scan at 5 hr. The median
times from the end of the bevacizumab infusion to the ﬁrst, second, and third
scan sessions were 1.9 hr (range, 1.4–2.3 hr), 5.6 hr (range, 4.9–8.6 hr), and
4 days (range, 3–5 days). Sudden technical difﬁculties, clinical problems,
and logistic issues were the reasons for missing scans and different time
intervals.
Until 3 hr prior to scanning, food and drinks were allowed. On the day of
a PET study, patients were asked to consume similar meals prior to scanning.
All patients received two venous catheters, one for tracer injection and the
other for blood sampling. Patients were positioned supine on the scanner
bed, with both tumor and aortic arch located inside the axial ﬁeld of view of
the scanner. Elastic body-restraining bandages were used to minimize move-
ment during scanning.
A 10 min dynamic scan was started simultaneously with an intravenous
injection of 370 MBq [15O]H2O (5 ml at a rate of 0.8 ml$s
1, followed by
a 35 ml saline ﬂush at a rate of 2 ml$s1). Thereafter, a 50 mAs low-dose CT
scan was performed for attenuation correction purposes. At least 20 min after
administration of [15O]H2O, a 60min dynamic scan was started simultaneously
with an intravenous injection of [11C]docetaxel (dissolved in a maximum
volume of 12 ml saline, infused at a rate of 0.8 ml$s1, and followed by a 35 ml
saline ﬂush at a rate of 2 ml$s1). The median injected dose of [11C]docetaxel
was 344 MBq (range, 122–388 MBq) with a median speciﬁc activity of 3.2
GBq$mmol1 (range; 1.0–25.8 GBq$mmol1). During PET scanning, blood
pressure was monitored with a Dinamap (Dash 4000, GE Medical Systems
Information Technologies, Inc., Milwaukee, Wisconsin).
Figure 6. Perfusion and [11C]docetaxel Uptake in
the Vertebral Body, which Represents Bone
Marrow, in Ten Individual Patients at Baseline
and after Administration of Bevacizumab
Horizontal bars represent median values.
(A) Perfusion (F).
(B) Net rate of inﬂux (Ki) of [
11C]docetaxel.
Data were normalized and all appropriate corrections
for dead time, decay, randoms, scatter, and attenuation
were applied. Using the 3D row actionmaximum likelihood
reconstruction algorithm, [15O]H2O and [
11C]docetaxel
scans were reconstructed into 26 (1x10, 8x5, 4x10, 2x15, 3x20, 2x30, and
6x60 s) and 36 (1x10, 8x5, 4x10, 2x15, 3x20, 2x30, 6x60, 4x150, 4x300, and
2x600 s) frames, respectively.
Blood Sampling
Sequential blood samples were collected in ACD vacutainers (8.5 ml, Becton
Dickinson, Heidelberg, Germany; Cat. No. 364606) at baseline, and at 3 hr
and 4 days after the end of the bevacizumab infusion. Prior to each sample,
3 ml–5 ml blood was discarded and the line was ﬂushed with 2 ml saline after
each sample. After collection, the blood samples were centrifuged immedi-
ately to obtain platelet-rich plasma (15 min; 20	C; 156 x g; N = 7 patients).
Platelet-rich plasma was further centrifuged to obtain platelet-poor plasma
(15 min; 20	C; 330 x g; N = 3 patients). Thereafter, plasma was stored at
20	C until analysis. Concentrations of VEGF (pg∙ml1) were assessed in
duplicate using a Quantikine enzyme-linked immunosorbent assay (ELISA)
kit (R&DSystems,Minneapolis, Minnesota). Vascular endothelial growth factor
concentrations in platelet-rich plasma were corrected for platelet count and
were expressed in pg$ml1 per 200,000 platelets$ml1.
After intravenous injection of [11C]docetaxel, 10 ml discrete venous samples
were collected manually at 2.5, 5, 10, 15, 20, 30, 40, and 60 min post-injection.
Blood samples were analyzed for radioactivity concentrations in blood and
plasma. Whole blood (0.5 ml) was weighted in duplicate and 0.05 ml 10%
Triton X-100 solution was added. After centrifuging the remaining whole blood
(5 min; room temperature; 4000 rpm), plasma was harvested and 0.5 ml
plasma was weighted in duplicate, again adding 0.05 ml 10% Triton X-100
solution. A well-counter, cross-calibrated against the PET scanner, was
used to determine activity concentrations. Samples were not analyzed for
radiolabeledmetabolites, as these were not detected previously (Van der Veldt
et al., 2011).
Input Functions
Kinetic analyses of data were performed using dedicated programs written
within the software environment Matlab (The MathWorks Inc., Natick, Massa-
chusetts). The ascending aorta in the [15O]H2O and [
11C]docetaxel images
was used to generate noninvasive image-derived input functions (IDIF), as
validated previously (van der Veldt et al., 2010a and 2011). Volumes of
interest (VOI) of 1 cm diameter were drawn over the ascending aorta in
approximately ten consecutive image planes of the frame in which the ﬁrst
pass of the bolus was best visualized. Projection of these VOIs onto all image
frames yielded the arterial time-activity curve (TAC) CA(t). A similar approach
was used for the pulmonary artery in approximately ﬁve consecutive planes,
thereby providing a TAC for the pulmonary circulation CV(t) (van der Veldt
et al., 2010a). The [11C]docetaxel plasma IDIF was obtained by multiplying
CA(t) with a sigmoid function (Gunn et al., 1998), which was obtained by
ﬁtting the plasma/whole blood ratios derived from the venous samples. As
the rapid [11C]docetaxel clearance precludes reliable input functions at later
time points, the generation of input functions of [11C]docetaxel was limited to
the ﬁrst 10 min of data (Van der Veldt et al., 2011).
Analysis of Perfusion and [11C]docetaxel Kinetics in Tumors
Scans were anonymized and randomly presented to an experienced observer
(I.B.) who was blinded to patients’ history and outcome. To delineate compa-
rable tumor VOIs, this observer analyzed all scans from one patient in the same
session. Low-dose CT images were converted to ECAT 7 format. Thereafter,
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primary tumors were delineated on low-dose CT images using the CAPP
software package (CTI/Siemens, Knoxville, Tennessee). Next, VOIs were
projected onto the dynamic images of the corresponding [15O]H2O and
[11C]docetaxel scans, thereby generating tumor TACs for [15O]H2O and
[11C]docetaxel, respectively.
The standard single-tissue compartment model was used to derive tumor
perfusion from [15O]H2O kinetics (Hermansen et al., 1998; van der Veldt
et al., 2010a). Using nonlinear regression, [15O]H2O tumor TACs were ﬁtted
to the single-tissue compartment model using IDIF as arterial input function
(van der Veldt et al., 2010a). The correction for pulmonary circulation blood
volume was included, as it improves the quality of the ﬁts without affecting
tumor perfusion values. Using this approach, the absolute test-retest vari-
ability of tumor perfusion is 0.03 ml$cm3$min1 (van der Veldt et al., 2010a).
The kinetics of [11C]docetaxel in tumors was described by a two-tissue irre-
versible compartment model, linearized using the Patlak method (Patlak et al.,
1983). When applying the Patlak method to the ﬁrst 10 min of dynamic PET
data with the starting time at 2 min, the Ki of [
11C]docetaxel has an absolute
test-retest variability of 0.003 ml$cm3$min1 (van der Veldt et al., 2011). In
addition, the retention index of [11C]docetaxel in tumor tissue was calculated
by dividing the measured radioactivity concentration at 10 min post-injection
by the integral of the plasma curve up to this time.
To analyze heterogeneity of tumor perfusion at the voxel level, parametric
perfusion images were generated (van der Veldt et al., 2010a). Hence, IDIFs
and a basis function implementation of the standard single-tissue compart-
ment model were applied (Boellaard et al., 2005; Lodge et al., 2000; Watabe
et al., 2005). Fifty logarithmically spaced, precomputed basis functions with
F/VT values, ranging from 0.1 to 2.0 min
1 were used and parametric perfusion
images were postsmoothed with a Gaussian ﬁlter of 10 mm full width at half
maximum. Then, VOIs previously deﬁned on the low-dose CT scans were
projected onto the parametric perfusion images. Next, voxel intensity histo-
grams were generated for the whole VOI, its center and its rim. A voxel was
considered to be part of the rim if at least one of the voxels in its 3D six-con-
nected neighborhood was outside the deﬁned VOI. In accordance with this
method, the median baseline volume of the whole tumor VOI was 13.3 cm3
(range, 1.7–278.5 cm3) with center and rim accounting for median volumes
of 2.5 cm3 (range, 0.1–183.8 cm3) and 9.1 cm3 (range, 1.5–81.3 cm3),
respectively. Similarly, voxel intensity histograms were generated for the Ki
of [11C]docetaxel, applying the Patlak method on a voxel basis. The voxel
intensity histograms were used to characterize tumor heterogeneity of
perfusion and [11C]docetaxel uptake, analyzing the following parameters:
percentage of voxels, mean value, standard deviation, median value, minimal
value, maximal value, kurtosis, and skewness of the distribution. More homog-
enous distributions are characterized by lower standard deviations and higher
kurtosis (more peaked distribution) of corresponding histograms.
Cardiac Output
Using dynamic [15O]H2O PET data, the cardiac output can be estimated by the
following equation (Knaapen et al., 2008):
Cardiac output=
ID
Z t
0
CV$dt
; (1)
where the injected radioactivity (ID) of [15O]H2O is divided by the area under
the curve of the blood activity in the pulmonary artery (CV) multiplied by the
duration of the ﬁrst pass of the bolus. The TAC of the pulmonary artery was
ﬁtted with a linear upslope and followed by an exponential downslope, which
was extrapolated to remove contamination of recirculating radioactivity.
Microcirculation in the Skin
In eight patients, microcirculation in the skin was investigated. At baseline,
3 hr and 4 days, nailfold capillaries in the dorsal skin of the third ﬁnger were
visualized using a capillary microscope (Serne´ et al., 2001). Capillary density
was deﬁned as the number of erythrocyte-perfused capillaries$mm2. First,
baseline capillary density was recorded for 2 min. Thereafter, venous
occlusion was applied to expose a maximal number of perfused capillaries.
To this end, a digital cuff was inﬂated to 60 mmHg for 60 s. Recordings
were presented randomly and in a blind fashion to an experienced investigator
(M.P.d.B.), who counted number of capillaries off-line from a videotape. Using
the same visual ﬁelds as used during baseline measurements, peak capillary
density during venous congestion was counted in the 60 s recordings. Day-
to-day variation of baseline capillary density and peak capillary density during
venous congestion were 2.3% ± 1.8% (Serne´ et al., 2002) and 9.5 ± 7.1%
(Serne´ et al., 2001), respectively.
Muscle Perfusion
On the low-dose CT scans, VOIs (diameter, 1 cm) were drawn over the erector
spinae muscle in ﬁve consecutive image planes. Projection of these muscle
VOIs onto the dynamic images of the corresponding [15O]H2O scan yielded
a muscle TAC for [15O]H2O. The standard single-tissue compartment model
was used to derive muscle perfusion (Hermansen et al., 1998) but without
correction for pulmonary circulation blood volume:
CTðtÞ= ð1 VAÞ$F$CAðtÞ5e
F
VT
t
+VA CAðtÞ; (2)
where CT(t) is the total measured tissue signal in tumor as function of time, F is
perfusion, VA is arterial blood volume, and VT is the volume of distribution
or partition coefﬁcient of water. To evaluate [11C]docetaxel kinetics in
normal tissue, muscle VOIs were also projected onto the corresponding
[11C]docetaxel image and those TACs were analyzed using the Patlak method
(Patlak et al., 1983).
[11C]docetaxel Clearance
To determine inﬂuence of bevacizumab on blood kinetics of [11C]docetaxel,
clearance of [11C]docetaxel was calculated using the following equation:
Clearance=
IDR
CPðtÞ$dt$BSA; (3)
where the injected dose (ID) of [11C]docetaxel is divided by the integral of the
plasma (CP) TAC multiplied by the body surface area.
Thyroid Perfusion
In those cases in which the thyroid gland was in the ﬁeld of view, additional
parametric perfusion images were generated, using 50 precomputed basis
functions with F/VT values, ranging from 0.1 to 15 min
1 and postsmoothing
with a Gaussian ﬁlter of 10 mm in full width at half maximum. Then, the thyroid
gland could be delineated on parametric perfusion images applying a semi-
automatic threshold technique (50% of the maximum voxel value with correc-
tion for local background; van der Veldt et al., 2010a). Thereafter, these VOIs
were projected onto the dynamic [15O]H2O images. Again, the standard
single-tissue compartment model (Equation 2) was applied to calculate
perfusion.
Perfusion and [11C]docetaxel Kinetics in Bone Marrow
Perfusion and [11C]docetaxel uptake were determined in the vertebral body,
representing active bone marrow. From the level of the main carina to ten
image planes downwards, VOIs (diameter, 1.5 cm) were deﬁned in the verte-
bral body on low-dose CT scans. These VOIs were projected onto dynamic
images of the [15O]H2O and [
11C]docetaxel scans, generating corresponding
TACs.
Equation 2 was applied to calculate vertebral body perfusion, whereas the
Patlak method (Patlak et al., 1983) was applied to determine [11C]docetaxel
uptake.
Statistics
Statistical analysis was performed using SPSS software (SPSS for Windows
16.0, SPSS, Inc., Chicago, IL). Correlations were explored using the Spear-
man’s correlation coefﬁcient. The Mann-Whitney test was used to compare
between groups. The Wilcoxon signed-rank test was used to compare
variables at 2 hr, 3 hr, 5 hr, and 4 days after bevacizumab administration
with baseline values. A two-tailed probability value of p value < 0.05 was
considered signiﬁcant.
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Chapter 9 
Summary 
 
 
 
 
       
 
Positron emission tomography (PET) is an imaging technique that may be useful for 
individualized treatment planning in cancer patients. For that purpose, radiolabeling 
anticancer drugs with positron emitters is promising, as these may then be used to 
monitor drug pharmacokinetics and pharmacodynamics in patients non-invasively. In this 
thesis, validation and clinical implementation of a newly radiolabeled anticancer drug, 
carbon-11 labeled docetaxel ([11C]docetaxel), in patients with lung cancer were 
presented.  
 
In Chapter 1, principles of PET and applications of several PET tracers in oncology were 
introduced. In addition, development of the novel PET tracer [11C]docetaxel and its 
validation in lung cancer patients was described.  
In Chapter 2, the role of PET and radiolabeled anticancer drugs in predicting tumor 
resistance was reviewed. In this chapter, the focus was on resistance pathways that may 
impede drug delivery to tumors and how PET can help to reveal these pathways. 
Mechanisms of drug resistance that were discussed included factors that may affect 
distribution of drugs within the body, bioavailability of drugs in the circulation, as well as 
transport of drugs to tumors. Within that framework, radiolabeled anticancer drugs that 
have been developed, together with their stage of clinical implementation, were 
reviewed. It was concluded that use of radiolabeled anticancer drugs (e.g. [18F]paclitaxel 
and [18F]fluorouracil) provides a unique means for personalized treatment planning and 
drug development. In this chapter, it was also argued that combining these specific PET 
tracers with other less specific ones, such as tracers for blood flow (e.g. [15O]H2O) and 
efflux transporters (e.g. [11C]verapamil), may provide additional information on drug 
resistance mechanisms. Finally, it was mentioned that radiolabeled anticancer agents 
may be valuable for evaluating optimal timing of combination therapies. 
As tumor perfusion may influence the delivery of radiolabeled drugs to tumors, the 
validity and reproducibility of dynamic [15O]H2O PET/CT scans for measuring tumor 
perfusion were assessed in Chapter 3. In addition, quantitative accuracy of parametric 
perfusion images was validated. To that end, eleven patients with non–small cell lung 
cancer (NSCLC) underwent two dynamic [15O]H2O PET scans on the same day. This 
validation study showed that the use of image derived input functions (IDIFs) obtained 
from the ascending aorta was an accurate alternative for arterial blood sampling when 
quantifying tumor perfusion. In addition, it was shown that image quality obtained with a 
clinical PET/CT scanner enabled generation of accurate parametric perfusion images. 
Volumes of interest (VOIs) delineated on low-dose computed tomography (LD-CT) scans 
had the highest reproducibility and changes of more than 16% in tumor perfusion were 
likely to represent treatment effects.                       
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 Chapters 4 to 7 described a series of steps that were followed in order to validate the 
use of [11C]docetaxel in clinical PET studies.                      
In Chapter 4, the biodistribution of [11C]docetaxel was determined in healthy male rats 
at 5, 15, 30 and 60 minutes after injection. This preclinical study showed the highest 
[11C]docetaxel uptake in spleen, followed by urine, lungs and liver, whereas brain and 
testes showed the lowest uptake. Within less than 5 minutes, [11C]docetaxel essentially 
had cleared from blood and plasma. This preclinical study was needed to obtain an initial 
estimate of the expected radiation dose in humans, which in turn was required for 
obtaining ethics permission to conduct human studies.                                         
In Chapter 5, biodistribution and actual human radiation dosimetry of [11C]docetaxel 
were determined in seven patients with solid tumors using whole body PET/CT scans. 
Gall bladder and liver showed high [11C]docetaxel uptake, whilst uptake in brain and 
normal lung was low. In the liver, the percentage injected dose at 1 hour was 47 ± 9%. 
[11C]docetaxel was rapidly cleared from plasma and no radiolabeled metabolites were 
detected. [11C]docetaxel uptake in tumors was moderate and highly variable between 
tumors. The effective dose of [11C]docetaxel ???? ???? ???·MBq-1. In contrast to the 
previous study in rats, [11C]docetaxel showed low uptake in human lungs. Therefore, it 
was concluded that [11C]docetaxel may be a promising tracer for tumors in the thoracic 
region.                                               
In Chapter 6, the feasibility of quantitative [11C]docetaxel scans in lung cancer patients 
was evaluated. In addition, it was investigated whether [11C]docetaxel kinetics were 
associated with tumor perfusion, tumor size, or dexamethasone administration. In this 
study, 34 lung cancer patients underwent dynamic PET-CT using [11C]docetaxel and 
[15O]H2O. The first 24 patients were premedicated with dexamethasone. For 
quantification of [11C]docetaxel kinetics, the optimal tracer kinetic model was developed. 
Tumor kinetics of [11C]docetaxel were irreversible and could be quantified using the 
Patlak method. Furthermore, it was shown that reproducible quantification of 
[11C]docetaxel kinetics in tumors was possible using an IDIF. In tumors, the net rate of 
influx (Ki) of [11C]docetaxel was variable and strongly related to tumor perfusion, but not 
to tumor size. In addition, patients pre-treated with dexamethasone, a potent inducer of 
the efflux transporter ABCB1, showed lower [11C]docetaxel uptake in tumors. In a 
subgroup of patients who subsequently received docetaxel therapy, relative high 
[11C]docetaxel uptake was related with improved tumor response. Accordingly, it was 
concluded that quantification of [11C]docetaxel kinetics in lung cancer was feasible in a 
clinical setting and that the observed variation in [11C]docetaxel kinetics between tumors 
may reflect differential sensitivity to docetaxel therapy.           
As pharmacokinetics of [11C]docetaxel at tracer doses may be different from those at 
therapeutic doses, the microdosing concept was validated for [11C]docetaxel in Chapter 
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7. The research question to be addressed was whether a PET study using a tracer dose of 
[11C]docetaxel could predict tumor uptake of unlabeled (cold) docetaxel during a 
therapeutic infusion. For this purpose, docetaxel-naïve lung cancer patients underwent 
two [11C]docetaxel PET scans, one after a bolus injection of a tracer dose [11C]docetaxel 
and another during a combined infusion of a tracer dose [11C]docetaxel and a therapeutic 
dose of docetaxel (75 mg·m-2). Compartmental and spectral analyses were used to 
quantify [11C]docetaxel tumor kinetics. In addition, [11C]docetaxel PET measurements 
were used to estimate the area under the curve (AUCTumor) of cold docetaxel in tumors. 
[11C]docetaxel Ki in tumors was comparable during microdosing and therapeutic scans. 
[11C]docetaxel AUCTumor during the therapeutic scan could be predicted reliably using an 
impulse response function derived from the microdosing scan together with the plasma 
curve of [11C]docetaxel during the therapeutic scan. At 90 minutes, the accumulated 
amount of cold docetaxel in tumors was < 1% of the total infused dose of docetaxel. 
[11C]docetaxel Ki derived from the microdosing scan correlated with AUCTumor of cold 
docetaxel during the therapeutic scan and with tumor response to docetaxel therapy. 
Based on these results, it was concluded that microdosing data of [11C]docetaxel PET can 
indeed be used to predict tumor uptake of cold docetaxel during chemotherapy. The 
study in this chapter provides a framework for investigating the PET microdosing concept 
for radiolabeled anticancer drugs in patients.       
                          
In Chapter 8, the effects of the anti-angiogenic drug bevacizumab on tumor perfusion 
and [11C]docetaxel uptake in non-small cell lung cancer (NSCLC) was investigated. 
Bevacizumab is a humanized monoclonal antibody that targets circulating vascular 
endothelial growth factor (VEGF) and subsequently prevents binding of VEGF to its 
receptors. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently 
normalize the abnormal tumor vasculature and contribute to improved delivery of 
subsequent chemotherapy. To investigate this concept, a study was performed in NSCLC 
patients using PET and [11C]docetaxel. In NSCLC, bevacizumab reduced both perfusion 
and [11C]docetaxel Ki within 5 hours. These effects persisted after 4 days and were not 
associated with significant changes in tumor heterogeneity of [11C]docetaxel uptake. 
Reduction in [11C]docetaxel delivery to tumors was accompanied by rapid reduction in 
circulating levels of VEGF, but not with changes in cardiovascular parameters such as 
blood pressure, cardiac output and capillary density in the skin. The clinical relevance of 
these findings is notable, as there was no evidence for substantial improvement in drug 
delivery to tumors after administration of bevacizumab. This study highlights the 
importance of drug scheduling and advocates further studies to optimize scheduling of 
anti-angiogenic drugs.  
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Chapter 10 
Discussion and future perspectives 
 
 
 
   
 
PET scans using radiolabeled anticancer drugs  
As mentioned in Chapter 2, numerous anticancer drugs have been radiolabeled with 
positron emitters. Since publication of Chapter 2 in 2008, more anticancer drugs have 
been developed as tracers for positron emission tomography (PET) including 
[11C]erlotinib (1-3) and [11C]sorafenib (4). There appears to be a discrepancy, however, 
between the number of radiolabeled anticancer drugs that have been developed and the 
relatively small number of clinical studies applying these PET tracers in patients. This 
discrepancy may be due to several potential caveats on the path from development to 
clinical implementation of a new PET tracer, which is very complex and is challenging due 
to technical, logistical, financial, and/or patient related issues. First of all, a complex and 
expensive research infrastructure is required (Figure 1): a cyclotron for production of 
positron emitters, an on-site good manufacturing practice (GMP) laboratory for synthesis 
of the tracer, a PET/CT scanner for acquisition of the images, an on-line blood sampler in 
case of arterial blood sampling, an on-site laboratory for measurements of radioactivity 
concentrations and radioactive metabolites in blood, and dedicated computers and 
software to analyze and quantify the PET data acquired (5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of facilities and highly qualified personnel required for development and clinical 
implementation of a radiolabeled anticancer drug. Required personnel for a specific facility are 
listed next to the corresponding facility.  
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Second, in addition to the facilities mentioned above, also highly qualified personnel is 
required: a cyclotron operator, a chemist who synthesizes the PET tracer, a 
radiopharmacist who is responsible for quality control of the tracer production, a 
technologist for acquiring the PET images, a (nuclear medicine) physician who is 
responsible for the medical condition of the patient as well as for arterial blood sampling, 
a chemist for analyzing blood samples during PET scanning, and a physicist responsible 
for acquisition protocols and data analyses. The short half-lives of most PET tracers 
require that the facilities and personnel mentioned above are located and working in the 
same building at very close proximity. Third, apart from the requirement of adequate 
facilities and personnel, patient related issues may arise. The biodistribution of a 
radiolabeled drug may limit its use to specific tumor types. High background uptake of a 
radiolabeled drug in e.g. the liver will make it inadequate for uptake measurements in 
tumors located in the liver. In addition, patients should be willing and physically able to 
undergo PET scans as well as arterial blood sampling. Fourth, clinical implementation of a 
novel PET tracer may be hampered by technical problems associated with the 
characteristics of a specific PET tracer, such as challenging tracer synthesis, rapid 
metabolism in vivo resulting in rapid ingrowth of radiolabeled metabolites, high non-
specific binding or poor reproducibility of the uptake parameter of interest. Fifth, from 
the above, it will be clear that the development of radiolabeled anticancer drugs is very 
expensive and time-consuming (6,7). Because of the complexity and high costs of PET 
scans using radiolabeled anticancer drugs, validation studies usually are performed in a 
limited number of patients. Therefore, the design of these studies should be as optimal 
as possible in order to obtain all relevant PET data. In this regard, the need for optimal 
acquisition of PET data should not be underestimated, as data can be acquired only once, 
whereas they can be (re)analyzed as often as needed.  
 
[15O]H2O PET/CT for measurement of tumor perfusion 
As tumor perfusion can be an important factor for the delivery of radiolabeled anticancer 
drugs to tumors, application of the established flow tracer [15O]H2O using a PET/CT 
scanner was validated in patients with lung tumors (Chapter 3). The short-half life of 
oxygen-15, which is 2.03 minutes, enables sequential PET scans using both [15O]H2O and 
a radiolabeled anticancer drug. However, the short-half life of oxygen-15 requires the 
presence of a nearby cyclotron. Apart from the potential application in combination with 
radiolabeled drugs, [15O]H2O PET/CT scans are increasingly used to assess response of 
the tumor vasculature to anti-angiogenic therapy (8-13). For example, in non-small cell 
lung cancer (NSCLC) patients treated with bevacizumab and erlotinib, a reduction in 
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tumor perfusion of more than 20% after three weeks was associated with improved 
progression-free survival (10).  
 
Biodistribution and radiation dosimetry of [11C]docetaxel  
Administration of [11C]docetaxel appeared to be safe in humans with an effective dose of 
4.7 μSv·MBq-1 (Chapter 5). In 2011, Kurdziel et  al. (14) evaluated the biodistribution 
and dosimetry of [18F]paclitaxel in healthy volunteers and newly diagnosed breast cancer 
patients. Like docetaxel, paclitaxel belongs to the family of taxanes (15). In the clinical 
treatment of cancer patients, the taxanes docetaxel and paclitaxel are often compared, 
as these drugs have similar mechanisms of action (16). Despite similarity in chemical 
structures, their metabolism is very distinct. Docetaxel metabolism is similar across 
species, whereas paclitaxel metabolism is very species dependent. For both drugs, 
hepatobiliary excretion is the main pathway of elimination and a major fraction of the 
dose is excreted in feces. As paclitaxel was radiolabeled with fluorine-18, which has a 
half-life of 109.8 minutes, the authors were able to perform whole-body PET/CT scans for 
three hours after injection of [18F]paclitaxel. Because of the longer half-life of fluorine-18, 
however, the effective dose of [18F]paclitaxel (28.8 μSv·MBq-1) was significantly higher 
than that of [11C]docetaxel. In accordance with the biodistribution of [11C]docetaxel 
(Chapter 5), [18F]paclitaxel showed high uptake in the gastrointestinal tract. Successive 
whole body PET scans showed that both [11C]docetaxel and [18F]paclitaxel accumulate in 
the liver and are subsequently excreted into the bile and ultimately into the intestine 
(Figure 2). The shorter half-life of [11C]docetaxel resulted in lower radiation dosimetry 
estimates in organs, but this prohibited measurements at three hours after injection. As 
a result, it was not possible to determine biological clearance of [11C]docetaxel at later 
time points. Therefore, further clearance of [11C]docetaxel was estimated according to 
physical decay after the last whole-body PET scan. Consequently, the radiation dosimetry 
of [11C]docetaxel may be somewhat underestimated in the gall bladder as well as the 
intestine. 
 
Biodistribution studies have demonstrated that both [11C]docetaxel and [18F]paclitaxel 
show low uptake in brain [Chapter 5; (14)]. The brain is protected by the blood-brain 
barrier, which prevents toxins from accumulating in brain tissue. In the blood-brain 
barrier, the efflux transporter ABCB1 (formerly known as P-glycoprotein or MDR1) is 
expressed (17,18). As both docetaxel and paclitaxel are well-characterized substrates of 
this efflux transporter (19,20), these drugs essentially cannot penetrate the brain and 
often show failure in tumors and metastases in the brain (21,22).  
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Figure 2. Four successive [11C]docetaxel whole body PET scans showing that [11C]docetaxel 
accumulates in liver, subsequently is excreted into bile and ultimately into intestine. Because of 
high [11C]docetaxel uptake in the liver, the present projection could not visualize the high uptake of 
[11C]docetaxel in the gall bladder (Chapter 5).  
 
As a result, several inhibitors of ABCB1, such as cyclosporin A and tariquidar, are under 
investigation in order to improve the uptake of ABCB1 substrates in the brain (23,24). 
Remarkably, increased uptake of [11C]docetaxel was observed in the pituitary gland 
(Figure 3). This increase can be explained by the fact that the posterior pituitary gland is 
not protected by the blood brain barrier. Therefore, it is conceivable that other anticancer 
drugs will show accumulation in the pituitary gland as well (14). Although acute side-
effects of chemotherapy on the pituitary gland, e.g. hypophysitis, are not commonly 
reported for most anticancer drugs, chemotherapy may have late effects. Koppelmans et 
al (25) have reported that breast cancer survivors, previously treated with chemo-
therapy, are more likely to develop pituitary adenomas than subjects without a history of 
cancer and chemotherapy treatment. They suggested that the development of pituitary 
adenomas may be related to an early postmenopausal status. However, the hypophyseal 
accumulation of [11C]docetaxel indicates that anticancer drugs can accumulate in 
pituitary tissue, suggesting that chemotherapy may also affect the pituitary gland. 
Therefore, further studies are warranted to investigate the (late) effects of chemotherapy 
on the pituitary gland. Furthermore, the biodistribution of [11C]docetaxel provided 
information on the background uptake of the tracer in normal organs, thereby identifying  
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Figure 3. Transverse (left), coronal (middle) and sagittal (right) PET images showing low 
[11C]docetaxel in the brain, but increased uptake in the pituitary gland (arrows).  
 
tumor types that can be monitored using [11C]docetaxel PET. High [11C]docetaxel uptake 
in liver and intestine makes it unlikely that the tracer can be applied for imaging of the 
abdominal region. In addition, relatively high [11C]docetaxel uptake in the vertebral body 
makes it also unlikely that [11C]docetaxel is useful for imaging bone metastases. 
Unfortunately, these findings exclude the use of [11C]docetaxel PET in patients with 
hormone refractory metastatic prostate cancer, as these patients frequently present with 
metastatic sites in paraaortic lymph nodes, pelvic lymph nodes and spine, in particular in 
the lumbar level of the spine (26). As 90% of patients with hormone refractory 
metastatic prostate cancer have bone metastases (26), high penetration of 
[11C]docetaxel in the vertebral body may partially explain the efficacy of docetaxel in this 
patient population (27). However, this hypothesis remains to be proven. Although 
[11C]docetaxel is not suitable for imaging of tumors in the abdomen, low [11C]docetaxel 
uptake in the thoracic region makes [11C]docetaxel an interesting tracer for tumors 
located in the thoracic region, including breast cancer and lung cancer. 
 
The estimated effective dose in humans extrapolated from rat studies was comparable to 
the measured dose in humans (5.4 vs. 4.7 μSv·MBq-1). However, the results of the 
preliminary biodistribution study in healthy male rats (Chapter 4) differed from the 
[11C]docetaxel results in humans (Chapter 5), as the animal study showed relatively high 
[11C]docetaxel uptake in lungs. In addition, the rat study was not able to predict high 
uptake of [11C]docetaxel in the gall bladder, as rats do not have a gall bladder. In the rat 
study, [11C]docetaxel was administered through a tail vein injection, followed by post 
mortem examinations of internal organs (Chapter 4; Figure 4). Such sacrifice 
experiments are time-consuming and require the sacrifice of many animals at multiple 
time points to determine pharmacodynamics and pharmacokinetics of the tracer. 
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Alternatively, small animal imaging offers the possibility of studying kinetics of a 
radiolabeled anticancer drug in mice and rats in vivo (28-30). Using dedicated small 
animal systems, a spatial resolution of ~ 2 mm can be achieved (31). The main challenge 
of small animal imaging studies, however, is the measurement of a metabolite corrected 
plasma input function, as extensive blood sampling is not possible in small animals. In 
case of larger animals, a clinical scanner can also be used (32). In particular, animal 
studies in monkeys will provide biodistribution results that are more comparable to those 
in humans (14,33).  
 
Research in animals has always been a vital step in the development of novel PET 
tracers. Prior to studies in humans, a biodistribution study is usually performed in 
animals to exclude high tracer uptake in organs that are highly sensitive to radiation 
exposure, such as the thyroid gland. In addition, animal studies are carried out to 
estimate the radiation dose in humans. As a result, medical ethics committees commonly 
require animal studies prior to administration of the radiolabeled drug in humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Biodistribution of [11C]docetaxel in healthy male rats.  
(A) PET scan showing the biodistribution of [11C]docetaxel in a male rat. The PET image was 
obtained using a High Resolution Research Tomograph (HRRT) with a spatial resolution of about 
2.5 mm. Red indicates the highest [11C]docetaxel uptake.  
(B) Standardized uptake values of [11C]docetaxel in organs as obtained from sacrifice experiments. 
Standardized uptake values were calculated as the ratio of tissue radioactivity concentration and 
injected dose normalized for body weight.  
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However, in case of positron emitters with a short half-life such as carbon-11 (20.3 
minutes), a different approach may be more appropriate. These short half-lives are 
associated with a low and predictable radiation dose. Therefore, for these short-lived 
tracers, animal studies could be omitted. Such an approach may help to reduce the 
number of animal experiments, may prevent incorrect interpretation due to animal-
human differences and may speed up the development of radiolabeled anticancer drugs. 
 
Quantification of [11C]docetaxel kinetics in tumors 
Since whole body PET scans do not provide data for absolute quantification of 
[11C]docetaxel kinetics in tumors, dynamic PET scans were performed (see Chapter 1). 
For only a few radiolabeled anticancer drugs, tumor kinetics in humans have been 
quantified previously using dynamic scanning [Chapter 6; (34-37)]. Quantitative 
measurements of [11C]docetaxel revealed rapid, but rather low irreversible uptake of 
[11C]docetaxel in tumors (Chapter 6). This relatively low [11C]docetaxel uptake in tumors 
was in line with the results obtained from the biodistribution study in patients (Chapter 
5). Despite its longer half-life, low irreversible tumor uptake has also been reported for 
the other radiolabeled taxane, [18F]paclitaxel (14). The relatively low tumor uptake of 
these radiolabeled taxanes may be explained by the rapid clearance of the two tracers 
from blood [Chapters 5 & 6; (14)]. Whereas radiolabeled metabolites have been detected 
for [18F]paclitaxel (33), no radiolabeled metabolites were seen for [11C]docetaxel 
(Chapters 5 & 6), making quantification of [11C]docetaxel kinetics less complex. In 
addition, the short half-life of [11C]docetaxel enables sequential measurements on the 
same day.  
 
Because of its low uptake in tumors, [11C]docetaxel PET is not suitable for detection of 
tumors. Nevertheless, monitoring tumor kinetics of [11C]docetaxel may be useful for 
other purposes. First, [11C]docetaxel PET, when combined with [15O]H2O PET, provides 
insight into the relation between tumor perfusion and [11C]docetaxel kinetics. In Chapters 
6 and 7, it was demonstrated that tumor perfusion is an important factor for delivery of 
both [11C]docetaxel and therapeutic doses of docetaxel to tumors. As a result, tumor 
perfusion may be predictive of tumor response to docetaxel therapy. These findings 
advocate further studies investigating the predictive value of tumor perfusion for tumor 
response to chemotherapy, at least in case of taxanes. Second, [11C]docetaxel kinetics 
may provide insight into ABCB1 dependent drug efflux and could be predictive of tumor 
uptake of other ABCB1 substrates, as overexpression of ABCB1 is found in many drug 
resistant tumors (38). Third, effects of other (anticancer) drugs on delivery of 
[11C]docetaxel can be evaluated. In this regard, not only anti-angiogenic drugs (Chapter 
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8), but also inhibitors of ABCB1 are of interest [Chapter 6, (39,40)]. In addition, 
inhibitors of ABCB1 may decrease the rapid clearance of [11C]docetaxel from blood 
(41,42), as ABCB1 is also extensively expressed in intestine and the biliary system (43), 
and may contribute to [11C]docetaxel elimination (44). Finally, [11C]docetaxel tumor 
kinetics may be useful for prediction of tumor response to docetaxel therapy, as 
preliminary results showed that the variable uptake of [11C]docetaxel in lung cancer 
tissue was associated with response to docetaxel treatment (Chapters 6 & 7). Larger 
studies are warranted to confirm the predictive value of [11C]docetaxel uptake in tumors.  
 
Concept of [11C]docetaxel microdosing 
In a PET microdosing study, usually less than 1% of the pharmacological dose of a drug 
is administered (45). As a result, kinetics of tracer doses may be different from those of 
therapeutic doses (46). Previously, other PET studies have shown that a therapeutic dose 
can significantly affect uptake of radiolabeled anticancer drugs in normal organs as well 
as in tumors (36,37,47,48). Therefore, the effects of a pharmacological dose on the 
kinetics of a microdose need to be evaluated for each radiolabeled anticancer drug 
separately. In Chapter 7, the kinetic behavior of [11C]docetaxel in tumors was monitored 
after a regular bolus injection of [11C]docetaxel as well as during an infusion of a 
therapeutic dose of docetaxel. Results showed that [11C]docetaxel PET can be used to 
predict uptake of therapeutic doses of docetaxel in tumors.  
 
However, implementation of studies evaluating the PET microdosing concept can be 
difficult as, compared with other PET studies, additional issues need to be addressed. 
First, recruitment of patients willing to participate in such studies can be challenging. 
Receiving their first chemotherapy while lying in a PET scanner can be a more stressful 
event, as patients will have less contact with family and/or friends for (emotional) 
support during chemotherapy infusion. Second, infusion of chemotherapy, in particular 
the first infusion of taxanes, may be associated with acute allergic reactions, including 
anaphylactic shock in rare cases. This potential risk for severe allergic reactions requires 
close monitoring of the patient during PET scanning, which needs to be discontinued 
immediately in case of suspicion of an allergic reaction. Third, the proposed study design 
is not applicable for oral anticancer drugs, which are usually administered on a daily 
basis. For these oral drugs, PET scanning with the radiolabeled anticancer drug 
(microdose) may be repeated during treatment with the oral drug. Then, the optimal 
time-point for PET scanning needs to be defined on the basis of pharmacokinetics of the 
oral anticancer drug under study (46). Only a small amount of administered docetaxel 
appears to accumulate in tumors. In Chapter 7, it was demonstrated that less than 1% of 
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the total infused dose of docetaxel accumulated in tumors. These findings indicate that 
there is an urgent need for strategies that selectively enhance drug delivery to tumors. 
Ultrasound triggering may be useful for this purpose, as it enables localized delivery of 
drug-loaded microbubbles to tumors (49). In addition, optimal scheduling of combined 
treatment strategies may improve the delivery of drugs to tumors, thereby enhancing 
treatment efficacy. In addition, also direct effects of other (anticancer) drugs on 
metabolism as well as drug delivery to tumors need to be investigated.  
 
Effects of bevacizumab on [11C]docetaxel delivery to tumors 
Using PET and a radiolabeled anticancer drug, it is possible to evaluate the (direct) 
effects of other anticancer drugs on tumor kinetics of the radiolabeled drug. In this 
regard, the effect of anti-angiogenic drugs is of special interest. Anti-angiogenic therapy 
might affect the abnormal tumor vasculature in three different ways: (i) no effect at all, 
(ii) excessive destruction of tumor vasculature and reduction in perfusion leading to 
increased hypoxia and necrosis, (iii) or after pruning of some abnormal vessels the 
structure of remaining tumor vessels may become more normal, resulting in increased 
perfusion and drug delivery (50). As previously described by Jain (50), anti-angiogenic 
drugs may normalize the structurally and functionally abnormal tumor vasculature, 
thereby enhancing efficacy of cytotoxic drugs. Based on results of previous studies by 
Jain (50,51), the next step (Chapter 8) was to investigate effects of the anti-angiogenic 
drug bevacizumab on tumor uptake of [11C]docetaxel in NSCLC patients. Bevacizumab, a 
monoclonal antibody that targets circulating vascular endothelial growth factor (VEGF), 
appeared to reduce both perfusion and net influx rate of [11C]docetaxel within 5 hours. 
These rapid effects persisted after 4 days. In line with the results of Chapter 8, a 20% 
decline in fluorine-18 labeled 5-fluorouracil ([18F]5-FU) uptake was also measured in 
human colorectal cancer at 24 hours after administration of bevacizumab (52). Currently, 
only a few clinical studies have investigated the (early) effects of anti-angiogenic drugs 
on perfusion and drug delivery in tumors. However, the results of these studies seem 
conflicting (52-55), indicating that more studies are warranted to elucidate the effects of 
anti-angiogenic therapy on delivery of anticancer drugs to tumors.  
 
Animal studies may be instrumental in elucidating the mechanism by which the observed 
effects could be explained. However, measuring drug uptake after anti-angiogenic 
therapy in an animal model will face other limitations, such as the artificial characteristics 
of a xenograft tumor model and the different effects of anti-angiogenic drugs on animal 
physiology as compared to human physiology, probably resulting in different time related 
effects. In addition, a clinical study in patients enables to measure effects of the anti-
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angiogenic drug bevacizumab on the human system, including the cardiovascular 
system, whereas a patient derived xenograft model in animals will not be affected by 
systemic effects of bevacizumab on the animal physiology, since bevacizumab targets 
human VEGF only. Animal studies may, however, be useful for investigating whether 
administration of a (cytotoxic) anticancer drug prior to an anti-angiogenic drug results in 
decreased clearance of the cytotoxic anticancer drug in tumors.  
 
The results presented in Chapter 8 highlight the importance of drug scheduling for the 
treatment of cancer patients. However, the impact of drug scheduling on the antitumor 
efficacy usually is not investigated. With regard to drug scheduling, studies have only 
shown that frequent administration of cytotoxic drugs at low doses, known as 
'metronomic' chemotherapy, can increase anti-angiogenic activity of drugs (56,57). No 
clinical studies have investigated the relation between the sequence of combination 
schedules consisting of anti-angiogenic drugs and the efficacy in cancer patients. 
Therefore, future studies should be focused on optimal scheduling of anti-angiogenic 
drugs in order to improve the efficacy of combination therapy.  
 
Future perspectives of [11C]docetaxel PET 
Although, at present, [11C]docetaxel PET cannot be used on a large scale because of its 
complexity and high costs, it is a promising technique for several investigations. PET 
studies using both [11C]docetaxel and tracers that can show in vivo functionality of 
multidrug resistance (MDR) transporters (e.g. (R)-[11C]verapamil) may provide more 
insight into the role of MDR transporters in [11C]docetaxel uptake by tumors (Chapter 2). 
Furthermore, effects of other (anticancer) drugs, including anti-angiogenic drugs and 
inhibitors of ABCB1, on delivery of [11C]docetaxel to tumors can be explored. In 
particular, [11C]docetaxel PET may help to define the optimal design of large clinical 
trials to investigate the effects of drug scheduling on efficacy in cancer patients. In 
addition, [11C]docetaxel PET may be useful to predict response to docetaxel therapy and 
select patients for docetaxel-containing treatment strategies, thereby contributing to a 
more personalized treatment planning in individual cancer patients. For these purposes, 
a less complex scan protocol would be useful. In future studies, the duration of an 
[11C]docetaxel PET scan could be reduced from 60 to 10 minutes, as only the first 10 
minutes of the data can be used for quantification. Finally, therapeutic [11C]docetaxel 
PET scans may be simplified. Assuming that plasma kinetics of [11C]docetaxel are 
comparable during microdosing and therapeutic scans, plasma kinetics of [11C]docetaxel 
during therapeutic infusion can be modeled by convolution of a measured bolus plasma 
curve. Applying this method, preliminary data suggest that [11C]docetaxel plasma curves 
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during therapeutic infusion can be predicted on the basis of the plasma curve from the 
microdosing study (Figure 5). As a result, tumor uptake of [11C]docetaxel and cold 
docetaxel could be solely predicted from the [11C]docetaxel microdosing scan. Further 
studies are warranted to validate this simplified concept for [11C]docetaxel and other 
radiolabeled drugs.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Measured plasma activity concentration during therapy (open circles) as predicted (solid 
line) by convolution of a measured bolus plasma curve with a modeled infusion curve (dashed line; 
constant infusion reaching the patient between 10 and 70 min after start of the infusion pump, 
dispersed with a mono-exponential dispersion function with a time constant of 10 min).           
Conclusions                        
PET using radiolabeled anticancer drugs is a promising method for better guided 
treatment planning in individual cancer patients. However, the development and clinical 
implementation of a new radiolabeled anticancer drug is very complex and can be 
challenging. In the present thesis, the novel PET tracer [11C]docetaxel was validated for 
use in lung cancer patients. Human PET studies showed that [11C]docetaxel may be a 
useful tracer for tumors located in the thoracic region, including breast cancer and lung 
cancer. Subsequently, quantitative PET data showed irreversible kinetics of 
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[11C]docetaxel in lung tumors. In addition, PET scans using [11C]docetaxel demonstrated 
that less than 1% of the therapeutic dose of docetaxel accumulated in lung tumors and 
that [11C]docetaxel delivery to tumors was significantly decreased by prior administration 
of the anti-angiogenic drug bevacizumab. The [11C]docetaxel PET studies presented in 
this thesis provide a framework for clinical validation of the PET microdosing concept of 
other radiolabeled anticancer drugs as well as for investigating effects of anti-angiogenic 
drugs on drug delivery to tumors in vivo.  
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De afgelopen jaren heeft de ontwikkeling van vele nieuwe geneesmiddelen de 
behandelmogelijkheden voor patiënten met kanker aanzienlijk uitgebreid. Het grote aantal 
beschikbare middelen heeft de behandeling van patiënten met kanker echter niet 
vereenvoudigd. Anti-kanker middelen zijn namelijk niet effectief in een substantieel aantal 
patiënten. Daarnaast gaat een behandeling met anti-kanker middelen vaak gepaard met vele 
en vaak ook ernstige bijwerkingen. Daarom is er behoefte aan een techniek die kan aangeven 
welke patiënten baat hebben bij een bepaalde behandeling en welke patiënten niet. Positron 
emissie tomografie (PET) is een beeldvormende techniek die mogelijk waardevol is om een 
geïndividualiseerd behandelplan voor patiënten met kanker op te stellen. Daartoe wordt een 
tracer dosis (speurdosis) van een anti-kanker middel gelabeld (gemerkt) met een positron 
emitter, zodat een anti-kanker middel met de PET scanner zichtbaar gemaakt kan worden in 
het lichaam. Dergelijke radioactief gelabelde anti-kanker middelen kunnen zo worden gebruikt 
om de farmacokinetiek en farmacodynamiek van geneesmiddelen niet invasief (d.w.z. via 
beeldvorming) in patiënten te vervolgen. In dit proefschrift worden de validatie en 
implementatie van een nieuw radioactief gelabeld anti-kanker middel, [11C]docetaxel, in 
patiënten met longcarcinoom gepresenteerd.  
 
In Hoofdstuk 1 zijn de principes van PET en de toepassingen van verscheidene PET tracers 
voor de oncologie geïntroduceerd. Daarnaast werden de ontwikkeling en validatie van de 
nieuwe PET tracer [11C]docetaxel in patiënten met longcarcinoom besproken.  
In Hoofdstuk 2 is beschreven hoe PET scans en radioactief gelabelde anti-kanker middelen 
resistentie in tumoren kunnen voorspellen. In dit hoofdstuk werd besproken hoe PET gebruikt 
kan worden om resistentiemechanismen te onderzoeken. Tot de mechanismen die bijdragen 
aan resistentie voor geneesmiddelen behoren de verdeling van geneesmiddelen in het lichaam, 
de beschikbaarheid van geneesmiddelen in de circulatie en het transport van geneesmiddelen 
naar tumoren. In dat kader werden de reeds gelabelde anti-kanker middelen en hun huidige 
klinische toepassing besproken. Er werd geconcludeerd dat het gebruik van gelabelde anti-
kanker middelen (bijvoorbeeld [18F]paclitaxel and [18F]fluorouracil) een unieke techniek is om 
de behandeling van patiënten met kanker te individualiseren. Daarnaast kan het radioactief 
labelen van anti-kanker middelen een rol spelen bij de ontwikkeling van nieuwe 
geneesmiddelen. In dit hoofdstuk werd ook besproken dat het combineren van deze specifieke 
PET tracers met andere minder specifieke tracers, zoals tracers voor doorbloeding 
(bijvoorbeeld radioactief gelabeld water; [15O]H2O) en efflux transporters (bijvoorbeeld 
[11C]verapamil), aanvullende informatie kunnen verschaffen over de mechanismen die 
betrokken zijn bij de resistentie tegen anti-kanker middelen. Tenslotte werd in dit hoofdstuk 
besproken dat gelabelde anti-kanker middelen nuttig zouden kunnen zijn om het optimale 
tijdstip van toediening voor combinatietherapie te bepalen.  
In Hoofdstuk 3 werd de reproduceerbaarheid van dynamische [15O]H2O PET/CT scans 
onderzocht. Met deze PET scans kan de doorbloeding (ook wel perfusie genoemd) in tumoren 
worden gemeten. Dit is van belang, aangezien de tumorperfusie het transport van gelabelde 
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 anti-kanker middelen naar tumoren mogelijk kan beïnvloeden. Daarnaast werd in dit hoofdstuk 
de kwantitatieve nauwkeurigheid van de parametrische perfusiebeelden van de [15O]H2O PET 
scans gevalideerd. Daartoe ondergingen elf patiënten met een niet-kleincellig longcarcinoom 
twee dynamische [15O]H2O PET scans op dezelfde dag. Deze validatiestudie toonde aan dat 
voor het kwantificeren van tumorperfusie de zogenaamde image derived input function (IDIF) 
een accuraat alternatief is voor arteriële bloedafnames. Een IDIF is gebaseerd op de afbeelding 
van de aorta ascendens in de PET scan en is daarom een niet-invasieve methode om de 
arteriële input te meten. Daarnaast werd in dit hoofdstuk aangetoond dat de verkregen 
beeldkwaliteit van de klinische PET/CT scanner het mogelijk maakt om goede parametrische 
perfusiebeelden te genereren. Volumes of interest (VOIs) die werden ingetekend op 
computertomografie scans hadden de hoogste reproduceerbaarheid. Op basis van de 
reproduceerbaarheid werd geconcludeerd dat veranderingen van meer dan 16% in 
tumorperfusie beschouwd mogen worden als een effect van een behandeling.    
                                            
Hoofdstukken 4 tot en met 7 zijn gewijd aan de achtereenvolgende stappen die werden 
genomen om de nieuwe tracer [11C]docetaxel in klinische PET-studies te gebruiken en te 
valideren.                            
In Hoofdstuk 4 werd de biodistributie van [11C]docetaxel in gezonde mannetjesratten bepaald 
op 5, 15, 30 en 60 minuten na injectie. Deze preklinische studie toonde aan dat [11C]docetaxel 
de hoogste opname heeft in achtereenvolgens de milt, de urine, de longen en de lever. In de 
hersenen en de testes werd daarentegen een zeer lage [11C]docetaxel opname gemeten. 
Binnen minder dan 5 minuten was [11C]docetaxel bijna volledig geklaard uit zowel het bloed 
als het plasma. Deze preklinische studie was vereist voor de medische ethische commissie, 
zodat de verwachte stralingsbelasting voor mensen kon worden geschat.        
In Hoofstuk 5 werden met whole body PET/CT scans de biodistributie en de dosimetrie van 
[11C]docetaxel bepaald in seven patiënten met solide tumoren. In de galblaas en de lever 
werden hoge [11C]docetaxel concentraties gemeten, terwijl de accumulatie in de hersenen en 
normaal longweefsel laag was. Al na 1 uur bevond bijna de helft, namelijk 47 ± 9%, van de 
geïnjecteerde dosis zich in de lever. [11C]docetaxel werd snel geklaard uit het plasma en er 
werden geen radioactief gelabelde metabolieten gedetecteerd in het perifere bloed. De opname 
van [11C]docetaxel in tumoren was beperkt en zeer variabel tussen de verschillende tumoren. 
Op basis van de resultaten van deze studie werd de effectieve dosis van [11C]docetaxel 
berekend op 4.7 ?Sv·MBq-1. In tegenstelling tot de eerdere studie in ratten, was de opname 
van [11C]docetaxel in de longen laag. Op basis van de studie in patiënten werd geconcludeerd 
dat [11C]docetaxel een veelbelovende PET tracer zou kunnen zijn voor tumoren in de thoracale 
regio.                              
In Hoofdstuk 6 werd onderzocht in hoeverre het gebruik van kwantitatieve [11C]docetaxel 
scans haalbaar is in patiënten met longcarcinoom. Daarnaast werd onderzocht of de kinetiek 
van [11C]docetaxel geassocieerd was met de perfusie en de grootte van tumoren. Tevens werd 
onderzocht of de inname van dexamethason, een middel dat in de klinische praktijk als 
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premedicatie voor docetaxel wordt gegeven, de opname van [11C]docetaxel in tumoren zou 
??????????????????. In deze studie ondergingen 34 patiënten met longcarcinoom dynamische 
PET-CT scans met [11C]docetaxel en [15O]H2O. De eerste 24 patiënten kregen voorafgaand aan 
de PET scans dexamethason toegediend. Om de kinetiek van [11C]docetaxel te kwantificeren 
werd eerst het optimale kinetische model ontwikkeld. De kinetiek van [11C]docetaxel in 
tumoren bleek irreversibel en kon goed worden gekwantificeerd met de zogenaamde Patlak 
methode. Verder werd vastgesteld dat het gebruik van een IDIF resulteerde in een goede 
reproduceerbaarheid van de metingen in tumoren. De netto influx (Ki) van [11C]docetaxel in 
tumoren bleek variabel en was sterk gerelateerd aan de perfusie, maar niet aan de grootte van 
tumoren. Daarnaast hadden patiënten die waren voorbehandeld met dexamethason, een 
middel dat de efflux transporter ABCB1 activeert, een lagere [11C]docetaxel opname in 
tumoren. Een subgroep van de patiënten werd ook behandeld met docetaxel. In deze subgroep 
leek een relatief hoge [11C]docetaxel opname in de tumor gerelateerd aan een betere respons 
van de tumor op docetaxel. In dit hoofdstuk werd geconcludeerd dat het kwantificeren van de 
kinetiek van [11C]docetaxel in longcarcinoom goed haalbaar is in de klinische setting. Verder 
zou de inter-tumorale variatie in opname van [11C]docetaxel een verschillende gevoeligheid 
voor een behandeling met docetaxel kunnen weerspiegelen.                
Aangezien de farmacokinetiek van een tracer dosis [11C]docetaxel verschillend zou kunnen zijn 
van een therapeutische dosis docetaxel, werd in Hoofdstuk 7 het zogenaamde concept van 
microdosering gevalideerd voor [11C]docetaxel. In dit hoofdstuk werd uitgezocht of het 
mogelijk is om met een tracerdosering van [11C]docetaxel de opname van ongelabeld (koud) 
docetaxel in tumoren te voorspellen tijdens een infusie met een therapeutische dosis 
docetaxel. Daartoe ondergingen patiënten met longcarcinoom, die niet eerder waren 
behandeld met docetaxel, twee PET scans: één na een bolus injectie met een tracerdosering 
van [11C]docetaxel en een andere tijdens een gecombineerde infusie van de tracerdosering van 
[11C]docetaxel met een therapeutische dosis van docetaxel (75 mg·m-2). Compartimenten- en 
spectraal-analyses werden gebruikt om de kinetiek van [11C]docetaxel in tumoren te 
kwantificeren. Daarnaast werd de area under the curve (AUCTumor; oppervlakte onder de curve) 
van koud docetaxel in tumoren geschat. Tijdens de tracer (microdosis) scan en de 
therapeutische scan was de Ki van [11C]docetaxel in tumoren vergelijkbaar. Door gebruik te 
maken van een zogenaamde impulse response function, die was gebaseerd op de metingen 
tijdens de tracer (microdosis) scan en de [11C]docetaxel plasmacurve tijdens de therapeutische 
scan, was het mogelijk om de AUCTumor van [11C]docetaxel gedurende de therapeutische scan 
betrouwbaar te schatten. Na 90 minuten was de geaccumuleerde hoeveelheid koud docetaxel 
in tumoren < 1% van de totale toegediende therapeutische dosis. De Ki van [11C]docetaxel van 
de microdosering scan correleerde zowel met de AUCTumor van koud docetaxel tijdens de 
therapeutische scan als met de respons van de tumor op de behandeling met docetaxel. Op 
basis van deze resultaten werd geconcludeerd dat de data van de microdosering scan 
inderdaad gebruikt kunnen worden om de opname van koud docetaxel in tumoren te 
voorspellen gedurende de chemotherapie. De studie in dit hoofdstuk verstrekt een kader 
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 waarin het concept van microdosering met niet invasieve PET scans voor andere radioactief 
gelabelde anti-kanker middelen in patiënten onderzocht kan worden.     
                         
In Hoofdstuk 8 werden de effecten van de angiogeneseremmer (vaatremmer) bevacizumab 
onderzocht op de perfusie en opname van [11C]docetaxel in longtumoren. Bevacizumab is een 
humaan monoklonaal antilichaam dat gericht is tegen de circulerende vasculaire endotheliale 
groeifactor (VEGF) en zo voorkomt dat VEGF kan binden aan de VEGF receptor. Verondersteld 
wordt dat angiogeneseremmers, zoals bevacizumab, tijdelijk het abnormale tumorvaatstelsel 
normaliseren en zo bijdragen aan een verbeterd transport van de daarna gegeven 
chemotherapie. Om dit concept te onderzoeken werd er een PET-studie verricht bij patiënten 
met een niet-kleincellig longcarcinoom. Al binnen vijf uur na toediening van bevacizumab 
namen zowel de perfusie als de opname van [11C]docetaxel significant af. Deze effecten waren 
na vier dagen ook nog steeds duidelijk aanwezig en waren niet geassocieerd met significante 
veranderingen in de heterogeniteit van [11C]docetaxel opname in tumoren. De verminderde 
opname van [11C]docetaxel ging samen met een snelle afname in de hoeveelheid circulerend 
VEGF in het bloed. Deze veranderingen waren echter niet geassocieerd met systemische 
veranderingen in cardiovasculaire parameters, zoals bloeddruk, hart-minuutvolume en 
capillaire dichtheid in de huid. De klinische relevantie van deze bevindingen is belangrijk, 
aangezien er geen aanwijzingen zijn gevonden dat bevacizumab het transport van 
chemotherapie naar tumoren verbetert. Het is belangrijk dat toekomstig onderzoek zich richt 
op het bepalen van de optimale tijdstippen voor de toediening van angiogeneseremmers, zodat 
deze middelen zo effectief mogelijk kunnen worden ingezet voor de behandeling van patiënten 
met een maligniteit.           
                      
Concluderend is het gebruik van radioactief gelabelde anti-kanker middelen een veelbelovende 
techniek om een meer specifieke behandeling voor individuele patiënten met kanker te 
realiseren. In dit proefschrift werd de nieuwe PET tracer [11C]docetaxel gevalideerd in 
patiënten met longcarcinoom. PET studies in patiënten lieten zien dat [11C]docetaxel mogelijk 
een nuttige tracer is voor tumoren in de thoracale regio, zoals mammacarcinoom en 
longcarcinoom. De opname van [11C]docetaxel in longtumoren was goed te meten. Er werd 
geschat dat uiteindelijk minder dan 1% van de toegediende therapeutische dosis van docetaxel 
in tumoren accumuleert. Daarnaast daalde de opname van [11C]docetaxel in tumoren wanneer 
de angiogeneseremmer bevacizumab werd toegediend. De studies met [11C]docetaxel in dit 
proefschrift bieden een goed raamwerk voor de klinische validatie van andere gelabelde anti-
kanker middelen. Op basis van de resultaten in Hoofdstuk 8 kan verder worden geconcludeerd 
dat de effecten van angiogeneseremmers op het transport van chemotherapie naar tumoren 
verder onderzocht dienen te worden.  
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jouw steun en liefde waren tegenslagen veel minder zwaar. Soms hebben we weinig tijd 
voor elkaar gehad, maar daar gaat nu verandering in komen. Ik hou veel van je!  
 
 
173
 
 
 
Curriculum vitae 
 
 
 
 
       
 
CURRICULUM VITAE 
 
Astrid Aplonia Maria van der Veldt was born on March 14th 1979 in Rotterdam, the 
Netherlands. After graduating from secondary school (gymnasium, Christelijk Lyceum 
Almelo) in 1997, she studied medicine at the University of Antwerp in Belgium. In 1999, 
she was allowed to study medicine in the Netherlands and she started her study at the 
VU University in Amsterdam. During her study, she participated in the ‘VUmc Honours 
Programme’. In addition, she worked as a student assistant on the research project 
entitled ‘FDG PET in detecting recurrent cervical cancer’ at the Department of Nuclear 
Medicine & PET Research of the VU University Medical Center under supervision of dr. 
C.F.M. Molthoff and prof. dr. O.S. Hoekstra. In February 2006, she graduated from 
medical school with honors. From 2006 to 2007, she worked as a research fellow at the 
Department of Medical Oncology of the VU University Medical Center. In this period, she 
investigated the clinical and pharmacodynamic aspects of sunitinib for advanced renal 
cell cancer under supervision of prof. dr. E. Boven, prof. dr. J.B.A.G. Haanen, and dr. 
A.J.M. van den Eertwegh. For this research project, she also worked at the Department 
of Medical Oncology of The Netherlands Cancer Institute, Antoni van Leeuwenhoek 
Hospital, Amsterdam, the Netherlands. In 2007, she started her PhD project on 
[11C]docetaxel in lung cancer at the Department of Nuclear Medicine & PET Research of 
the VU University Medical Center under supervision of prof. dr. A.A. Lammertsma, prof. 
dr. E.F. Smit, dr. ir. M. Lubberink, and dr. N.H. Hendrikse. In this period, she continued 
her previous research on sunitinib for advanced renal cell cancer. For her research 
projects, she received several awards including the Merit Award of the American Society 
of Clinical Oncology and the Chris Meijer Award of the CCA/V-ICI. In January 2011, she 
started her specialization in Internal Medicine at the Department of Internal Medicine of 
the VU University Medical Center, headed by prof. dr. M.H.H. Kramer. The research 
projects performed at the Departments of Medical Oncology and Nuclear Medicine & PET 
Research have resulted in a double dissertation consisting of two different theses entitled 
‘Sunitinib for advanced renal cell cancer – clinical and pharmacodynamic aspects’ and 
‘Towards personalized treatment planning of chemotherapy: [11C]docetaxel PET studies 
in lung cancer patients’, respectively. In the future, Astrid hopes to combine patient care 
with scientific research.  
 
177
 
 
 
Publications 
 
 
 
 
       
 
PUBLICATIONS 
 
1. Hooft L, Van der Veldt AA, Van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, Molthoff CF. 
[18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i 
expression in the primary tumor. J Clin Endocrinol Metab 2005;90:328-34.  
 
2. Van der Veldt AA, Hooft L, Van Diest PJ, Berkhof J, Buist MR, Comans EF, Hoekstra OS, 
Molthoff CF. Microvessel density and p53 in detecting cervical cancer by FDG PET in cases of 
suspected recurrence. Eur J Nucl Med Mol Imaging 2006;33:1408-16.   
 
3. Van der Veldt AA, Hadithi M, Paul MA, Van den Berg FG, Mulder CJ, Craanen ME. An unusual 
cause of hematemesis: Goiter. World J Gastroenterol 2006;12:5412-5.  
 
4. Van der Veldt AA, Kleijn SA, Pernet PJ, Oostra RJ, Jansweijer MC. Unilateral partial absence of 
the fallopian tube in Williams syndrome: a new feature? Clin Dysmorphol 2007;16:195-6.  
 
5. Van der Veldt AA, Van den Eertwegh AJ, Boven E. Adverse effects of the tyrosine-kinase 
inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer. Ned Tijdschr 
Geneeskd 2007;151:1142-7.  
 
6. Hooft L, Van der Veldt AA, Hoekstra OS, Boers M, Molthoff CF, Van Diest PJ. Hexokinase III, 
cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules. Clin 
Endocrinol 2008;68:252-7.   
 
7. Van der Veldt AA, Van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E. Reversible cognitive 
disorders after sunitinib for advanced renal cell cancer in patients with preexisting 
arteriosclerotic leukoencephalopathy. Ann Oncol 2007;18:1747-50.  
 
8. Nanayakkara PW, Van der Veldt AA, Simsek S, Smulders YM, Rauwerda JA. Verapamil-induced 
erythermalgia. Neth J Med 2007;65:349-51.  
 
9. Van der Veldt AA, Lammertsma AA, Hendrikse NH. [11C]Docetaxel and positron emission 
tomography for noninvasive measurements of docetaxel kinetics. Clin Cancer Res 2007; 
13:7522.  
 
10. Helgason HH, Mallo HA, Droogendijk H, Haanen JG, Van der Veldt AA, Van den Eertwegh AJ, 
Boven E. Brain metastases in patients with renal cell cancer receiving new targeted treatment. 
J Clin Oncol 2008;26:152-4.  
 
11. Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Bex A, De Gast G, Haanen JB, Boven E. 
Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer 
Res 2008;14:2431-6. 
181
 12. Van der Veldt AA, Boven E, Helgason HH, Van Wouwe M, Berkhof J, De Gast G, Mallo H, Tillier 
CN, Van den Eertwegh AJ, Haanen JB. Predictive factors for severe toxicity of sunitinib in 
unselected patients with advanced renal cell cancer. Br J Cancer 2008; 99:259-65. 
 
13. Van der Veldt AA, Van Wouwe M, Van den Eertwegh AJ, Van Moorselaar RJ, Van Geijn HP. 
Metastatic renal cell cancer in a 20-year-old pregnant woman. Urology 2008;72:775. 
 
14. Hendrikse NH, Luurtsema G, Van der Veldt AA, Lubberink M. Positron emission tomography for 
modeling pathophysiological processes in vivo. Curr Opin Drug Discov Devel 2008;11:717-25. 
 
15. Van Cruijsen H, Van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, 
Giaccone G, Haanen JB, Van den Eertwegh AJ, Boven E, Hoekman K, De Gruijl TD. Sunitinib-
induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell 
frequency predicts progression-free survival. Clin Cancer Res 2008; 14:5884-5892. 
 
16. Van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized 
treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting 
tumour resistance. Curr Pharm Des 2008;14:2914-31.  
 
17. Van der Veldt AA, Buist MR, Van Baal MW, Comans EF, Hoekstra OS, Molthoff CF. Clarifying the 
diagnosis of clinically suspicious recurrent cervical cancer: impact of 18F-FDG PET. J Nucl Med 
2008;49:1936-43. 
 
18. Bex A, Van der Veldt AA, Blank C, Van den Eertwegh AJ, Boven E, Horenblas S, Haanen JB. 
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful 
resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J 
Urol 2009;27:533-9. 
 
19. Van der Veldt AA, Boven E, Vroling L, Broxterman HJ, Van den Eertwegh AJ, Haanen JB. 
Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol 
2009;27:1339-40.  
 
20. Vroling L, Van der Veldt AA, De Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, Van Cruijsen H, 
Verheul HM, Van den Eertwegh AJ, Hoekman K, Boven E, Van Hinsbergh VW, Broxterman HJ. 
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated 
with sunitinib. Angiogenesis 2009;12:69-79.  
 
21. Van Cruijsen H, Van der Veldt AA, Hoekman K. Tyrosine kinase inhibitors of VEGF receptors: 
clinical issues and remaining questions. Front Biosci 2009;14:2248-2268.  
182
       
 
22. Van der Veldt AA, Kleijn SA, Nanayakkara PW. Silicone breast implants and anaplastic large T-
cell lymphoma. JAMA 2009;301:1227.   
 
23. Van der Veldt AA, Boven E, Bex A. Re: Response of the primary tumor to neoadjuvant 
sunitinib in patients with advanced renal cell carcinoma. AA Thomas, BI Rini, BR Lane, J 
Garcia, R Dreicer, E A Klein, AC Novick and SC Campbell. J Urol 2009;181:518-523. 
 
24. Van Erp NP, Eechoute K, Van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, 
Van der Straaten T, Baak-Pablo R, Wessels JA, Guchelaar HJ, Gelderblom H. Pharmacogenetic 
pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009;27:4406-
12.  
 
25. Van der Veldt AA, De Boer MP, Boven E, Eringa EC, Van den Eertwegh AJ, Van Hinsbergh VW, 
Smulders YM, Serné EH. Reduction in skin microvascular density and changes in vessel 
morphology in patients treated with sunitinib. Anticancer Drugs 2010;21:439-46.  
 
26. Van der Veldt AA, Comans EF, Thunnissen FB, Hendrikse NH, Smit EF, Van der Hoeven JJ. Re: 
Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence 
and disease pattern. Clin Radiol 2010;65:94-6.  
 
27. Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Progression of a caval 
vein thrombus in two patients with primary renal cell carcinoma on pretreatment with 
sunitinib. Acta Oncol 2010;49:520-3.  
 
28. Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Haanen JB, Boven E. Choi response 
criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer 
treated with sunitinib. Br J Cancer 2010;102:803-9.  
 
29. Bex A, Van der Veldt AA, Boven E, Haanen JB. Re: Surgical resection of renal cell carcinoma 
after targeted therapy. AA Thomas, BI Rini, AJ Stephenson, JA Garcia, A Fergany, V 
Krishnamurthi, AC Novick, IS Gill, EA Klein, M Zhou and SC Campbell. J Urol 2010;183:1646-
7.   
 
30. Van Schaik AM, Kleijn SA, Van der Veldt AA, Van Tilburg W. Te veel dokters kiezen de dood. 
Medisch Contact 2010;25:1218-1220.  
 
31. Van der Veldt AA, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, Van der 
Hoeven JJ, Windhorst AD, Lammertsma AA, Lubberink M. Biodistribution and radiation 
dosimetry of (11)C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 
2010;37:1950-8. 
 
183
 32. De Boer MP, Van der Veldt AA, Lankheet NA, Wijnstok NJ, Van den Eertwegh AJ, Boven E, 
Serné EH. Sunitinib-induced reduction in skin microvascular density is a reversible 
phenomenon. Ann Oncol 2010;21:1923-4.   
 
33. Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Boven E. Targeted therapies in renal 
cell cancer: recent developments in imaging. Target Oncol 2010;5:95-112.  
 
34. Van Erp NP, Mathijssen RH, Van der Veldt AA, Haanen JB, Reyners AK, Eechoute K, Boven E, 
Wessels JA, Guchelaar HJ, Gelderblom H. Myelosuppression by sunitinib is flt-3 genotype 
dependent. Br J Cancer 2010;103:757-8. 
 
35. Meijerink MR, Van Waesberghe JH, Van Schaik C, Boven E, Van der Veldt AA, Van den Tol P, 
Meijer S, Van Kuijk C. Perfusion CT and US of colorectal cancer liver metastases: a correlative 
study of two dynamic imaging modalities. Ultrasound Med & Biol 2010;36;1626-36. 
 
36. Kleijn S, Van der Veldt A. An entirely subcutaneous implantable cardioverter–defibrillator.       
N Engl J Med 2010;363:1577.  
 
37. Van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, Lammertsma AA, 
Lubberink M. Quantitative parametric perfusion images using 15O-labeled water and a clinical 
PET/CT scanner: test-retest variability in lung cancer. J Nucl Med 2010;51:1684-90.   
 
38. Van der Veldt AA, E Boven. Responsmeting bij patiënten met niercelcarcinoom tijdens 
behandeling met angiogeneseremmers. Angiogenese Journaal 2010.  
 
39. Van der Veldt AA, Haanen JB, Van den Eertwegh AJ, Boven E. Targeted therapy for renal cell 
cancer: current perspectives. Discov Med 2010;10:394-405. 
 
40. Van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, Van Erp NP, Van den 
Eertwegh AJ, Haanen JB, Mathijssen RH, Wessels JA. Genetic polymorphisms associated with a 
prolonged progression-free survival in patients with metastatic renal cell cancer treated with 
sunitinib. Clin Cancer Res 2011;17:620-9.  
 
41. Van der Veldt AA, Kleijn SA. Advances in pancreatic neuroendocrine tumor treatment. N Engl J 
Med 2011;364:1873.  
 
42. Boven E, Meijerink MR, Vroling L, Van der Veldt AA. Surrogate markers of anti-angiogenic 
therapies. Chapter in: Angiogenesis and therapeutic targets in cancer, 2011.  
 
43. Van der Veldt AA, Lubberink M, Lammertsma AA, Smit EF. Comment on Cho et al.: Usefulness 
of FDG PET/CT in determining benign from malignant endobronchial obstruction. Eur Radiol 
2011;21:2148-9.  
184
       
 
44. Van der Veldt AA, Lubberink M, Greuter HN, Comans EF, Herder GJ, Yaqub M, Schuit RC, Van 
Lingen A, Rizvi SN, Mooijer MP, Rijnders AY, Windhorst AD, Smit EF, Hendrikse NH, 
Lammertsma AA. Absolute quantification of [11C]docetaxel kinetics in lung cancer patients 
using positron emission tomography. Clin Cancer Res 2011;17:4814-24. 
 
45. Van der Veldt AA, Vroling L, De Haas RR, Koolwijk P, Van den Eertwegh AJ, Haanen JB, Van 
Hinsbergh VW, Broxterman HJ, Boven E. Sunitinib-induced changes in circulating endothelial 
cell-related proteins in patients with metastatic renal cell cancer. Int J Cancer 2011.  
 
46. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, De Boer MP, Greuter HN, Hendrikse NH, 
Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, Smit, EF. 
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications 
for scheduling of anti-angiogenic drugs. Cancer Cell 2012;21:82-91. 
 
47. Vermaat JS, Gerritse FL, Van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, 
Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. 
???????????????????????????????????? ?????????????????????? ???????????????-free and overall 
survival in metastatic renal cell cancer patients. Eur Urol 2012.  
 
48. Van der Veldt AA, Smit EF. Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J 
Med 2012;366:1637.   
 
 
 
 
 
 
 
 
 
 
 
185
 






